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Summary ix 
Summary 
Nuclear factor-κB (NF-κB) transcription factors are involved in controlling numerous 
cellular processes, including inflammation, innate and adaptive immunity, and cell 
survival. In this study I show that the immunosuppressive measles virus (MV, 
Morbillivirus genus, Paramyxoviridae) has evolved multiple functions to interfere with 
NF-κB signaling in epithelial cells. The MV P, V, and C proteins, also involved in 
preventing host cell interferon responses, were found to individually suppress NF-κB-
dependent reporter gene expression upon triggering of classical NF-κB pathways, 
including TNF receptor-, RIG-I-like receptor-, or Toll-like receptor-signaling. The MV V 
protein showed the strongest suppression of classical NF-κB activity, while the 
inhibitory capacities of P or C were less pronounced. Reporter gene assays involving 
overexpression either of the IKK complex, which phosphorylates the inhibitor of κB to 
liberate NF-κB dimers, or the NF-κB dimer p65/p50 itself, indicate that MV V targets 
canonical NF-κB signaling downstream of the IKK complex. Accordingly, co-
immunoprecipitation (CoIP) experiments revealed that the V protein of MV, but not 
the P or the C protein, binds to the Rel-homology domain (RHD) of the NF-κB subunit 
p65. Both domains of the RHD of p65, responsible either for DNA binding or IκBα and 
p50 binding, were shown to be involved in the interaction with MV V. IκBα and p50, 
which are associated to p65 in non-stimulated cells, were not bound by any of the P 
gene products in CoIP experiments. Further CoIP experiments from cells co-expressing 
all NF-κB complex members, p65, p50, and IκBα, together with MV V simultaneously, 
suggest that binding of p50, IκBα and MV V to p65 are independent of each other and 
that MV V does not influence the composition of the NF-κB complex. However, the 
presence of V abolished nuclear accumulation of p65 upon TNFα stimulation as 
observed by confocal microscopy. Inhibition of TNFα-mediated nuclear accumulation 
was also observed in some cells expressing MV P, but all MV C-expressing cells showed 
nuclear p65 upon TNFα stimulation indicating that the C protein acts in the nucleus to 
suppress canonical NF-κB activity. Retention of p65 in the cytoplasm by the V protein is 
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neither due to direct binding of MV V to the nuclear localization signal (NLS) of p65 as 
revealed by CoIP experiments involving p65 mutants deficient in their NLS nor do MV V 
and importin α 5 compete for p65 binding. Notably, the short C-terminal domain of the 
V protein (VCTD), which is also involved in binding STAT2, IRF7, and MDA5, was 
sufficient for the interaction and for preventing reporter gene activity. As revealed by 
mutational analysis of the VCTD, binding of p65 and also of IRF7 to MV V involves at 
least two independent sites located at loop1 and 2 of VCTD. The C-terminal domain of V 
was found to be completely identical in the Schwarz MV vaccine strain, which was 
used during this study, and a wild type MV isolate. Consequently, the capacity to 
suppress NF-κB activity and the ability to bind to p65 were also equal. Interestingly, 
the VCTD is also highly conserved among different paramyxoviruses. As revealed by 
reporter gene assays and CoIP experiments the V proteins of canine distemper virus 
and Nipah virus exhibit the same NF-κB inhibitory potency and binding affinity to the 
RHD of p65 as MV V. In contrast, the parainfluenza virus type 5 V protein did not bind 
to p65 and therefore cannot interfere with NF-κB activation. Besides inhibition of the 
classical NF-κB pathway, interference of MV P gene products with the alternative NF-
κB signaling was investigated as well. CoIP experiments suggested binding of RelB 
specifically to MV V, as already observed for p65. In contrast, p100, the precursor of 
p52, showed no interaction with any of the MV proteins similar to p50, whereas p52 
was found to interact with both MV P and V. 
The effect of MV V on NF-κB activity was also investigated in the viral context. 
Therefore different recombinant viruses were generated, including the parental virus, 
a virus with a knock out of the V protein, and a virus in which the knock out was 
rescued by expression of the V protein from an inserted ORF. As illustrated by growth 
curves and Western blotting of the viral proteins, the V knock out virus exhibited the 
same growth kinetics on Vero and A549 cells as the viruses expressing the V protein. 
NF-κB-dependent reporter gene assays and quantitative real-time RT-PCR on NF-κB-
dependent genes upon infection did not reveal a major impact of the presence of V on 
NF-κB activation in epithelial cells to a certain time point. This indicates that the P and 
C proteins can substitute for the inhibitory effects of the V protein in these cells. 
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1 Introduction 
1.1 Measles virus – a representative of the virus family 
Paramyxoviridae 
Measles virus (MV) is a non-segmented, negative-sense RNA virus and belongs 
therefore to the order of Mononegavirales. It is further grouped into the family of 
Paramyxoviridae, which consists of two subfamilies the Paramyxovirinae and the 
Pneumovirinae. MV is part of the Morbillivirus genus in the Paramyxovirinae subfamily 
along with respiroviruses, rubulaviruses, henipaviruses, and avulaviruses (Fig. 3-14A).  
1.1.1 The measles virus virion – composition of the viral particle 
MV is a pleomorphic, enveloped virus with a wide range of diameters between 180 nm 
and 1 µm (Lund et al., 1984; Nakai and Imagawa, 1969). However, most of the virions 
appear to have a spherical shape with an average diameter between 100 and 300 nm 
(Rima and Duprex, 2011) (Fig. 1-1A). The lipid bilayer envelope derived from the host 
cell encloses the negative sense, single stranded RNA genome, which comprises 15,894 
nucleotides and contains six genes, separated from each other by trinucleotide 
intergenic sequences. These six genes in the order 3’-N-P-M-F-H-L-5’ encode eight 
proteins due to leaky scanning of cellular ribosomes and RNA editing by the viral 
polymerase complex (Fig. 1-1B). The transcription units are flanked by a leader (Le) 
region at the 3’-terminus encoding a short RNA of 56 nucleotides and a 40 nucleotide 
long trailer (Tr) region at the 5’-terminus. Six of the viral proteins are components of 
the virion. The 58kDa nucleocapsid (N) protein encapsidates the viral genome to 
protect it from cellular RNAses forming the ribonucleo-protein complex (RNP), which is 
the basic unit of infectivity (Fig. 1-1A). Each N protein associates with exactly six 
nucleotides of the genome. This may explain why MV strictly follows the "rule of six", 
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which states that the genome must consist of a multiple of six nucleotides to get 
properly packaged and to replicate efficiently (Kolakofsky et al., 2005). The viral RNA-
dependent RNA polymerase (vRdRp) is composed of the large (L) protein and the 
phosphoprotein (P), with L bearing the enzymatic activity and P serving as non-
catalytic co-factor. The P (54 kDa) and the L (247 kDa) protein associate with the RNP, 
which is additionally coated with the 38 kDa matrix (M) protein (Liljeroos et al., 2011), 
mediating virus assembly and budding (Cathomen et al., 1998; Iwasaki et al., 2009). 
The viral hemagglutinin (H) and fusion (F) glycoproteins surround the virion and are 
responsible for viral entry and exit. The type 2 membrane protein H (69 kDa) builds a 
dimer or a dimer of dimers (Hashiguchi et al., 2007) and mediates attachment of the 
virion to the cell by recognition of the cellular receptors, whereas the integral type 1 
membrane protein F (60 kDa) forms trimers that require proteolytic cleavage to be 
able to fuse cell membranes (Zhu et al., 2003).  
 
Figure 1-1 Measles virus – the basics 
(A) Schematic representation of a MV virion. The negative strand RNA genome is enclosed by the N protein building 
the ribonucleoprotein (RNP) complex, which is associated with the viral polymerase composed of the large protein 
(L) and the phosphoprotein (P). The matrix (M) protein links the RNP to the viral glycoproteins, the fusion (F) and 
the hemagglutinin (H) protein, located on the cellular plasma membrane. (B) The MV genome comprises six genes. 
The P gene allows expression of three different proteins. (C) Schematic overview of the MV life cycle. The whole 
replication cycle takes place in the cytoplasm. Upon binding to the cognate cellular receptor, fusion of viral and 
cellular membranes is initiated mediating entry of MV. Transcription and replication take place subsequently and 
the newly synthesized RNP is transported to the plasma membrane, where assembly and budding takes place. 
Adapted from (Moss and Griffin, 2006). 
A B
C
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The two non-structural proteins, V and C, are additionally expressed from the P gene 
(Fig. 1-2). Co-transcriptional RNA editing allows expression of the 32 kDa V protein. In 
this process, the viral polymerase stutters at a defined editing site and inserts an 
additional non-templated guanosine (G) into the transcript of the P gene between 
nucleotide 748/749 that leads to the V mRNA and a frameshift of the open reading 
frame (ORF) at that position (Cattaneo et al., 1989). Thus, the translated V protein has 
a 231 aa long N-terminal domain identical to the P protein (PVNTD), but a unique 
cysteine-rich C-terminal domain (VCTD) of 68 aa.  
 
Figure 1-2 Measles virus P gene products 
In addition to the P protein, the nonstructural proteins V and C are expressed due to insertion of an additional 
guanosine (G) between nucleotides 751 and 752 of the mRNA by RNA editing (MV V) or translation of an alternative 
ORF initiating 19 nucleotides downstream of the P/V start codon (MV C). Adapted from (Schuhmann et al., 2011). 
The VCTD was shown to incorporate two zinc atoms forming zinc finger motifs that are 
highly conserved among paramyxoviruses (Liston and Briedis, 1994). All members of 
the Paramyxovirinae subfamily are able to edit their P gene mRNA, however, the 
number of inserted G residues varies (Goodbourn and Randall, 2009). Expression of 
the C protein is achieved through leaky scanning of ribosomes and the use of an 
alternative translation initiation site on the P and V mRNAs downstream of the P/V 
start codon. This results in translation of an alternative ORF and the expression of the 
21 kDa C protein (Bellini et al., 1985). Neither C nor V is essential for MV replication 
(Radecke and Billeter, 1996; Schneider et al., 1997), however, all P gene products were 
shown to be key players of MV evading the immune system (Rima and Duprex, 2011).  
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1.1.2 The viral life cycle 
Viral entry 
In order to enter a cell the MV virion attaches to the cell surface via the H protein that 
binds to the cellular entry receptors (Fig. 1-1C). Three different receptors were 
identified so far: Signaling lymphocytic activation molecule (SLAM), also known as 
CD150, is thought to be the primary MV receptor in terms of MV pathogenesis (Tatsuo 
et al., 2000). SLAM is a costimulatory molecule expressed on activated T-cells, B-cells, 
macrophages, mature dendritic cells (DCs), platelets, and thymocytes explaining the 
highly lymphotropic nature of MV (Sidorenko and Clark, 2003). Recently, the so far 
elusive epithelial entry receptor, which was already known to exist (Ludlow et al., 
2010; Tahara et al., 2008; Takeda et al., 2007), was identified. Two independent 
studies characterized nectin-4, or poliovirus receptor-like protein 4 (PVRL4), as the MV 
entry receptor found on epithelial cells (Muhlebach et al., 2011; Noyce et al., 2011). 
Nectin-4 is expressed within adherens junctions, complexes that provide strong 
mechanical attachment between epithelial cells. The first identified, but least 
pathologically relevant receptor is CD46 or membrane cofactor protein (MCP) (Dorig et 
al., 1993; Naniche et al., 1993). Although expressed on nearly all nucleated human 
cells, CD46 can only be utilized by cell culture adapted vaccine viruses in vitro (Yanagi 
et al., 2009). However, there is recent evidence that vaccine viruses do not use CD46 in 
vivo (Kato et al., 2012). 
Upon binding of the H protein to the cellular receptor, major conformational changes 
in the mature F protein are triggered, followed by insertion of the fusion peptide into 
the target membrane and ultimately in formation of a fusion pore, leading to the 
release of the RNP into the cytoplasm (Plemper et al., 2011). 
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Replication cycle 
Once the RNP is released into the cytoplasm of the cell, viral gene expression and 
replication are set up (Fig. 1-1C). Therefore, the vRdRp transcribes the viral genes into 
mRNAs, which were shown to be 5’-capped and 3’-polyadenylated (Hall and Meulen, 
1977; Yoshikawa et al., 1986). In contrast, the transcribed leader RNA is uncapped 
exhibiting 5′ triphosphates. At every gene border, the viral polymerase either 
dissociates from the genome or reinitiates transcription of the next gene. This results 
in an mRNA gradient since genes closer to the 3’-end of the genome are transcribed to 
a higher extent than more distal genes (Cattaneo et al., 1987). The mRNAs are 
translated into proteins by the cellular translation machinery. At a certain point of 
infection, the vRdRp switches from the transcription to replication mode. This occurs 
probably when enough N protein is synthesized to encapsidate immediately the 
antigenomic RNA which serves as template for generation of new genomes. The 
emerging genome is cotranscriptionally packaged by N proteins generating new RNPs. 
Viral exit 
Both viral glycoproteins F and H are translated as transmembrane proteins and 
transported to the cell plasma membrane. The M protein mediates the interaction of 
the newly synthesized RNPs with the regions of the plasma membrane where the 
glycoproteins have been inserted to support assembly (Iwasaki et al., 2009). Finally, 
the virus is able to bud from the plasma membrane (Fig. 1-1C). 
Incorporation of the glycoproteins into the cellular membrane, can lead to fusion with 
uninfected cells, mediated by binding of H to receptors on neighboring cells activating 
the fusion function of F. This leads to the formation of multinucleated giant cells also 
known as syncytia, a hallmark of MV infected cells (Bunting, 1950). Syncytia formation 
and cell to cell spread is the main spreading strategy of MV. 
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1.1.3 Measles virus infection in vivo 
The measles virus is highly infectious to humans and causes measles, a disease that is 
still an important cause of child morbidity and mortality in many parts of the world, 
even though a safe and effective vaccine is available (Griffin et al., 2012). In 2010, 
there were around 140.000 measles deaths globally, with 95 % of them occurring in 
low-income countries with weak health infrastructures. The “MEASLES INITIATIVE” 
launched in 2001 helped to increase the vaccination rate among one-year old children 
from 72% in 2000 to 85% in 2010, which resulted in a 74% drop in measles deaths 
between 2000 and 2010 worldwide (WHO, 2012). The clinical symptoms of the disease 
like fever, rash, and conjunctivitis are just the signs of the adaptive immune responses 
against infection and not responsible for any deaths. However, MV infection induces 
several week of immunosuppression resulting in increased susceptibility to secondary 
infections that are the main causes of measles induced death (Griffin, 2010). Rare but 
serious complications of measles affect the central nervous system. 0.1% of the 
patients develop measles encephalitis within two weeks of the onset of the rash (Moss 
and Griffin, 2012). Another CNS complication that occurs months to years after acute 
infection is subacute sclerosing panencephalitis (SSPE) which is caused by a persistent 
measles virus infection. It is found in about one in 10,000–100,000 patients and most 
often occurs in people infected with measles virus before two years of age. 
Fortunately, measles vaccination programmes reduced the incidence of SSPE 
dramatically (Campbell et al., 2007).  
Infection route of MV 
Measles virus spreads among individuals via the respiratory route. Virus-containing 
droplets produced by sneezing or coughing enter the respiratory tract. Different to 
what was assumed in the past, initial infection with MV does not occur in epithelial 
cells of the upper respiratory tract, as revealed by infection studies with macaques (de 
Swart et al., 2007; Leonard et al., 2008) . Instead, the infection is rather initiated in the 
lower respiratory tract, where alveolar macrophages and DCs are infected transporting 
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MV to local lymphoid tissue (Ferreira et al., 2010; Lemon et al., 2011). The close spatial 
proximity to SLAM-positive T- and B- cells in this tissue amplifies the infection and 
promotes dissemination throughout the body. Infection of epithelial cells might come 
into play during the late phase of infection, when infected lymphocytes carry virus to 
the basal side of the respiratory epithelium infecting respiratory epithelial cells 
probably via nectin-4. Later on, the virus is released from these cells at the apical 
domain facilitating the viral transmission back into the airways. The proposed role of 
epithelial cells during virus exit is supported by a study in which a virus blind for the 
epithelial receptor remained virulent in rhesus macaques, but could not be released 
into the airways (Leonard et al., 2008). 
MV-induced immunosuppression and life-long immunity  
The MV-induced immune suppression comprises several phenomena concerning the 
adaptive immune response, like lymphopenia, predominance of Type 2 cytokine 
responses, and suppression of lymphocyte proliferation (Griffin, 2010). However, the 
underlying mechanisms are not well understood. The loss of lymphocytes 
(lymphopenia) might be due to increased susceptibility of the cells to apoptosis 
(Fugier-Vivier et al., 1997; Okada et al., 2000). Increased levels of Th2 cytokines such as 
interleukin-4 (IL-4), IL-10 and IL-13 produced by regulatory and CD4+ T-cells during MV 
infection (Griffin and Ward, 1993) leads on the one hand to an environment favoring 
B-cell maturation to establish the humoral memory important for life-long immunity 
against MV infection, on the other hand, macrophage activation is depressed and 
therefore induction of type 1 responses required for combating new pathogens is 
hampered (Griffin, 2010). Furthermore, MV F and H glycoproteins were shown to 
directly suppress proliferation of peripheral blood mononuclear cells (PBMCs), like 
lymphocytes, monocytes or a macrophages due to interaction with an unidentified 
molecule of the cell surface of PBMCs (Schlender et al., 1996). Considered together, 
these findings constitute the ’immunological paradox’ of measles virus infections: On 
the one hand most individuals successfully clear an infection and establish life-long 
immunity against MV, on the other hand they suffer from several weeks of immune 
suppression (Beckford et al., 1985).   
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1.2 The transcription factor family NF-κB – an important player 
during an antimicrobial immune response 
The nuclear factor-κB (NF-κB) was discovered in 1986 as a regulator of expression of 
the κ light chain gene in B cells (Sen and Baltimore, 1986). Since then, extensive 
research was done on the NF-κB family of transcription factors and revealed the 
involvement of NF-κB in numerous fundamental cellular processes. Besides its crucial 
role in cell survival, differentiation, and proliferation, NF-κB plays its most important 
part in the regulation of the immune system (Hayden and Ghosh, 2012). Thus, it 
controls not only the development and homeostasis of immune cells and lymphoid 
organs but is also an indispensable regulator during an immune response (Hayden et 
al., 2006). Activation of pattern recognition receptors (PRRs) such as Toll-like receptors 
(TLRs) and RIG-I-like receptors (RLRs) results in NF-κB-regulated expression of a large 
variety of cytokines and antimicrobial effector molecules that propagate and elaborate 
the initial recognition event of an invading pathogen (Dev et al., 2011). Besides this 
fundamental role in the innate immune system, NF-κB is activated upon T-cell and B-
cell receptor (TCR and BCR) engagement controlling the adaptive immune response as 
well (Ghosh et al., 1998). Accordingly, it is obvious that NF-κB is a key player during the 
host response to infection and is therefore a common target of microbial pathogens. 
1.2.1 The NF-κB family and its inhibitors 
The mammalian NF-κB family comprises five members: p65 (RelA), RelB, c-Rel, p50 
(NF-κB1), and p52 (NF-κB2). The p50 and p52 proteins are generated by proteolytic 
processing of the precursor proteins p105 and p100, respectively. The NF-κB subunits 
exist as homo- or heterodimers in the cell. All family members share a structurally 
conserved N-terminal region of about 300 amino acids, named the Rel homology 
domain (RHD). The RHD, which contains a nuclear localization signal (NLS), is critical for 
binding to cognate DNA-sequences termed κB motifs, homo/heterodimerization, and 
interaction with specific inhibitory proteins (Ghosh et al., 2012). Only p65, RelB, and 
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c-Rel possess a C-terminal transactivation domain (TAD), which is essential to initiate 
transcription. In contrast to Rel proteins, p50 and p52 lack the TAD (Fig. 1-3). However, 
p50 and p52 form either heterodimers with the Rel proteins to positively regulate 
transcription or homodimers to function as repressors by competing with TAD-
containing dimers for binding to κB sites (Hayden and Ghosh, 2012). The main 
activated form of NF-κB is a heterodimer of p65 associated with the p50 subunit.  
 
Figure 1-3 The mammalian NF-κB family and its inhibitors 
In mammalian cells five NF-κB family members exist, p65 (RelA), RelB, c-Rel, p105/p50 and p100/p52. p50 and p52 
are derived from longer precursor proteins p105 and p100, respectively. While p105 is constitutively processed, 
p100 needs a specific stimulus to induce processing. All NF-κB family members contain an N-terminal Rel-homology 
domain (RHD), but only p65, RelB, and c-Rel comprise a C-terminal transactivation domain (TAD). RelB contains 
additionally a leucine zipper (LZ) at the N-terminus. The inhibitor of NF-κB (IκB) family consists of IκBα, IκBβ, and 
IκBε and contain ankyrin repeat motifs (ANK) in their C-termini. Due to the presence of ANK repeats, the C-terminal 
domains of the precursors p100 and p105 are called IκB-like domains. According to (Ghosh et al., 2012). 
A hallmark of the NF-κB pathway is its regulation by inhibitor of κB (IκB) proteins. In 
unstimulated cells, NF-κB dimers are retained in the cytoplasm by these regulatory 
proteins, which include IκBα, IκBβ and IκBε. They are characterized by the presence of 
multiple ankyrin repeats at their C-terminus. These 33-amino acid motifs mediate 
protein-protein interactions with the RHD of NF-κB dimers. Thereby IκB proteins mask 
the NLS within the NF-κB dimers and sequester them in the cytosol in a 
transcriptionally inactive state (Hinz et al., 2012). The ankyrin repeats are also present 
in the C-terminal domains of the p100 and p105 precursors, which also function as IκBs 
(Fig. 1-3).  
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1.2.2 NF-κB activation: Two distinct pathways 
Two major pathways for activation of NF-κB are described, the classical (canonical) and 
alternative (non-canonical) pathway (Fig. 1-4) (Oeckinghaus et al., 2011). Although a 
wide range of diverse receptors stimulate the classical NF-κB signaling, only a selected 
set of receptors within the TNF receptor superfamily appears to initiate the alternative 
pathway.  
 
Figure 1-4 Two different NF-κB signaling pathways 
The classical pathway is activated by a variety of inflammatory signals. Activation of this pathway depends on the 
IKK complex which phosphorylates IκBα to induce its degradation allowing NF-κB dimers to enter the nucleus. The 
alternative pathway is activated by triggering of the receptors for lymphotoxin-β and BAFF or CD40. This pathway 
requires NF-κB-inducing kinase (NIK) and IKKα which induce processing of p52 from p100, resulting in activation of 
the p52/RelB heterodimer.  
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The classical NF-κB signaling pathway 
The classical pathway is induced by pro-inflammatory cytokines, such as tumor-
necrosis factor α (TNFα) and interleukin-1 (IL-1), by triggering innate immune receptors 
like TLRs and RLRs, as well as by antigen-receptor engagement (BCR and TCR). Signaling 
in the classical pathways generally occurs through the recruitment of adaptor proteins 
to the receptors resulting in signaling platforms crucial for the recruitment and 
activation of the central mediator of these pathways, namely the IκB kinase (IKK) 
complex. The 700-900 kDa IKK complex contains two catalytical subunits, IKKα and 
IKKβ, as well as a regulatory subunit IKKγ (NEMO (NF-κB essential modulator)) (Liu et 
al., 2012). It has been shown that IKKα and IKKβ form heterodimers in vivo and interact 
with the regulatory subunit NEMO through their C-terminal NEMO-binding-domain 
(NBD). The NBD peptide on its own was shown to inhibit the interaction between IKKγ 
and IKKα/IKKβ in a dominant negative manner and blocks activation of NF-κB. (May et 
al., 2000; May et al., 2002). Both IKKα and IKKβ contribute to the activation of classical 
signaling pathways, although in many cases IKKβ is sufficient as catalytical subunit. 
However, the regulatory subunit of the IKK complex, IKKγ is essential to activate these 
pathways (Solt and May, 2008). Upon activation, the IKK complex phosphorylates IκB-
proteins at specific serine residues, for example serines 32 and 36 of IκBα. 
Subsequently, the phosphorylated IκBα is ubiquitinated at lysines 21 and 22, which 
targets it for its degradation by the 26S proteasome. The NF-κB dimers are released 
and translocate to the nucleus where they bind to specific DNA sequences, called κB 
sites with the consensus sequence GGGRNNYYCC (N - any base, R - purine, 
Y - pyrimidine), to activate transcription of target genes (Hayden and Ghosh, 2012).  
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The alternative NF-κB pathway 
The alternative pathway responds to signals of a selected set of receptors within the 
TNF superfamily such as lymphotoxin-β receptor (LTβR), B-cell activating factor 
receptor (BAFFR) and CD40 (Sun, 2011). In unstimulated cells, a protein complex of 
TRAF2, TRAF3 and cIAP mediates constitutive proteasomal degradation of one of the 
central kinases of alternative signaling namely the NF-κB-inducing kinase (NIK). Upon 
receptor ligation, the complex is recruited to the receptor leading to a switch from 
NIK- towards TRAF3-ubiquitin-dependent degradation. This allows NIK accumulation 
(Liao et al., 2004; Qing et al., 2005) which then binds and phosphorylates IKKα. In 
contrast to classical NF-κB signaling, the alternative pathway depends strictly on IKKα 
and is independent of IKKβ and IKKγ (Senftleben et al., 2001). Activated IKKα then 
cooperates with NIK in phosphorylation of C-terminal serine residues of the NF-κB 
precursor p100. This results in p100 ubiquitination and proteasomal processing 
generating p52, eliminating the IκB-like function of p100 at its C-terminus. Therefore, 
the p52/RelB dimer is no longer sequestered in the cytosol and can translocate to the 
nucleus where it initiates expression of a variety of genes responsible for the 
functional cellular outputs of the alternative pathway, like development of secondary 
immune organs, presentation of self-antigens by thymic epithelial cells, or isotype 
switching of peripheral B cells. However, the precise identity of the target genes still 
remains elusive (Razani et al., 2011).  
Besides its crucial role in the signaling cascade of the alternative pathway NIK also 
exhibits the capacity to activate the IKK complex, the gatekeeper of the classical 
pathway, through phosphorylation of IKKα (Ramakrishnan et al., 2004; Zarnegar et al., 
2008). As a result, nearly all receptors initiating the alternative pathway also activate 
p65/p50 dimers which are part of the classical NF-κB signaling pathway. This leads to a 
cross talk between the classical and the alternative NF-κB pathway (Oeckinghaus et al., 
2011). 
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1.3 The innate immune response during MV infection 
1.3.1 Activation of the innate immune system by RNA viruses  
The first line of host defense against an invading pathogen is the innate immune 
system. Activation of innate immune cells rapidly generates an anti-microbial 
environment to defend pathogens in a general way. The sensors of the cells to 
recognize signs of infection are the PRRs which are triggered by microbial components 
known as pathogen associated molecular patterns (PAMPs). Among the array of PRRs, 
TLRs and RLRs are the primary receptors in controlling infections by RNA viruses. 
Triggering of these receptors induces a series of signaling cascades and leads to 
activation of multiple transcription factors, such as NF-κB and interferon regulatory 
factors (IRFs), resulting in the expression of proinflammatory cytokines and type I 
and III interferons (IFNs), which are potent antiviral effector proteins.  
Toll-like receptor signaling 
The Toll receptor was originally identified in Drosophila and shown later on to be 
essential for the defense against infections by fungi (Hashimoto et al., 1988; Lemaitre 
et al., 1996). Subsequently, a human homolog was identified and to date ten members 
of Toll-like receptors are known in humans. TLRs contain leucine-rich repeats required 
for pathogen recognition and Toll/interleukin-1 receptor (TIR) domains responsible for 
initiation of downstream signaling (Takeda and Akira, 2004). 
Each TLR is able to detect distinct molecular patterns of microorganisms. While TLR1, 
2, 4, 5, 6, and 11 bind mainly protein components of bacteria and parasites on plasma 
membranes, TLR3, 7, 8, and 9, which are found in the endosomal membrane, are the 
main sensors for viruses recognizing the nucleic acids that are internalized during an 
infection via endocytosis (Kumar et al., 2011). TLR3, which is expressed in various cell 
types, recognizes dsRNA, whereas TLR7 and 8 are restricted to immune cells and sense 
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ssRNA (Kawasaki et al., 2011). TLR9 also found exclusively in immune cells is activated 
by unmethylated CpG motifs within the DNA of the pathogen. In case of MV infection 
TLR3 was shown to be activated (Berghall et al., 2006) and wild type (wt) MV H protein 
was reported to bind to TLR2, activating downstream signaling (Bieback et al., 2002). 
 
Figure 1-5 Endosomal TLR-signaling 
Activation of the endosomal Toll-like receptors (TLRs) 3, 7, 8, and 9 by nucleic acids of pathogens leads to 
recruitment of the appropriate adaptor proteins and subsequent downstream signaling, which ends up in the 
activation of different transcription factors and cytokine expression. 
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Triggering of TLR signaling by the appropriate ligand causes the recruitment of adaptor 
proteins to the cytoplasmic TIR domain. Nearly all TLRs utilize myeloid differentiation 
primary response gene 88 (MyD88) as adaptor. Only TLR3 does not recruit MyD88, but 
TIR-domain-containing adapter-inducing interferon-β (TRIF) (Yamamoto et al., 2004) 
(Fig. 1-5). 
Upon recruitment to the TLRs, MyD88 binds a subset of Interleukin-1 receptor-
associated kinases (IRAKs) such as IRAK4, IRAK1 and IRAK2. Subsequently, IRAK kinases 
dissociate from MyD88 and interact with TRAF6, which ubiquitinates itself and 
activates the formation of a complex of transforming growth factor β–activated kinase 
1 (TAK1), TAK1-binding protein 1 (TAB1), TAB2 and TAB3. The TAK1 complex then 
activates the IKK complex leading to NF-κB activation as descript in chapter 1.2.2 
(Takeuchi and Akira, 2010). Simultaneously, it stimulates the mitogen-activated 
protein kinase (MAPK) pathway to facilitate activation of the transcription factor AP-1 
(activator protein-1) (Fig. 1-5). In plasmacytoid dendritic cells (pDC), TLR7, 8, and 9 
additionally activate IRF7 by a TRAF3-dependent mechanism resulting in the 
expression of type I IFNs (Honda et al., 2005).  
In contrast, the TRIF-dependent TLR signaling activates IRF3 in addition to NF-κB and 
AP-1. Upon recruitment of TRIF to TLR3, it associates with TRAF6 and TRAF3. 
Subsequently, TRAF6 stimulates in cooperation with receptor-interacting protein 1 
(RIP1) the TAK1 complex, which leads to activation of MAPK and NF-κB, whereas 
TRAF3 mediates TBK1/IKKi dependent phosphorylation of IRF3 and consequently 
expression of type I IFN genes (Fig. 1-5) (Hacker et al., 2006). TLR4 triggers the MyD88-
dependent as well as the TRIF-dependent pathway (Takeuchi and Akira, 2010). 
RIG-I-like receptor signaling 
The RNA helicase RIG-I (retinoic acid-inducible gene I) was initially identified as a 
cytoplasmic PRRs for viral RNAs (Yoneyama et al., 2004) followed closely by the 
characterization of the other two RLR family members MDA5 (melanoma-
differentiation–associated gene 5) and LGP2 (laboratory of genetics and physiology 2) 
(Yoneyama et al., 2005). The RLRs RIG-I and MDA5 are composed of two caspase 
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activation and recruitment domains (CARDs) at their N-terminus, a central DExD/H-box 
helicase domain, and a C-terminal regulatory domain (Ireton and Gale, 2011). The 
helicase domain of RIG-I and MDA5 is responsible to bind viral RNAs and exerts ATPase 
activity, whereas the CARDs mediate downstream signaling. As LGP2 lacks the CARD 
domains it has rather regulatory functions. 
 
 
Figure 1-6 RLR signaling pathways 
The RIG-I-like receptor (RLR) signaling pathway can be activated via RIG-I or MDA5, which bind RNA with a 5’ 
triphosphate (5’ppp-RNA) and short double-strand RNA (dsRNAs) or long dsRNAs, respectively. Upon ligand binding 
RLRs dimerize and bind to IPS-1, which is located in the mitochondrial membrane activating kinases and 
subsequently transcription factors to initiate expression of inflammatory cytokines or type I interferons (IFNs). 
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With the exception of pDCs, RIG-I and MDA5 are the primary sensors in nearly all cell 
types for RNA virus infections. However, they were shown to recognize different RNA 
viruses (Kato et al., 2006; Loo et al., 2008). The virus specificity of RIG-I and MDA5 is 
determined by the RNA species they detect. RIG-I is activated by uncapped 
5′-triphosphate (5′-ppp) RNA (Hornung et al., 2006; Pichlmair et al., 2006), but for 
recognition of short dsRNA 5′-ppp it might be dispensable (Hausmann et al., 2008; 
Kato et al., 2008). The distinct natural ligand of MDA5 remains still elusive, however, 
MDA5 is thought to bind to long, stable dsRNA structures (Kato et al., 2008; Pichlmair 
et al., 2009). RIG-I detects both negative and positive strand RNA viruses among them 
Sendai virus (SeV), rabies virus (RV), or Hepatitis C virus (HCV), while MDA5 has been 
shown to detect picornaviruses such as encephalomyocarditis virus (EMCV) (Gitlin et 
al., 2006; Kato et al., 2006). Interestingly, MV and other negative strand RNA viruses 
were shown to be recognized by both RIG-I and MDA5 (Berghall et al., 2006; Ikegame 
et al., 2010). Under steady-state conditions the best characterized receptor RIG-I is 
present in a closed, inactive conformation shielding the CARDs. Upon triggering, an 
ATP-dependent conformational change occurs enabling the helicase domain to bind 
RNA. Subsequently, RIG-I dimerizes and the CARDs are released and accessible for 
further signaling (Cui et al., 2008). The initial recognition by RIG-I is also tightly 
controlled by ubiquitination events. K63-linked ubiquitination by TRIM25 and RNF135 
have been found to be required for activation, whereas K48-linked ubiquitination by 
RNF125 leads to downregulation of RIG-I-mediated signaling (Arimoto et al., 2007; 
Gack et al., 2007; Oshiumi et al., 2010). Upon activation, RIG-I and MDA5 interact with 
interferon-beta promoter stimulator 1 (IPS-1) through homophilic interactions 
between CARD domains (Kawai et al., 2005). IPS-1, also known as MAVS, Cardif, or 
VISA, is located at the outer mitochondrial membrane, which was shown to be 
important for downstream signaling (Meylan et al., 2005; Seth et al., 2005; Xu et al., 
2005). Once RIG-I or MDA5 interact with IPS-1, a complex is recruited to IPS-1 including 
TRAF6, TNF receptor type 1-associated DEATH domain (TRADD), Fas-associated death 
domain (FADD) and RIP1, mediating activation of the IKK complex through cleavage of 
caspase-8/-10 to activate NF-κB. Activated IPS-1 also associates with TRAF3, followed 
by activation of TBK1 and IKKi to activate IRF3 and IRF7 analogous to TRIF-dependent 
IRF activation (Kumar et al., 2011) (Fig. 1-6).   
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1.3.2 Strategies of measles virus to evade innate immune responses – 
it’s all about the P gene products 
Since MV replication activates innate immune responses (Rima and Duprex, 2011), 
mainly through triggering of RIG-I and MDA5 or TLR3, it has developed several 
strategies to circumvent the full range of innate immune responses and the 
accompanied establishment of an anti-viral environment. MV was shown to interfere 
with innate immune responses at different stages. Its most upstream target is MDA5. 
The MV V protein binds to the helicase domain of MDA5 but not RIG-I, thereby 
blocking its activation by dsRNA and consequently inhibiting MDA5-mediated IFN 
expression (Andrejeva et al., 2004; Childs et al., 2007). Recently, it was shown that the 
V protein also binds to LGP2 probably mediating a complex between RIG-I and LGP2, 
which renders RIG-I unable to respond to RIG-I-specific PAMPs (Childs et al., 2012). 
Both interactions are mediated through the C-terminal domain of V and are conserved 
among paramyxovirus V proteins. Furthermore, V proteins of a subset of 
paramyxoviruses, including MV V, were reported to inhibit IRF3 activation, eventually 
through binding to IRF3 (Irie et al., 2012). The most downstream inhibition of PRR-
induced IFN expression, is probably controlled by the C protein, which was shown to 
act in the nucleus to evade IFN expression by yet unidentified mechanisms (Sparrer et 
al., 2012). In MV infected pDCs, TLR7 and 9 signaling was shown to be suppressed 
(Schlender et al., 2005). Again the V protein is responsible for the inhibition of IFN 
induction through MyD88-dependent TLR signaling acting as a decoy substrate for IKKα 
(Pfaller, 2009).  
Besides inhibition of IFN expression, MV proteins also inhibit IFN-signaling, which 
involves activation of the janus kinases (JAK) and the transcription factors signal 
transducers and activators of transcription (STAT) 1 and 2 upon IFN receptor (IFNR) 
triggering. MV P and V bind through their common N-terminus to STAT1, inhibiting its 
phosphorylation upon stimulation with type I IFN and subsequently the expression of 
IFN-stimulated genes (ISGs), which are important anti-viral effectors (Devaux et al., 
2007; Ohno et al., 2004). Furthermore, MV V binds to the kinase domain of JAK1, an 
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additional mechanism to prevent phosphorylation of STAT1 (Caignard et al., 2007). MV 
V binds STAT2 as well, but with its C-terminal domain thus blocking the nuclear 
translocation of STAT2 presenting a further mechanism to inhibit ISG expression 
(Ramachandran et al., 2008). The C protein was found to inhibit IFN signaling as well, 
but by a so far unknown mechanism (Shaffer et al., 2003). Recently, a role for the MV 
N protein in IFN signaling inhibition was suggested (Takayama et al., 2012). 
In summary, MV has evolved multiple and powerful strategies to counteract IRF3/7-
dependent IFN induction and STAT-dependent IFN signaling mainly mediated by the P-
gene products (Goodbourn and Randall, 2009).  
1.4 Objective of the study 
While numerous recent studies on paramyxovirus innate immune antagonistic 
activities have shed light on how control of IRF3/7 and STAT is achieved, their potential 
to interfere with NF-κB is less well studied. However, activation of the NF-κB pathway 
is of critical importance during an immune response and thus it is likely that MV 
modulates this pathway. Therefore, I wanted to assess the capacity of the MV proteins 
to interfere with NF-κB signaling and to understand the underlying mechanism of the 
presumed inhibition. For this purpose different biochemical and virological assays 
were performed in cultured cells either transiently expressing MV proteins or infected 
with MV. 
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2 Material and Methods 
2.1 Material 
2.1.1 Chemicals 
All chemicals were purchased from the following companies: BD, Biorad, Fluka, 
Invitrogen, Merck, Roth, Sigma-Aldrich, Serva, VWR Prolab. 
2.1.2 Enzymes and recombinant proteins 
All restriction enzymes and the appropriate buffers were purchased from New England 
Biolabs. All additional enzymes were purchased with the appropriate buffers from the 
listed companies. 
DNA polymerase Manufacturer 
Pfu DNA Polymerase Fermentas 
Phusion High Fidelity DNA Polymerase NEB 
Taq DNA Polymerase Biomaster 
DNase/RNase Manufacturer 
TURBO DNase Deoxyribonuclease I, RNase free Fermentas 
RNase A Macherey&Nagel 
Reverse Transcriptase Manufacturer 
Transcriptor Reverse Transcriptase Roche 
RNase inhibitor Manufacturer 
SUPERase-In Ambion 
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Ligase Manufacturer 
T4 DNA Ligase  New England Biolabs 
Phosphatase Manufacturer 
Calf Intestine Alkaline Phosphatase (CIAP)  New England Biolabs 
Protease Inhibitor Manufacturer 
Complete ULTRA Protease Inhibitor Cocktail Tablets Roche 
Recombinant Protein Manufacturer 
Human TNFα Biomol 
2.1.3 Commercial kits 
Plasmid purification Manufacturer 
Nucleobond Xtra Midi Macherey&Nagel 
Cloning Manufacturer 
QIAquick Gel Extraction Kit Qiagen 
QIAEX II Gel Extraction Kit Qiagen 
QIAquick Nucleotide Removal Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
Luciferase reporter gene assay Manufacturer 
Dual Luciferase Reporter Assay System Promega 
RNA isolation Manufacturer 
RNeasy Mini Kit Qiagen 
Real time PCR Manufacturer 
Quantitect SYBR Green PCR Kit Qiagen 
Transfection Manufacturer 
ProFection Mammalian Transfection System-CaPO4 Promega 
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2.1.4 Additional reagents 
Additional reagents Manufacturer 
1 kb DNA Ladder New England Biolabs 
0,25 % Trypsin-EDTA Gibco 
Anti-Flag M2-Agarose Sigma-Aldrich 
Anti-HA Affinity Matrix; (clone 3F10) Roche 
dNTP Set Bioline 
Immobilon-P blotting membrane (PVDF) Millipore 
Lipofectamine 2000  Invitrogen 
Oligo(dT)12-18 Primer Invitrogen 
PCR Marker New England Biolabs 
Precision Plus Protein Standards Biorad 
Protein A-Sepharose GE Healthcare 
Vectashield Mounting Medium for Fluorescence Vector Laboratories 
Versene Gibco 
Whatman Blotting Paper Machery-Nagel 
Western Lightning Plus ECL Chemiluminescence 
Substrate 
Perkin Elmer 
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2.1.5 Antibodies 
Primary antibodies 
(antigen) 
Host Manufacturer Dilution 
WB IF 
Anti-c-Rel rabbit Cell Signaling #4727 1:1000 - 
Anti-Flag M2  mouse Sigma-Aldrich - 1:200 
Anti-Flag M2 rabbit Sigma-Aldrich 1:10000 - 
Anti-HA (3F10) rat Roche 1:1000 - 
Anti-IκBα (L35A5) mouse Cell Signaling #4814 1:1000 - 
Anti-MV N (2D7) mouse Abcam ab9882 1:500 - 
Anti-MV N mouse Millipore MAB8906  1:500 - 
Anti-MV N-FITC mouse Millipore MAB8906F - 1:2000 
Anti-MV P (37069) 
(aa 2-15) 
rabbit D.Gerlier (Chen et al., 2003) 1:10000 - 
Anti-MV VCTD  (WBA/10/2) 
(aa 286-299) 
rabbit Metabion; custom-made 1:5000 - 
Anti-MV C (1240) (aa 176-186) rabbit R. Cattaneo 1:2500 - 
Anti-MV C (FEA/10/1)  
(aa 176-186) 
rabbit Metabion; custom-made 1:2500 - 
Anti-p65 rabbit Santa Cruz sc-109 1:1000 1:200 
Anti-p65 (C22B4) rabbit Cell Signaling #4764 1:1000 - 
Anti-p65-CT rabbit Millipore #06-418 1:1000 - 
Anti-p100/p52 rabbit Cell Signaling #4882 1:1000 - 
Anti-p105/50 rabbit Cell Signaling #3035 1:1000 - 
Anti-RelB (H-200) rabbit Santa Cruz sc-28689 1:1000 - 
Anti-RelB (C1E4) rabbit Cell Signaling #4922 1:1000 - 
Anti-RV P (P160-5) rabbit S. Finke 1:50000 - 
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Secondary 
antibodies 
(antigen) 
Host Manufacturer Dilution 
WB IF 
Anti-mouse HRP goat Jackson ImmunoResearch Laboratories 1:20000 - 
Anti-rabbit HRP goat Jackson ImmunoResearch Laboratories 1:20000 - 
Anti-rat HRP goat Jackson ImmunoResearch Laboratories 1:5000 - 
Anti-human HRP goat Jackson ImmunoResearch Laboratories 1:20000 - 
Anti-mouse 
tetramethylrhodamine 
goat MoBiTec 
- 1:1000 
Anti-rabbit Alexa Fluor 
488 
goat MoBiTec 
- 1:1000 
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2.1.6 Buffers and solutions 
All solutions and buffers were made in double distilled water (ddH2O). If solutions had 
to be autoclaved it is indicated. Unless indicated otherwise, all solutions were stored at 
room temperature. LB medium and LB plates were supplemented with the appropriate 
antibiotics: ampicillin (100 µg/ml), or kanamycin (25 µg/ml). 
Mini Preparation 
Flexi I 100 mM Tris-HCl pH 7.5 
10 mM EDTA 
200 μg/ml RNase 
Stored at 4°C 
Flexi II 200 mM NaOH 
1 % (w/v) SDS 
Flexi III 3 M potassium acetate 
2 M acetic acid, pH 5.75 
 
Agarose gel electrophoresis 
10x TAE 2 M Tris-HCl, pH 7.8 
0.25 M Sodium acetate x 3 H2O 
0.25 M EDTA 
1x TAE + EtBr 200 ml 10x TAE 
150 μl Ethidium bromide solution 1% 
Add ddH2O to 2 l 
OG loading buffer 50 % (v/v) 10x TAE 
15 % (w/v) Ficoll 400 
0.125 % (w/v) Orange G 
10x TE 100 mM Tris-HCl, pH 7.5 
10 mM EDTA 
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Blue juice 0.125 % (w/v) Bromphenol blue 
0.125 % (w/v) Xylenecyanol 
0.125 % (w/v) Orange G 
15 % (w/v) Ficoll 400 
50 % (v/v) 10x TAE 
Store at -20°C 
1 kb marker 380 μl 1x TE 
100 μl Blue juice 
20 μl 1 kb DNA ladder (New England Biolabs) 
Store at 4°C/-20°C 
PCR marker 167 μl Gel loading dye blue (6x) 
733 μl H2O 
100 μl PCR Marker (New England Biolabs) 
Store at 4°C/-20°C 
 
SDS-PAGE 
Jagow gel buffer 3 M Tris-HCl, pH 8.45 
0.3 % (w/v) SDS 
Jagow anode buffer 200 mM Tris-HCl, pH 8.9 
Jagow cathode buffer 100 mM Tris-HCl, pH 8.25 
100 mM Tricine 
0,1 % (w/v) SDS 
Protein lysis buffer 62.5 mM Tris-HCl, pH 6.8 
2 % (w/v) SDS 
10 % (w/v) glycerol 
6 M Urea 
5 % (v/v) β-mercaptoethanol 
0.01 % (w/v) Bromphenol blue 
0.01 % (w/v) Phenol red 
Store at -20°C 
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Stacking gel 4% 3.5 ml Jagow gel buffer 
1.4 ml acrylamide 29:1 Rotiphorese Gel 40 
18 l TEMED 
116 l APS (10 %) 
9 ml H2O 
Separating gel 10% 12 ml Jagow gel buffer 
9 ml acrylamide 29:1 Rotiphorese Gel 40 
2 ml glycerol 
17 l TEMED 
175 l APS (10%) 
12.9 ml H2O  
 
Western blotting 
10x Semi dry buffer 480 mM Tris-HCl pH 8.6 
390 mM Glycine 
0.05 % (w/v) SDS 
1x Semi dry buffer 100 ml 10x Semi dry buffer 
180 ml Methanol abs. 
720 ml H2O 
1x PBS 1.37 M NaCl 
27 mM KCl 
12 mM KH2PO4 
65 mM Na2HPO4x2H2O (pH 7.4) 
PBS-Tween 1x PBS 
0.05 % Tween 20 
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Co-Immunoprecipitation 
Standard Co-IP buffer 50 mM Tris-HCl pH 7.5 
150 mM NaCl 
2 mM EDTA 
1 mM Na3VO4 
0.5 % (v/v) NP-40 
Store at 4°C 
Add 1 Complete Protease Inhibitor Tablet per 50 ml before use 
Sepharose A Co-IP Buffer Buffer A: 100 mM Tris pH 8.0 
Buffer B: 10 mM Tris pH 7.4 
Store at 4°C 
PBS 5mM EDTA 1x PBS 
5mM EDTA 
 
Immunofluorescence 
3 % PFA/PBS 1x PBS 
3 % (w/v) paraformaldehyde 
80 % Acetone 800 ml acetone p.a. 
Add ddH2O to 1l 
50mM NH4Cl/PBS 1x PBS 
50mM NH4Cl 
PBS/0.5 % Triton X-100 1x PBS 
0.5 % (v/v) Triton X-100 
PBS/2,5 %milk/0.1 % Triton 
X-100 
1x PBS 
0.1 % (v/v) Triton X-100 
2.5 % (w/v) milk powder 
PBS/0.1 % Triton X-100 1x PBS 
0.1 % (v/v) Triton X-100 
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Bacteria growth media 
LB 85 mM NaCl 
0.5 % (w/v) Bacto yeast extract 
1 % (w/v) Bactotryptone 
1 mM MgSO4 
Autoclaved and stored at 4 °C 
LB ++ 1x LB 
20 mM MgSO4 
10 mM KCl 
LB plates 1 l LB medium 
15 g Agar 
2.1.7 Bacteria and cell lines 
The E.coli strain XL1 Blue (Stratagene) was used for amplification of plasmids. 
Cell line Description 
HEK-293T        
(ATCC-CRL-11268) 
HEK-293 was established from a human primary embryonic kidney 
transformed by adenovirus type V (Graham et al., 1977). The cell line 
HEK-293T is a derivative, which constitutively expresses the simian virus 
40 (SV40) large T antigen. 
HEp-2            
(ATCC-CCL-23) 
The HEp-2 cell line was initiated from tumors that had been produced in 
irradiated-cortisonized weanling rats after injection with epidermoid 
carcinoma tissue from the larynx of a 56-year-old male (Toolan, 1954). 
A549             
(ATCC-CCL-185) 
The A549 cell line was developed from culturing of cancerous lung tissue 
in the explanted tumor of 58-year-old Caucasian male (Giard et al., 
1973). A549 cells are human alveolar basal epithelial cells. 
293-3-46 Derived from the human embryonic kidney 293 cell line. The cells 
constitutively express T7 RNA polymerase together with MV 
nucleocapsid protein and phosphoprotein (Radecke et al., 1995) 
Vero-hSLAM This cell line is a derivative of Vero cells which constitutively expresses 
the human SLAM receptor (Ono et al., 2001). 
Vero              
(ATCC- CCL-81) 
The Vero cell line was established from the kidney of a normal adult 
African green monkey (Yasumura, 1963). 
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2.1.8 Oligonucleotides 
Primers were purchased from Metabion.  
Primers for cloning: 
# Primer name Sequence (5’-3’) 
11 NBD-Peptide forw ATA GAA TTC CTA GAC TGG AGC TGG TTA CTC GAG ATA 
12 NBD-Peptide rev TAT CTC GAG TAA CCA GCT CCA GTC TAG GAA TTC TAT 
17 p65 EcoRV forw ATA GCC ACC GAT ATC ATG GAC GAA CTG TTC CCC 
34 p65 XhoI rev  TAT CTC GAG TTA GGA GCT GAT CTG ACT 
39 p50 HindIII forw ATA AAG CTT GCC ACC ATG GCA GAA GAT GAT 
40 flag p50 HindIII forw 
ATA AAG CTT GCC ACC ATG GAC TAC AAA GAC GAT GAC 
GAT AAA GCA GAA GAT GAT CCA 
41 p50 XhoI rev ATA CTC GAG TTA AAC TTT CCC AAA GAG GTT 
43 p65 HindIII forw ATA AAG CTT GCC ACC ATG GAC GAA CTG TTC CCC 
44 p65 flag XhoI rev 
ATA CTC GAG CTA TTT ATC GTC ATC GTC TTT GTA GTC GGA 
GCT GAT CTG ACT CAG 
45 p65 1-309 XhoI rev ATA CTC GAG TTA GAA GGT CTC ATA TGT 
46 p65 1-309 flag XhoI rev  
ATA CTC GAG TTA TTT ATC GTC ATC GTC TTT GTA GTC GAA 
GGT CTC ATA TGT 
47 p65 310-551 HindIII forw  ATA AAG CTT GCC ACC ATG AAG AGC ATC ATG AAG 
48 
p65 310-551 flag XhoI 
rev  
TAT CTC GAG TTA TTT ATC GTC ATC GTC TTT GTA GTC GGA 
GCT GAT CTG ACT 
49 p65 310-551 XhoI rev  TAT CTC GAG TTA GGA GCT GAT CTG ACT 
50 flag-PIV5-V EcoRI forw 
ATA GAA TTC GCC ACC ATG GAC TAC AAA GAC GAT GAC 
GAT AAA GAT CCC ACT GAT CTG 
51 p50 RHD 1-399 XhoI rev ATA CTC CAG TTA CTT CTG ACG TTT CCT 
52 MV-V E235A forw 
CCA TTA AAA AGG GGC ACA GAC GCG CGA TTA GCC TCA 
TTT GGA ACG G 
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53 MV-V E235A rev 
CCG TTC CAA ATG AGG CTA ATC GCG CGT CTG TGC CCC TTT 
TTA ATG G 
54 MV-V R233A forw 
CAC CCA TTA AAA AGG GGC ACG CAC GCG AGA TTA GCC 
TCA TTT GGA ACG G 
55 MV-V R233A rev 
CCG TTC CAA ATG AGG CTA ATC TCG CGT GCG TGC CCC TTT 
TTA ATG GGT G 
56 MV-V R233A,E235A forw 
CAC CCA TTA AAA AGG GGC ACG CAC GCG CGA TTA GCC 
TCA TTT GGA ACG G 
58 p65 1-300 XhoI rev ATA CTC GAG TTA CTC CTC AAT CCG GTG 
59 p65 NLS- 301AAA forw 
GAT CGT CAC CGG ATT GAG GAG GCA GCT GCA AGG ACA 
TAT GAG ACC TTC AAG AGC 
60 p65 NLS- 301AAA rev 
GCT CTT GAA GGT CTC ATA TGT CCT TGC AGC TGC CTC CTC 
AAT CCG GTG ACG ATC 
62 Nipah V XhoI rev TAT CTC GAG TTA ACC GCA GTG GAA GCA 
67 flag Nipah V HindIII forw 
ATA AAG CTT GCC ACC ATG GAC TAC AAA GAC GAT GAC 
GAT AAA GAT AAA TTG GAA CTA 
70 flag-p65 HindIII forw  
ATA AAG CTT GCC ACC ATG GAC TAC AAA GAC GAT GAC 
GAT AAA GAC GAA CTG TTC CCC 
71 flag-p65 180 XhoI rev ATA CTC GAG TTA AGA AAG GAC AGG CGG 
72 p65 181 HindIII forw ATA AAG CTT GCC ACC ATG CAT CCC ATC TTT GAC 
73 
HA-importin a3 NheI 
forw 
ATA GCT AGC GCC ACC ATG TAT CCT TAT GAC GTG CCT GAC 
TAT GCC AGC CTG GGA GGA CCT GCG GAC AAC GAG AAA 
CTG 
74 importin a3 NotI rev ATA GCG GCC GCC TAA AAC TGG AAC CCT TC 
75 
HA-importin a4 NheI 
forw 
ATA GCT AGC GCC ACC ATG TAT CCT TAT GAC GTG CCT GAC 
TAT GCC AGC CTG GGA GGA CCT GCC GAG AAC C CC AGC 
TTG GAG 
76 importin a4 NotI rev ATA GCG GCC GCT TAA AAA TTA AAT TCT TT 
77 
HA-importin a 5 NheI 
forw 
ATA GCT AGC GCC ACC ATG TAT CCT TAT GAC GTG CCT GAC 
TAT GCC AGC CTG GGA GGA CCT ACC ACC CCA GGA AAA 
GAG 
78 importin a5 NotI rev ATA GCG GCC GCT CAA AGC TGG AAA CCT TCC AT 
79 
flag-CDV PVNTD HindIII 
forw  
ATA AAG CTT GCC ACC ATG GAC TAC AAA GAC GAT GAC 
GAT AAA GCA GAG GAG CAG GCC TAT 
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81 CDV-V XhoI rev ATA CTC GAG TCA TTT GAG GTC TTG GGA 
115 c-Rel HindIII forw ATA AAG CTT GCC ACC ATG GCC TCC GGT GCG TAT 
116 c-Rel XhoI rev TAT CTC GAG TTA TAC TTG AAA AAA TTC 
118 
MV VdC dloop1 BsmBI 
forw 3' ATA CGT CTC CTG GAT GCA ACC CAA TGT GCT CG 
119 
MV VdC dloop2 BsmBI 
reverse 5' ATA CGT CTC CTC CAC CGC ACA TTG GGT TGC ACC A 
120 
MV VdC dloop2 BsmBI 
forw 3' ATA CGT CTC CTG GAA CCT GCG GGG AAT GTC CC 
121 
MV VdC dloop2 BsmBI 
forw 3' ATA CGT CTC CTG GAT GCA CCT GCG GGG AAT GTC CC 
124 MV PdeltaV mut fwd 
TAG GGC CAG CAC TTC CGG GAC ACC CAT TAA GAA GGG 
CAC AGA CGC GAG ATT AGC CTC ATT 
125 MV PdeltaV mut rev 
AAT GAG GCT AAT CTC GCG TCT GTG CCC TTC TTA ATG GGT 
GTC CCG GAA GTG CTG GCC CTA 
126 
MV VdC dloop1 BsmBI 
reverse 5' ATA CGTCTC C TCC ACC GTG CCC CTT TTT AAT GGG 
129 
flag p100/p52 HindIII 
forw 
ATA AAG CTT GCC ACC ATG GAC TAC AAA GAC GAT GAC 
GAT AAA GAG AGT TGC TAC AAC CCA 
131 p52 BamHI rev TAT GGA TCC TCA CCT CCT CCA GCT CCT 
CP 
50 
MV V NotI rev ATA TGC GGC CGC TTA TTC TGG GAT CTC 
CP 
127 
PIV5 V XhoI rev TAT CTC GAG TTA AGT ATC TCG TTC 
CP 
201 
V SnaBI+5nt fwd ATA TAC GTA CCA CCA TGG CAG AAG AGC AGG CA 
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Primers for quantitative real-time RT-PCR 
Primer name Sequence (5’-3’) Annealing Temperature 
GAPDH for TGG TAT CGT GGA AGG ACT CA 53 °C 
GAPDH rev CCA GTA GAG GCA GGG ATG AT 53 °C 
IFNβ forw TCC AAA TTG CTC TCC TGT TG 47°C 
IFNβ rev GCA GTA TTC AAG CCT CCC AT 47°C 
IL-6 forw TAGTCCTTCCTACCCCCAATTTCC 53 °C 
IL-6 rev TTGGTCCTTAGCCACTCCTTC 53 °C 
MV-N forw TCA GAA CAA GTT CAG TGC AG 48°C 
MV-N rev CTT ACC ATC TCT TGC CCT AA 48°C 
RANTES forw GAGCTTCTGAGGCGCTGCT 53 °C 
RANTES rev TCTAGAGGCATGCTGACTTC 53 °C 
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2.1.9 Plasmids 
Plasmids commercially available 
Plasmid name Vector Description Provider 
Flag-c-Rel pcDNA 
Expression plasmid for the human NF-κB 
subunit c-Rel with N-terminal flag-tag  
Addgene #27253 
Flag-RelB pReceiver 
Expression plasmid for the human NF-κB 
subunit RelB with N-terminal flag-tag 
GeneCopoeia     
#EX-G0029-M11 
p100 pCMV4 
Expression plasmid for the human NF-κB 
subunit p100 
Addgene #23287 
p50 pCMV4 
Expression plasmid for the human NF-κB 
subunit p50 
Addgene #21965 
p52 pCMV4 
Expression plasmid for the human NF-κB 
subunit p52 
Addgene #23289 
p65 pCMV4 
Expression plasmid for the human NF-κB 
subunit p65/RelA 
Addgene #21966 
pCR3 pCR3 
Eukaryotic expression vector; CMV promoter 
controlled 
Invitrogen 
pRL-CMV pRL-CMV Renilla luciferase; CMV promoter controlled Promega 
RelB 
pCMV-
SPORT6 
Expression plasmid for the human NF-κB 
subunit RelB 
Open Biosystems  
#1010-7507797 
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Plasmids kindly provided  
Plasmid name Vector Description Provider 
Flag-ΔRIG-I pEFBos 
Expression plasmid for human RIG-I CARD 
domain (aa 1-284) with N-terminal flag-tag 
A.Krug 
Flag-IKKα pRK7 
Expression plasmid for human IKKα with 
N-terminal flag-tag 
K. Ruckdeschel 
Flag-IPS1 pCMV 
Expression plasmid for human IPS1 with 
N-terminal flag-tag 
S.Akira 
Flag-TRIF pRK7 
Expression plasmid for human TRIF with 
N-terminal flag-tag 
K. Ruckdeschel 
IKKβ-flag pRK7 
Expression plasmid for human IKKβ with 
C-terminal flag-tag 
K. Ruckdeschel 
Myc-MyD88 pRK7 
Expression plasmid for human IKKβ with 
N-terminal myc-tag 
K. Ruckdeschel 
p55A2-luc pBL 
Firefly luciferase controlled by NF-κB binding 
sites (Yoneyama et al., 1996) 
T.Fujita 
 
Plasmids generated in this laboratory: 
Unless otherwise indicated all ORFs were cloned into the pCR3 vector. 
Plasmid name Description Generated by 
FIag-MV C 
Expression plasmid for measles virus C protein of the 
Schwarz strain with N-terminal flag-tag 
C.Pfaller 
FIag-MV P 
Expression plasmid for measles virus P protein of the 
Schwarz strain with mutations avoiding the expression of 
the C protein and N-terminal flag-tag 
C.Pfaller 
FIag-MV V 
Expression plasmid for measles virus V protein of the 
Schwarz strain with mutations avoiding the expression of 
the C protein and N-terminal flag-tag 
C.Pfaller 
Flag-IKKγ 
Expression plasmid for human IKKγ/NEMO with 
N-terminal flag-tag in pCAGGS vector 
M. Rieder 
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Ig pCR3 vector with Ig-tag sequence upstream of MCS K. Brzózka 
Ig-MV C 
Expression plasmid for measles virus C protein of the 
Schwarz strain 
C.Pfaller 
Ig-MV P 
Expression plasmid for measles virus P protein of the 
Schwarz strain with mutations avoiding the expression of 
the C protein and N-terminal Ig-tag 
C.Pfaller 
Ig-MV PCTD 
Expression plasmid for the C-terminal domain (aa 233-
507) of measles virus P protein of the Schwarz strain and 
N-terminal Ig-tag 
C.Pfaller 
Ig-MV PVNTD 
Expression plasmid for the common N-terminal domain 
(aa 1-232) of measles virus P and V protein of the 
Schwarz strain with mutations avoiding the expression of 
the C protein and N-terminal Ig-tag 
C.Pfaller 
Ig-MV V 
Expression plasmid for measles virus V protein of the 
Schwarz strain with mutations avoiding the expression of 
the C protein and N-terminal Ig-tag 
C.Pfaller 
Ig-MV VCTD 
Expression plasmid for the C-terminal domain (aa 233-
299) of measles virus V protein of the Schwarz strain and 
N-terminal Ig-tag 
C.Pfaller 
MV C 
Expression plasmid for measles virus C protein of the 
Schwarz strain 
S.Moghim 
MV P 
Expression plasmid for measles virus P protein of the 
Schwarz strain with mutations avoiding the expression of 
the C protein 
C.Pfaller 
MV V 
Expression plasmid for measles virus V protein of the 
Schwarz strain with mutations avoiding the expression of  
C.Pfaller 
MV V dIRF7 
Expression plasmid for measles virus V protein of the 
Schwarz strain with point mutation 259AAAA avoiding 
IRF7 binding 
C. Pfaller 
MV Vwt 
Expression plasmid for wild type measles virus V protein 
of the D5 genotype with mutations avoiding the 
expression of the C protein 
C.Pfaller 
RV P Expression plasmid for rabies virus P protein K. Brzózka 
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Plasmids generated during this thesis: 
 
Unless indicated otherwise all ORFs were cloned into the pCR3 vector. 
Plasmid name Description 
Template 
(provider) 
Primers 
c-Rel 
Expression plasmid for the human NF-κB 
subunit c-Rel 
pcDNA-flag-c-Rel 115; 116  
flag-CDV V 
Expression plasmid for canine distemper 
virus V protein with mutations avoiding 
the expression of the C protein and 
N-terminal flag-tag 
pCG-CDV VΔC 
(V. von Messling) 
79; 81 
flag-NiV V 
Expression plasmid for nipah virus V 
protein with mutations avoiding the 
expression of the C protein and 
N-terminal flag-tag 
pGexGp2-NiV VΔC 
(K.P. Hopfner) 
62; 67 
flag-p50 
Expression plasmid for the human NF-κB 
subunit p50 with N-terminal flag-tag 
pCMV4-p50 40; 41 
flag-p50 RHD 
Expression plasmid for the REL homology 
domain (aa 1-366) of human p50 with 
N-terminal flag-tag 
pCMV4-p50 40; 51 
flag-p52 
Expression plasmid for the human NF-κB 
subunit p52 with N-terminal flag-tag 
pCMV4-p52 129; 131 
flag-p65 
Expression plasmid for the human NF-κB 
subunit p65/RelA with N-terminal flag-
tag in pCDNA3.1 vector 
pCMV4-p65 17; 34 
flag-p65 NTD 
Expression plasmid for the N-terminal 
domain of human p65 RHD (aa 1-180) 
with N-terminal flag-tag 
pCR3-p65 70; 71 
flag-PIV5 V 
Expression plasmid for Para-influenza 
virus type 5 V protein and N-terminal 
flag-tag 
pCR3-PIV5 V 
(C.Pfaller) 
50;CP 127  
HA-importin α3 
Expression plasmid for human importin 
α3 with N-terminal HA-tag 
pCMVTNT-T7-
importin α3 
 (Addgene #26680) 
73; 74 
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HA-importin α4 
Expression plasmid for human importin 
α4 with N-terminal HA-tag 
pCMVTNT-T7-
importin α4 
(Addgene #26679) 
75; 76 
HA-importin α5 
Expression plasmid for human importin 
α5 with N-terminal HA-tag 
pCMVTNT-T7-
importin α5 
(Addgene #26677) 
77; 78 
Ig-NBD 
Expression plasmid for Nemo binding 
domain of IKKα (aa738-743) with 
N-terminal Ig-tag (May et al., 2000) 
Annealing of 
primers 
11; 12 
MV V dMDA5 (1) 
Expression plasmid for measles virus V 
protein of the Schwarz strain with point 
mutation R233A avoiding MDA5 binding 
pCR3-MV V 54; 55 
MV V dMDA5 (2) 
Expression plasmid for measles virus V 
protein of the Schwarz strain with point 
mutation E235A avoiding MDA5 binding 
pCR3-MV V 52; 53 
MV V dMDA5 (1/2) 
Expression plasmid for measles virus V 
protein of the Schwarz strain with point 
mutations R233A E235A avoiding MDA5 
binding 
pCR3-MV V 56; 57 
MV V Δloop1 
Expression plasmid for measles virus V 
protein of the Schwarz strain with 
deletion of aa 233-250 therefore 
insertion of two Glycins  
pCR3-MV V 126; 118 
MV V Δloop1 
Expression plasmid for measles virus V 
protein of the Schwarz strain with 
deletion of aa 256-266 therefore 
insertion of two Glycins  
pCR3-MV V 119; 121 
p50 
Expression plasmid for the human NF-κB 
subunit p50  
pCMV4-p50 39; 41 
p65 
Expression plasmid for the human NF-κB 
subunit p65/RelA 
pCMV4-p65 43; 49 
p65-flag 
Expression plasmid for the human NF-κB 
subunit p65/RelA with C-terminal flag-
tag 
pCMV4-p65 43; 44 
p65 1-300 
Expression plasmid for the REL homology 
domain of human p65 lacking the NLS 
(aa 1-300) 
pCMV4-p65 43; 58 
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p65 TA-flag 
Expression plasmid for transactivation 
domain (aa 310-551) of human p65 with 
C-terminal flag-tag  
pCMV4-p65 47; 48 
p65 CTD-flag 
Expression plasmid for the C-terminal 
domain of human p65 RHD (aa 181-309) 
with C-terminal flag-tag 
pCR3-p65 72; 46 
p65 NLS- (K301A,R302A,K303A) pCR3-p65 59; 60 
p65 RHD 
Expression plasmid for the REL homology 
domain (aa 1-309) of human p65 
pCMV4-p65 43; 45 
p65 RHD-flag 
Expression plasmid for the REL homology 
domain (aa 1-309) of human p65 with 
C-terminal flag-tag 
pCMV4-p65 43; 46 
RelB 
Expression plasmid for the human NF-κB 
subunit RelB 
Digestion of 
pCMVSPORT6-
RelB with EcoRI; 
NotI 
none 
 
Full length plasmid Origin/Cloning strategy 
pBS-HHRz-MVvac2-HdRz(sc) C. Pfaller 
pBS-HHRz-MVvac2-ATU-MCS-HdRz(sc) C. Pfaller 
pBS-HHRz-MVvac2-VKO-ATU-MCS- 
HdRz(sc) 
Site directed mutagenesis of the editing site 
within the P gene (Schneider et al., 1997) within 
the helper plasmid pSK-NotI-ATU-SacII. Used 
primers: 124 + 125. Insertion into pBS-HHRz-
MVvac2-ATU-MCS-HdRz(sc) with NotI + SacII. 
pBS-HHRz-MVvac2-VKO-ATU-MCS-
VdCdW- HdRz(sc) 
Insertion of the V ORF with mutated editing site 
and mutation in the start codon of the C ORF into 
pBS-HHRz-MVvac2-VKO-ATU-MCS-HdRz(sc) using 
primers CP 201, CP 50 and restriction enzymes 
SnaBI and NotI. 
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2.1.10 Viruses 
Virus Description 
MVvac2  
Recombinant measles virus generated from the full-length cDNA 
plasmid pBS-HHRz-MVvac2-HdRz(sc). The virus has equivalent 
nucleotide sequence to Moraten and Schwartz vaccine strains 
(GeneBank accession numbers AF266287 and AF266291) (del Valle et 
al., 2007). The Moraten and Schwartz vaccines share an identical 
sequence in spite of a nominally different origin.  
MVvac2 MCS 
The full length cDNA plasmid pBS-HHRz-MVvac2-ATU-MCS-HdRz(sc) 
was used for rescue of the recombinant measles virus. It is a 
derivative of MVvac2 generated by insertion of a multiple cloning site 
between the P and the M gene flanked by the 5‘-UTR and the 3’-UTR 
of the P gene. 
MVvac2 VKO MCS 
Recombinant measles virus generated from the full length plasmid 
pBS-HHRz-MVvac2-VKO-ATU-MCS-HdRz(sc). The virus is a derivative 
of MVvac2 MCS generated by a point mutation within the V editing 
site to destroy V mRNA production (Radecke and Billeter, 1997; 
Schneider et al., 1997). The introduced point mutation is silent for 
the P and C protein.  
MVvac2 VKO MCS V 
The full length cDNA plasmid pBS-HHRz-MVvac2-VKO-ATU-MCS-
VdCdW-HdRz(sc) was used for rescue of the recombinant measles 
virus. It was generated by insertion of the V ORF with mutated 
editing site into the MCS of pBS-HHRz-MVvac2-ATU-MCS-VKO-
HdRz(sc). Thus the expression of the V protein is restored in the 
recombinant virus MVvac2 VKO MCS V. 
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2.1.11 Equipment 
Instrument Manufacturer 
Agarose vertical gel electrophoresis apparatus Peqlab 
Bacteria culture incubator ISF-1-W Kühner 
Centrifuges: 
Centrifuge 5417C  
Centrifuge 5804R  
Centrifuge Evolution RC 
Biofuge pico 
Varifuge 3.0R 
 
Eppendorf 
Eppendorf 
Sorvall 
Heraeus 
Heraeus 
Cell culture incubator Sanyo 
Chemiluminescence developing system Fusion FX7 Vilber-Lourmat 
Gel Doc system BioRAD 
Freezers: 
-20°C 
-80°C Il Shin 
 
Liebherr 
Nunc 
Laminar Flow Sterileguard ClassII TypeA/B3 Baker Company 
LightCycler 2.0 Roche 
Luminometer Centro LB 960 Berthold 
Magnetic stirrer/heater VELP Scientifica 
Mixer 5432 Eppendorf 
Microscopes: 
Laser scanning microscope LSM 510 Meta 
Light microscope TMS 
UV-Light microscope IX71 
 
Carl Zeiss 
Nikon 
Olympus 
Neubauer improved cell-counting chamber Marienfeld 
PH-meter  VWR International 
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PIPETBOY acu IBS 
Pipettes (2/2,5/10/20/200/1000µl) Eppendorf; Gilson 
Polyacrylamid gel electrophoresis system  Peqlab 
Power supply Power Pack P25 Biometra 
Roller mixer SRT2 Stuart 
Semi-Dry blotting system  Peqlab 
Shaker Swip SM25 Edmund Bühler 
Spectrophotometer Nanodrop ND-1000 Peqlab 
Thermocycler T3 Biometra 
Thermomixer 5436 Eppendorf 
Thermostated hot-block 5320 Eppendorf 
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2.2 Methods 
2.2.1 Molecular biological methods 
Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) allows the cyclic enzymatic amplification of 
defined DNA fragments in vitro. Short oligonucleotide-fragments, which anneal to the 
complementary strains of the DNA template in an inverse orientation, determine the 
ends of the amplified DNA fragment. In the presence of dNTPs thermostable DNA 
polymerases extend these forward- and reverse-primers along the denaturated single 
stranded DNA generating a complementary DNA strand.  
Standard PCR 
Phusion DNA polymerase was used for standard PCR. The man-made chimera is 
composed of a unique dsDNA-binding domain fused to a Pyrococcus-like proofreading 
polymerase. The 3’→5’ proof-reading capacity will excise mismatched 3’-terminal 
nucleotides from primer-template complexes and incorporate the correct. PCR 
reactions were set up according to the following standard protocol: 
Component Amount/Volume 
Template-DNA 10 ng 
Primer fwd (10 μM) 5 μl 
Primer rev (10 μM) 5 μl 
dNTPs (25 µM per NTP) 0.8 μl 
5x Buffer HF or GC 20 μl 
DMSO 3 μl 
Phusion polymerase (2U/µl) 1 μl 
ddH2O Ad 100 μl 
Material and Methods 44 
The following PCR program was applied: 
Step Temperature/Time Cycles 
Initial denaturation 98°C; 30 s 1 
Denaturation 98°C; 30 s 
30 Annealing 45-60°C; 30 s 
Elongation 72°C; 15 s/kb 
Extension 72°C; 10 min 1 
Storage 4°C; ∞ 1 
Correct size of PCR product was validated by agarose gel electrophoresis. For 
purification of PCR products the QIAquick PCR Purification Kit was used following the 
protocol of the manufacturer.  
Mutagenesis PCR 
Pfu DNA polymerase from the marine archaebacterium Pyrococcus furiosus was used 
for mutagenesis PCR. Pfu DNA polymerase possesses also a 3’→5’ proof-reading 
capacity. PCR reactions were set up according to the following standard protocol: 
Component Amount/Volume 
Template-DNA 10 ng 
Primer fwd (10 μM) 2.5 μl 
Primer rev (10 μM) 2.5 μl 
dNTPs (25 µM per NTP) 1 μl 
Pfu buffer with MgCl2 (10x) 10 μl 
Pfu polymerase (2.5 U/µl) 1 μl 
ddH2O Ad 100 μl 
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The following PCR program was applied:  
 
Step Temperature/Time Cycles 
Initial denaturation 95°C; 30 s 1 
Denaturation 95°C; 10 s 
25 Annealing 45-60°C; 30 s 
Elongation 68°C; 4 min/kb 
Extension 68°C; 30 min 1 
Storage 4°C; ∞ 1 
 
Correct size of PCR product was validated by agarose gel electrophoresis. 
Subsequently, DNA was digested with DpnI restriction enzyme for at least 3 hours at 
37 °C to remove all methylated template DNA (methylation generated during bacterial 
plasmid DNA amplification). 10 µl newly synthesized mutated plasmid DNA was 
directly transformed into bacteria for amplification. 
Enzymatic manipulation of DNA 
Digestion of DNA with restriction endonucleases  
For the sequence-specific cleavage of DNA molecules samples were incubated with 
restriction endonucleases in appropriate reaction conditions. The amount of enzyme 
and DNA, buffer, temperature and duration of the reaction were adjusted according to 
the manufacturer’s instructions. The digested DNA fragments were subjected to 
agarose gel electrophoresis for analysis or purification. 
Dephosphorylation of linearized vector DNA  
Restriction of vector DNA with a single enzyme may lead to subsequent re-ligation. 
Therefore, 5’-termini of vector DNA were dephosphorylated using calf intestinal 
phosphatase. The dephosphorylation was incubated for one hour at 37 °C. The 
linearized, dephosphorylated vectors were subjected to agarose gel electrophoresis for 
purification. 
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Ligation of DNA fragments  
For the ligation of linearized vectors with DNA-fragments the T4 DNA ligase was used. 
This enzyme catalyzes the formation of phosphodiester bonds between adjacent 3’-OH 
and 5’-phosphate ends in dsDNA. The ligation reaction was incubated overnight at 
16 °C. 
Component Volume 
Digested insert (PCR product) 10 µl 
Linearized vector 0.5 µl 
T4 DNA ligase 0.5 µl 
10 x T4 DNA ligase buffer 2 µl 
ddH2O ad 20 µl 
Agarose gel electrophoresis 
Double stranded DNA fragments can be separated according to their size on agarose 
gels. Agarose was added to 1 x TAE-buffer to obtain a final concentration between 
0.7 % (w/v) - 2.0 % (w/v). The agarose suspension was boiled in a microwave until it 
was completely solubilized. Prior to loading DNA samples were mixed with 20 % 
Orange G loading buffer. Additionally, a DNA molecular weight standard (PCR or 1 kb 
ladder) was loaded. For visualization of DNA by UV-light the running buffer contained 
0.075 % ethidium bromide in 1 x TAE buffer. The gel was run for 0.5-1 h with 120 V. 
DNA fragments were visualized under UV illumination (312 nm) in a Gel 
Documentation system (BioRad).  
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Extraction of DNA from agarose gels 
PCR products and linearized vectors for ligation were isolated from agarose gels and 
purified using the QIAquick Gel extraction kit (Qiagen). Full length vectors were 
purified using the QIAEX II Gel extraction kit (Qiagen). The DNA fragment was excised 
from the agarose gel with a clean, sharp scalpel. The DNA was extracted from the gel 
slice according to the manufacture’s protocol. DNA was eluted by adding 30 to 50 μl 
sterile H2O to the center of the membrane followed by centrifugation for 1 min. DNA 
was stored at -20 ºC before further use. 
Transformation of competent bacteria 
To transform XL-1 Blue competent bacteria with plasmid DNA using the heat shock 
method, 1 µg of DNA was added to 50 µl of bacteria preparation (thawed on ice), 
mixed and incubated on ice for 20 min. After a heat shock (42 °C, 2 min), the bacteria 
were cooled on ice for 5 min. 
Then 200 µl of LB++ were added and the bacterial suspension was incubated for 30 
min at 37°C with shaking at 800 rpm. Thereafter, 100 μl of the transformation mixture 
was plated on LB agar plates containing suitable antibiotics. Plates were incubated up-
side down at 37°C overnight to allow growth of transformants and isolate single 
colonies.  
Cultivation and storage of bacteria 
Single colonies were picked from the plates and cultured in small scale (mini 1 ml) or 
large scale (50 ml) at 37°C on a rotary shaker. Therefore, LB-medium, supplemented 
with either ampicillin (100 μg/ml) or kanamycin (30 μg/ml), was inoculated with cells 
of a single colony of transformed bacteria. For the long term strain storage 1-2 ml of a 
freshly saturated bacterial culture were centrifuged at 3000 g for 5 min. The 
supernatant was removed and the bacteria were resuspended in ¼ volume of 
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LB/ampicillin. To generate a glycerol stock ¼ volume of 87 % glycerol was added and 
the cell suspension was mixed. The mixture was stored at -80°C.  
Plasmid preparation on analytical scale (Miniprep) 
Bacteria were harvested by centrifugation (30 sec, 14,000 rpm). The bacteria pellet 
was resuspended in 200 µl Flexi I (5 min, shaking). After lysis by addition of an equal 
amount of Flexi II and incubation for 5 min, the preparation was neutralized with 
200 µl Flexi III, and chilled on ice for 5 min. The precipitate was removed by 
centrifugation for 10 min at 14000 rpm and the supernatant was transferred to a new 
reaction tube, which contained 400 μl of isopropanol. The precipitated DNA was 
pelleted by centrifugation (14,000 rpm, 4 °C, 10 min), dried at room temperature and 
solubilized in 50 µl of H2O. To validate ligation of the correct insert, a control digest of 
1 μg DNA was carried out using the appropriate restriction enzymes and subjected to 
agarose gel electrophoresis. 
Plasmid preparation on preparative scale (Midiprep) 
Large scale plasmid preparations were carried out using the Nucleobond PC 100 kit or 
the Nucleobond Xtra Midi kit (Macherey-Nagel) as described by the manufacturer’s 
protocol. DNA concentrations were determined using the Nanodrop 1000 and DNAs 
were stored at -20 °C. Plasmid DNA sequencing was carried out by GATC biotech. 
Requested concentrations are 30-100 ng/µl plasmid DNA and 10 pmol/µl sequencing 
primer, both in 20 μl volume. Software of DNAMAN 6.0 and Chromas 1.45 was applied 
to analyze acquired sequences. 
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RNA isolation and reverse transcription (RT) PCR 
 RNA from mammalian cells was isolated using the RNeasy Mini Kit (QIAGEN) according 
to the manufacturer’s instructions. RNA concentration was determined on a Nanodrop 
1000 (Peqlab), and RNAs were stored at -86 °C. Purified RNA was treated with DNaseI 
(Fermentas) for 45 min at 37 °C according to the supplier’s protocol, to remove 
contamination with genomic DNA. Reverse transcription reactions were set up using 
Transcriptor Reverse Transcriptase (Roche) and Oligo-dT primers (Invitrogen). For RT 
PCR the following mix was prepared: 
Component Amount/Volume 
RNA 1 µg 
Oligo-dT (100 ng/µl) 0.5 µl 
ddH2O ad 7.1 µl 
 
The mix was heated to 65°C for 10 min and subsequently chilled on ice for 5 min 
before adding: 
Component Amount/Volume 
RT-Buffer 2 µl 
SUPERase-In 0.25 µl 
dNTP mix (25 µM per NTP)  0.4 µl 
 
The final RT reaction was heated for 30 min to 55°C, followed by 85°C for 5 min. The 
cDNA was stored at -20°C. For DNA-visualization, agarose gel electrophoresis was 
carried out. For quantitative analyses of a certain gene, qRT-PCR was undertaken. 
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Quantitative real-time RT-PCR 
For quantitative analyses of cellular mRNA levels after transfection or infection, the 
total RNA was isolated 24 h p.t./p.i. and reverse transcribed to single strand cDNA. 
Samples were diluted 1:5 and as reference a standard curve was generated by a 10-
fold dilution series of one cDNA sample (5 dilutions 1:1, 1:10, 1:100, 1:1,000, 
1:10,000). The dilutions were set to relative values for quantification of the samples. A 
master mix was prepared containing specific primers and SYBR Green, a cyanine dye 
which preferentially binds to newly transcribed dsDNA. To normalize the results, the 
same samples were subjected to qRT-PCR with primers for a (steady) housekeeping 
gene. The standards, the cDNA 1:5, and a no template sample (negative control) were 
distributed to LightCycler capillaries and placed into a rotor. 
For qRT-PCR a 20 µl PCR-mix was prepared: 
Component Amount/Volume 
cDNA 1 µl 
Primer 1 1 µl 
Primer 2 1 µl 
SYBR Green Master Mix 10 µl 
ddH20 ad 20 µl 
 
The qRT-PCR-program was comprised of the following steps: 
Temperature Time Cycles 
95°C 15 s 1 
94°C 15 s 
55 Annealing T 20 s 
72°C 10 s 
 
The melting curve was generated using following conditions: 
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Temperature Time 
95°C 10 s 
40°C 20 s 
to 95°C 0.1 °C/s 
40°C 30 s 
 
The LightCycler software 4.0 was used to obtain a relative quantification, and values of 
single samples were calculated from the standard curve. Finally, target gene mRNA 
values were normalized against GAPDH. All qRT-PCR assays were carried out in 
duplicates (standard deviations depicted as error bars). For Western blot analysis, 
additional wells were transfected with the same mixture used for transfection of cells 
later subjected to real-time PCR analysis. These cells were lysed directly in SDS sample 
buffer. 
2.2.2 Cell biological methods 
Cell culture 
Cells were grown in cell culture flasks (T25, T75, T175) with Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10 % (v/v) Fetal Calf Serum (FCS), 2 mM L-
Glutamine, 40 U/ml penicillin and 40 µg/ml streptomycin. All media and 
supplementary products were purchased from Gibco. In the case of 293-3-46 cells and 
Vero-hSLAM cells 2 mg/ml G418 (Calbiochem) was added to the medium on alternate 
passages. All used cell lines were cultured at 37 °C in an atmosphere with a relative 
humidity of 90 % and a CO2 content of 5 %. Twice a week, cells were suspended by 
trypsinization and split in ratio 1/6 to 1/10 into fresh cell culture flaks. 
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Thawing and freezing of eukaryotic cells 
Cells were harvested and resuspended in freezing medium containing 92 % (v/v) 
DMEM 3+ and 8 % (v/v) DMSO. 1 ml cell suspension was transferred into a cryo-tube 
and immediately stored at -80 °C (liquid nitrogen (-160 °C) for long term storage). Cells 
were thawed rapidly at 37 °C and immediately transferred into 10 ml culture medium 
to dilute the DMSO. Afterwards cells were centrifuged, resuspended with fresh culture 
medium and transferred to a tissue culture dish.  
Transfection 
One day prior transfection cells were seeded such that they would be at 50 - 60 % 
confluence at the time of transfection. Cells were transfected with appropriate 
transfection reagents. For transfection of less than two plasmids, polyethyleneimine 
(PEI) solution (1 mg/ml) was used. PEI was pre-incubated in DMEM w/o additives for 5 
min, subsequently mixed with the DNA (2.5 µl PEI/µg DNA) for 20 min and added to 
the cells. For transfection of more than two plasmids, Lipofectamine2000 (2.5 µl 
Lipofectamine/µg DNA) was used. It was pre-incubated with DMEM w/o additives for 5 
min. Plasmids DNA was diluted in DMEM w/o additives and combined with diluted 
Lipofectamine/DMEM mix. Following incubation of 20 min, the solution was added to 
the cells. For virus rescue, 293-3-46 cells were transfected with calcium phosphate 
using the ProFection Mammalian Transfection System according to the 
manufacture’s protocol. 
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2.2.3 Biochemical and protein biochemical methods  
SDS polyacrylamide gel electrophoresis (SDS-PAGE)  
For analysis of endogenous protein expression or protein overexpression after 
transfection or infection, cells were lysed with an appropriate amount of SDS- 
containing protein lysis buffer. Subsequently, lysates were boiled (5 min, 95 °C) to 
denature the proteins. SDS surrounds the protein with a negative charge and the ß-
mercaptoethanol prevents the reformation of disulfide bonds. The analytical 
separation of proteins was accomplished by discontinuous SDS-PAGE. Migration of the 
SDS-protein complexes through polyacrylamide gels in an electric field largely depends 
on their molecular mass. For electrophoresis 10 % polyacrylamide separating gels and 
4 % polyacrylamide stacking gels were prepared. Proteins were electrophoretically 
separated at a constant voltage of 40 V overnight. To estimate apparent molecular 
weights of analyzed proteins an appropriate molecular weight marker was loaded next 
to the denatured proteins onto the gels. Jagow anode and cathode buffer were used as 
running buffers (see appendix for gels and buffers). Subsequent to SDS-PAGE, the 
polyacrylamide gel was subjected to Western Blotting.  
Western blot analysis and immunodetection  
For immunoblot analysis, proteins separated by SDS-PAGE were electrophoretically 
transferred onto a PVDF membrane using a semi-dry blotting device (Peqlab). 
Therefore the stacking gel was removed and the separating gel was rinsed by 
submerging it briefly in semi dry buffer for 10 min. PVDF membranes were activated in 
100% methanol, and rinsed in semi dry buffer. The gel was then placed face-to-face 
with the membrane, sandwiched by Whatman paper (all soaked in semi-dry buffer) 
and electroblotted for 2 h at 400 mA/gel. After electroblotting the transferred proteins 
are bound to the membrane providing access for the detection by specific antibodies. 
To avoid unspecific binding the membrane was incubated in blocking solution (5 % 
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(w/v) non-fat dried milk in PBS at room temperature for 1 h or at 4 °C overnight on a 
shaker. The membrane was briefly washed three times with PBS-T. For specific 
detection of proteins the membrane was incubated with primary antibody solution for 
at least 1 h on a shaker. Alternatively, the membrane was incubated at 4°C overnight. 
After washing three times with PBS-T the membrane was incubated with an HRP-
conjugated α-immunoglobulin secondary antibody for 2 h on a shaker. Finally, the 
membrane was washed three times with PBS-T for 10 min. For developing the 
Western-Blot, the detection kit ECL reagent (PerkinElmer Life Sciences) was used 
according to the manufactor’s protocol. Membranes were directly subjected to Vilber 
Lourmat Fusion FX7 to visualize protein bands due to Chemiluminescence. 
Immunoprecipitation (IP)  
In order to identify protein interaction partners, Co-IP was applied. HEK-293T cells 
were seeded in a 6 cm dish and transfected with cDNAs coding for potential 
interaction partners. One day after transfection the cells were detached from the dish 
by 1 ml PBS + 5 mM EDTA. The cell suspension was centrifuged (5 min, 4 °C, 2,500 rpm) 
and the pellet was lysed (1 h, 4 °C) with 500 µl Co-IP buffer containing a protease 
inhibitor. Afterwards the lysates were cleared (10 min, 4 °C, 14,000 rpm) and 
transferred to a new tube. 50 µl of the supernatant was mixed with 50 µl protein lysis 
buffer as a control (input) for controlling the amount of total protein expression (10 
%). For precipitation of proteins the remaining supernatant (90 %) was incubated with 
a specific matrix (Flag, HA, or Sepharose A). 
Incubation with Flag-matrix and precipitation 
The remaining 450 µl of the cleared lysates were incubated with 100 μl anti-Flag M2-
Agarose at 4°C on a rotator overnight. This matrix is composed of agarose beads that 
are covalently linked to anti-Flag-antibody, thus capturing Flag-tagged proteins. In case 
the Flag-tagged protein interacts with another protein in the cell lysate, the whole 
complex stays captured to the matrix. The matrix was washed three times with 500 µl 
Co-IP buffer (10 min, 4 °C and subsequent centrifugation 2 min, 4 °C, 14,000 rpm) to 
remove unspecifically adsorbed proteins and subsequently heated in 100 µl protein 
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lysis buffer at 95°C for 5 min. Purified proteins were detected by SDS-PAGE and 
Western blotting.  
Incubation with Sepharose A-matrix and precipitation 
Besides using the Flag-matrix it is possible to precipitate proteins with Protein A-
Sepharose. Protein A, which is covalently conjugated to sepharose, specifically binds to 
the Ig-part of antibodies. It was used for the immunoprecipitation of Ig-tagged 
proteins. For preparation of Sepharose A, it was washed twice with buffer A (1.5 g 
Sepharose A/50 ml buffer) (30 min, 4 °C and centrifugation 2 min, 4 °C, 2,000 rpm) on a 
roller mixer. After a further centrifugation step, buffer A was removed and the beads 
incubated with 50 ml of buffer B (30 min, 4 °C). Afterwards, beads were centrifuged (2 
min, 4 °C, 3,500 rpm), reconstituted in 7.5 ml buffer B and aliquots of 1 ml stored at 4 
°C. Prior usage, the beads were washed three times with 500 µl Co-IP buffer. For 
precipitation of proteins, the cleared cell lysates (90 %) were incubated with 100 µl 
SepharoseA-matrix (o/n, 4 °C) and washed three times with 500 µl Co-IP buffer (10 
min, 4 °C and subsequent centrifugation 2 min, 4 °C, 14,000 rpm). 100 µl protein lysis 
buffer was added to the matrix. Purified proteins were detected by SDS-PAGE and 
Western blotting. 
Incubation with HA matrix and precipitation 
The cleared cell lysates containing proteins with an HA-tag were purified using 50 µl of 
an anti-HA affinity matrix, which consists of a rat monoclonal antibody against the HA-
tag coupled to agarose beads. After overnight incubation the beads were washed as 
described before and subsequently 100µl protein lysis buffer were added to remove 
the proteins from the beads. Afterwards, the lysis buffer was subjected to SDS-PAGE 
and Western Blotting. 
Immunofluorescence microscopy 
HEp2 cells were seeded on coverslips in 24-wells. After 24 h cells were transfected 
with 500 ng of plasmids using Lipofectamine 2000 transfection reagent, incubated for 
additional 24 h and then treated with 10 ng/ml TNFα. Cells were fixed after 30 min in 
3% paraformaldehyde for 20 min at room temperature and were permeabilized in 
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0.5% Triton X-100 in phosphate-buffered saline (PBS). After blocking with 2,5% milk in 
0,1% Triton X-100/PBS, fixed cells were incubated with primary antibodies, α-p65 
(rabbit; sc-109; Santa Cruz) diluted 1:50 and α-flag (mouse; Sigma) diluted 1:200 in 
0,1% Triton X-100/PBS for 1 h at 4°C, followed by incubation with fluorescence-labeled 
secondary antibodies (goat α-rabbit Alexa Fluor 488 and α-mouse 
tetramethylrhodamine, both from Molecular Probes) at a dilution of 1:200 in 0,1% 
Triton X-100/PBS for 1 h at 4°C. Nuclear chromatin was stained by adding TO-PRO-3-
iodide (Molecular Probes, 1:1000) to the secondary antibodies. Confocal laser scanning 
microscopy was performed with a Zeiss LSM510 Meta laser system using a Zeiss 
Axiovert 200 microscope. Excitation of Alexa Fluor 488, tetramethylrhodamine, and 
TO-PRO-3-iodide occurred at wavelengths of 488 nm, 543 nm, and 633 nm, 
respectively.  
Luciferase assay 
To examine NF-κB activity, the dual luciferase reporter system was applied. Therefore 
HEK-293T cells were seeded into 24-well plates one day prior to transfection. A 
plasmid for NF-κB-dependent firefly luciferase p55A2-luc (100 ng), a vector for CMV 
promoter controlled Renilla luciferase pRL-CMV (10 ng) and the indicated amounts of 
expression vectors were transfected using Lipofectamine 2000 transfection reagent 
(Invitrogen). The total amount of DNA was kept constant by supplementation with 
pCR3. In case of stimulation cells were treated with 10ng/ml TNFα. Cells were 
harvested in 200 µl passive lysis buffer (Promega) at the indicated time points and 
luciferase activities were determined from 20 µl of the lysates using Dual Luciferase 
Reporter Assay System (Promega) and the Berthold Lumat LB 9501 luminometer 
according to the manufacturer’s instruction. Firefly luciferase activities were 
normalized to Renilla luciferase activities, and mean values of mock-treated cells were 
set to 1. The mean and the standard deviation were calculated out of two 
measurements. For Western blotting, reporter assay lysates were mixed 1:1 with 
protein lysis buffer. 
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2.2.4 Virological methods 
Generation of recombinant MV from cDNA (virus rescue) 
In order to reconstitute infectious virus from cloned cDNA, 293-3-46 cells were 
detached with Versene/Trypsin-EDTA (5:1) and seeded in 6-well plates. 10 µg of the 
plasmid coding for the full length MV antigenome together with the helper plasmid 
pEMC-MV L (20 ng) were transfected using the CaPO4 ProFection Mammalian 
Transfection System from Promega according to the manufacturer’s instructions. After 
incubation for 6 h under standard conditions the transfected cells were washed twice 
with DMEM 3+ and grown in 2 ml DMEM 3+ at 37 °C over night. On the next morning 
the cells were heat shocked for 3 h at 42 °C. Afterwards the cells were incubated under 
standard conditions for 24 h. In the meantime Vero-hSLAM cells were seeded in 
100 mm dishes. On the next day transfected 293-3-46 cells were taken up together 
with the medium, dropped onto the Vero-hSLAM cells and incubated at 37 °C until 
syncytia are formed. Each syncytium is picked under sterile conditions, transferred to 
Vero-hSLAM cells seeded on a 6-well plate and incubated at 32 °C. As soon as the all 
cells are infected the 6-well plate is frozen at -20 °C. After thawing, the cell debris was 
removed by low speed centrifugation (1800 rpm, 4 °C, 10 min) and the supernatants 
were aliquoted and frozen to -80 °C. Afterwards supernatants of positive rescues were 
titrated and used for stock production. 
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Virus titration 
For virus titration, Vero cells were seeded into 96-well plates. Virus stock was thawed 
and a 10-fold dilution series was prepared (7 x 450 μl DMEM + 50 μl virus/virus 
dilution). 2 hours after seeding of the cells they were infected with 100 μl of the virus 
dilution (in duplicates). 48 hours p.i., cells were fixed with acetone 80 % and stained 
with an antibody coupled to FITC against the MV N protein. Foci were counted from 
each well using a fluorescence microscope, and foci forming units per ml (ffu/ml) were 
calculated from these results.  
Generation of virus stocks 
For virus stock production, 5x106 Vero cells were infected in suspension with an MOI 
0.01. Cells were resuspended every 10 min. 1 h p.i., infected cells were seeded in T75 
flask, grown at 32 °C and 72 h post infection (p.i.) flasks were frozen at -20 °C. After 
thawing, cell debris was removed by low speed centrifugation (1,800 rpm, 4 °C, 5 min) 
and aliquots of the cleared supernatant were stored at -80 °C. To determine the 
infectious titers of the virus stocks, supernatants were titrated. 
Virus growth curve 
To analyze growth kinetics of distinct viruses, growth curves were prepared. Therefore, 
Vero or A549 cells were infected in suspension at an MOI 0.01. Every 10 min the 
infected cells were resuspended. 1 h p.i., infected cells were washed once with DMEM 
3+ and seeded into 6-well plates (1 well/virus/timepoint). 6 h p.i. the first 6-well plate 
was frozen. At 24 h, 48 h, 72 h, and 96 h p.i., further 6-well plates were frozen. 
Afterward, 6-well plates are thawed again, centrifuged at 1800 rpm for 10 min at 4 °C 
to remove cell debris and supernatants were titrated to determine the infectious titers 
at the given time points. 
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3 Results 
3.1 Measles virus P gene products suppress NF-κB activation 
upon TNFR stimulation  
Proteins expressed from the P gene of MV (P, V, and C) were shown to counteract 
multiple host innate immune pathways, including IRF3/7 and JAK/STAT signal 
transduction, whereas interference of the proteins with NF-κB signaling is only poorly 
investigated. Therefore, I wanted to determine whether they also influence NF-κB 
activity.  
The canonical NF-κB signaling pathway can be activated by various stimuli including 
tumor necrosis factor α (TNFα), a cytokine regulating immune functions as well as 
inflammatory responses (Ghosh and Karin, 2002). 
In a first step, the effect of MV P gene derived proteins on NF-κB activation in response 
to TNFα stimulation was investigated. To analyze NF-κB activity I used an NF-κB-
dependent dual luciferase assay based on two independent vectors. The plasmid for 
NF-κB-dependent expression (p55A2-luc) contains a firefly luciferase reporter gene 
under control of a trimeric repeat of the NF-κB-binding motif (PRDII) in the context of 
the IFNβ-promoter (Yoneyama et al., 1996). The plasmid pRL-CMV is composed of a 
renilla gene driven by a CMV promoter and used for normalization of transfection 
efficiency. 
The reporter plasmids were cotransfected in HEK-293T cells together with increasing 
amounts of expression vectors for MV P, V or C of the Schwarz strain. The start codon 
of the C protein was changed by site directed silent mutagenesis to prevent expression 
of MV C, in case of all P or V expressing plasmids, as described previously (Pfaller and 
Conzelmann, 2008). The P protein of rabies virus (RV-P), which suppresses activation of 
IRF-3 and STAT1/STAT2 nuclear import but has no influence on NF-κB signaling, was 
used as a negative control (Brzózka et al., 2005; Brzózka et al., 2006). Cells were 
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stimulated with 10 ng/ml TNFα 18 h post transfection and 6 h prior to cell lysis and 
NF-κB dependent luciferase activity was determined.  
 
Figure 3-1 Measles virus P gene products suppress NF-κB activation upon TNFR stimulation 
Increasing amounts (200 ng, 400 ng, 600 ng) of expression plasmids encoding for MV P, V, C, RV P or empty vector 
(EV) were transfected into HEK-293T cells with the NF-κB dependent reporter plasmid p55A2-luc and pRL-CMV for 
normalization. After 18 h cells were stimulated with 10 ng/ml recombinant human TNFα. NF-κB driven luciferase 
activity was determined 6 h post stimulation by a dual luciferase assay. The bars represent the means and the error 
bars the standard deviation of two independent experiments. Depicted is a representative experiment out of four 
repeats. Western Blot of cell lysates were probed with α-MV P/V, α-MV C or α-RV P antibodies by Western Blotting 
to determine the expression levels. Adapted from (Schuhmann et al., 2011). 
All three P gene products MV P, V and C had a considerable and dose-dependent 
inhibitory effect on TNFα-mediated NF-κB activation (Fig. 3-1). The V protein showed 
the strongest suppression, while the inhibitory capacity of MV P and C was less 
prominent. In contrast, RV P exhibited no NF-κB suppressive potential. 
These results indicate that MV P, V and C interfere with TNFα mediated NF-κB 
activation, but to a different extent.  
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3.2 NF-κB signaling via PRRs can be suppressed by MV P gene 
products 
Triggering of PRRs, like RLRs or TLRs also lead to activation of NF-κB. To test the ability 
of MV P gene products to interfere with RIG-I mediated NF-κB activation the C-
terminal deletion mutant ΔRIG-I (aa 1-284) that was shown to constitutively activate 
NF-κB (Yoneyama et al., 2004) was used. Dual luciferase reporter gene assays were 
performed in HEK-293T cells expressing ΔRIG-I as well as increasing amounts of MV P, 
V, C or RV P as control. Expression of the ΔRIG-I mutant alone led to more than 40 fold 
induction of NF-κB activity (Fig. 3-2A).  
 
Figure 3-2 NF-κB signaling via PRRs can be suppressed by MV P gene products 
Increasing amounts ( 200 ng, 400 ng , 600 ng) of vectors encoding for the indicated MV proteins were transfected 
into HEK-293T cells with either 200 ng of expression plasmids for ΔRIG-I (A), IPS-1(B), MyD88 (C), or TRIF (D) and the 
NF-κB dependent reporter system (100 ng p55A2/ 10 ng pRL-CMV). After 24 h cells were lysed and NF-κB activity 
was determined by a dual luciferase assay. The depicted values are means of two independent experiments and 
their standard deviation is displayed by error bars. Depicted are representative experiments out of three repeats. 
Lower panel: Expression of the viral proteins was assessed by Western blotting. Adapted from (Schuhmann et al., 
2011). 
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In the presence of MV V at the highest dose, activity was suppressed to nearly basal 
level. MV P had a less pronounced inhibitory effect even though it was expressed at 
much higher levels, as indicated by Western blotting using an antibody recognizing 
both MV P and V (Fig 3.2A, bottom panel). The MV C protein had intermediate 
suppressive capacity, while RV P had no significant influence on NF-κB activation. 
Signaling of the PRRs RIG-I and MDA5 is transmitted via the adaptor molecule IPS-1, 
while signal transduction of TLRs involves the adaptors MyD88 (TLR1, -2, -4, -5, -6, -7, -
8, -9) or TRIF (TLR3) (Kawai and Akira, 2009). To address the question whether MV P, V, 
and C are able to generally counteract NF-κB activation by RLRs and TLRs dual 
luciferase reporter gene assays were performed using overexpression of IPS-
1(Fig. 3-2B), MyD88 (Fig. 3-2C), or TRIF (Fig. 3-2D) for stimulation of NF-κB activity. 
Analogous with the previous experiments all MV P gene derived proteins were able to 
suppress the adaptor induced NF-κB activation, whereas expression of RV P had no 
effect (Fig. 3-2A). The level of reduction of NF-κB activity achieved by MV P and V 
appeared to be similar in these experiments; however, Western blotting revealed 
lower expression levels of MV V confirming the previous finding that the V protein is 
the most potent inhibitor of canonical NF-κB activity among the MV P gene products.  
3.3 MV V inhibits NF-κB signaling downstream of the IKK 
complex 
The previous experiments revealed that the MV P gene products suppress multiple 
pathways that lead to activation of the canonical NF-κB signaling cascade, including 
TNFR-, RLR- and TLR-signaling. All these canonical NF-κB signaling pathways converge 
on the IKK complex that is composed of the kinases IKKα, IKKβ and IKKγ (NEMO). In 
order to test whether the inhibition by MV P, V or C occurs at or downstream of these 
kinases, NF-κB-dependent luciferase expression was activated by overexpressing IKKα, 
IKKβ and IKKγ in HEK-293T cells. As positive control, the Ig-tagged NEMO-binding 
domain (NBD) was used (Ig-NBD). The NBD peptide binds to IKKγ and inhibits the 
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formation of the IKK complex which is essential for canonical NF-κB activation (May et 
al., 2000). Expression of Ig-NBD resulted in a dose dependent inhibition of IKK 
complex-induced activity, while the Ig-tag alone as well as RV P did not interfere with 
the NF-κB activation (Fig. 3-3A). The presence of MV V led to a dose dependent and 
effective reduction of the IKK complex-induced NF-κB activation comparable to the 
inhibition achieved by expression of Ig-NBD. Expression of MV P and MV C had less 
pronounced effects on NF-κB activation by the IKK complex.  
 
Figure 3-3 MV V inhibits NF-κB signaling downstream of the IKK complex 
(A) HEK-293T cells were transfected with expression plasmids encoding for IKKα, IKKβ and IKKγ (100 ng each) 
together with increasing amounts (200 ng, 400 ng, 600 ng) of vectors coding for the indicated proteins or empty 
vector and the NF-κB dependent reporter system (100 ng p55A2/ 10 ng pRL-CMV). After 12 h the cells were lysed 
and the luciferase activity was measured by dual luciferase assay. The bars represent the means and the error bars 
the standard deviation of two independent experiments. A representative experiment out of three repeats is 
shown. (B) Plasmids encoding for p65 and p50 (150 ng each) and increasing amounts (300 ng, 600 ng) of vectors 
encoding the indicated proteins were transfected into HEK-293T cells with the dual luciferase reporter system. Cells 
were lysed 12 h after transfection followed by determination of normalized NF-κB dependent luciferase activity. The 
depicted values are means of two independent experiments and their standard deviation is displayed by error bars. 
Shown is a representative experiment out of three repeats. Adapted from (Schuhmann et al., 2011). 
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To further spot the step where MV V inhibits canonical NF-κB activation, we induced 
NF-κB dependent luciferase activity by coexpression of the NF-κB subunits p65 and p50 
which assemble to the main heterodimer of NF-κB. Expression of MV V reduced the 
NF-κB activity induced by p65/p50 significantly and dose-dependently, whereas MV P 
and C showed only minor inhibitory potential (Fig. 3-3B). As expected, presence of Ig-
NBD had no effect on p65/p50 mediated NF-κB activity, as this inhibitor acts upstream 
of the transcription factors. These experiments indicate that the V protein of MV 
inhibits canonical NF-κB signaling downstream of the IKK complex.  
3.4 MV V specifically binds the NF-κB subunit p65 
The NF-κB heterodimer p65/p50 is bound to its inhibitor IκBα in unstimulated cells. In 
order to elucidate the molecular mechanism of MV P gene products to suppress 
canonical NF-κB activation, we assessed the potential of the viral proteins to interact 
with NF-κB complex members p65, p50 and IκBα in co-immunoprecipitation (CoIP) 
experiments. Extracts from HEK-293T cells coexpressing Ig-tagged MV P, V, or C 
proteins and p65 from transfected plasmids were purified by protein A-conjugated 
sepharose beads. To exclude unspecific binding of p65 to the Ig-tag or the beads the 
plasmid expressing the Ig-tag alone was coexpressed with p65 as control. Precipitates 
were subjected to SDS-PAGE and analyzed by Western blotting using antibodies 
against p65 or human IgG. Immunoprecipitation of the Ig-tagged proteins was efficient 
(Fig. 3-4A; lower right panel). In fact, the NF-κB subunit p65 was specifically co-
precipitated with Ig-MV V, whereas no interaction of p65 with the Ig-tagged P or C 
constructs was detectable (Fig. 3-4A; upper right panel).  
In further experiments, binding of p50 (NF-κB1) to flag-tagged MV proteins was 
analyzed. Flag-p65 was included as positive control. Cell extracts were purified with 
α-flag M2 affinity gel, precipitates were subjected to SDS-PAGE and analyzed by 
immunoblotting using antibodies specific for p50 and the flag epitope. While flag-p65 
efficiently co-precipitated p50, no interactions of the p50 NF-κB subunit with any of 
the flag-MV proteins could be detected (Fig. 3-4B).  
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Figure 3-4 MV V specifically binds the NF-κB subunit p65 
(A) HEK-293T cells were used to express p65 in combination with the indicated Ig-tagged proteins or the Ig-tag (Ig) 
itself (3 µg each). After 24 h cells were lysed under native conditions and Ig-tagged proteins were pulled down using 
protein A conjugated sepharose beads. Binding of p65 to measles proteins was visualized by Western blotting. 
Depicted is a representative experiment out of four repeats. (B) p50 was coexpressed in HEK-293T cells with the 
indicated flag proteins or empty vector (EV) (3 µg each). Cells were lysed 24 h post transfection and flag-tagged 
measles proteins were immunoprecipitated using anti-flag M2 affinity gel. Interactions of p50 and flag-proteins 
were analyzed by Western blotting. A representative experiment out of three is shown. (C) HEK-293T cells were 
cotransfected with vectors encoding the indicated flag-tagged constructs or empty vector (EV). CoIP assay was 
performed as described above and the proteins were stained with the indicated antibodies. A representative 
experiment out of three is shown. Adapted from (Schuhmann et al., 2011). 
To test whether any of the MV P gene products can bind to IκBα, flag tagged MV P, V, 
and C were expressed in HEK-293T cells. Flag-p65 and flag-p50 were included as 
positive controls. Cell extracts were purified with α-flag M2 affinity gel and precipitates 
were analyzed by Western blotting using antibodies against the flag epitope or IκBα. 
None of the MV P gene products were able to co-purify endogenous IκBα, whereas 
flag-p65 as well as flag-p50 showed efficient pull down of IκBα (Fig. 3-4C). 
Taken together these results indicate that only MV V, but not MV P and C, binds to the 
NF-κB subunit p65. IκBα and p50, which are associated to p65 in non-stimulated cells, 
were found not to interact with any of the P gene products.  
WB: 
α-human PO
WB: α-p65 p65
Ig-MV V
Ig-MV C
Ig-MV P
Ig
Input 10% CoIP 90%
EV fl
ag
-M
V
 P
fl
ag
-M
V
 V
fl
ag
-M
V
 C
fl
ag
-p
65
WB: α-flag
WB: α-p50 p50
flag-MV V
flag-MV C
flag-MV P
flag-p65
Input 10% CoIP 90%
A B
p65 p65 p50 p50
flag-MV V
flag-MV C
flag-MV P
EV fl
ag
-M
V
 P
fl
ag
-M
V
 V
fl
ag
-M
V
C
fl
ag
-p
65
Ig Ig
-M
V
 P
Ig
-M
V
 V
Ig
-M
V
 C
Ig Ig
-M
V
 P
Ig
-M
V
 V
Ig
-M
V
 C
EV fl
ag
-M
V
P
fl
ag
-M
V
V
fl
ag
-M
V
 C
fl
ag
-p
50
Fl
ag
-p
65
C
Endogenous IκBα
IκBα
flag-p50
flag-p65
Input 10% CoIP 90%
WB: α-flag
WB: α-IκBα
EV fl
ag
-M
V
P
fl
ag
-M
V
V
fl
ag
-M
V
 C
fl
ag
-p
50
Fl
ag
-p
65
Endogenous IκBα
Results 66 
 
3.5 RHD of p65 is sufficient for interaction with MV V 
All NF-κB subunits comprise an N-terminal RHD, which is responsible for dimerization, 
DNA-binding, and nuclear import. To determine if MV V binds to the RHD of p65, a 
fragment of p65 spanning from aa 1-309 (p65 RHD) was constructed and Co-IP 
experiments with flag-MV P, V, C were performed in HEK-293T cells. α-flag M2 affinity 
gel was used to purify the extracts. Immunoblotting of the precipitates with an 
antibody specific for the N-terminus of p65 revealed that the p65 RHD was efficiently 
pulled down by flag-MV V (Fig. 3-5A). 
 
Figure 3-5 RHD of p65 is sufficient for interaction with MV V 
(A) HEK-293T cells were cotransfected with vectors encoding for the indicated flag-tagged constructs or empty 
vector (EV) and the RHD of p65 (aa 1-309). CoIP assays were performed as described above and RHD-p65 was 
stained using α-p65 (Cell Signaling; 3035). A representative experiment out of three is shown. (B) MV V was 
coexpressed with the indicated flag tagged proteins or empty vector (EV) (3µg each) in HEK-293T cells. CoIP 
experiments were performed as described above and MV V was stained using α-MV VCTD. Depicted is a 
representative experiment out of three repeats. Adapted from (Schuhmann et al., 2011). 
Notably, RHD p65 also showed some affinity to MV P, though considerably weaker 
than to MV V. A weak affinity of the MV P protein to bind p65 was also observed 
occasionally in pull down experiments with flag tagged p65 and authentic, untagged 
MV proteins (data not shown). Taken together, we observed that MV V binds with a 
strong affinity to the RHD of p65, while a weak interaction of MV P with the RHD of 
p65 was suggested. To further verify the specificity of MV V to the RHD of p65 
interaction of flag-tagged p65, RHD p65, p50 and RHD p50 to MV V were assessed 
within one experiment. Therefore, I constructed the RHD of p50 spanning from aa 1-
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366 and the other constructs with a flag tag. CoIP experiments of the flag tagged 
proteins with authentic, untagged MV V confirmed specific binding of V to flag-p65 and 
flag-RHD p65, while no interaction of V and flag-p50 or flag-RHD p50 could be detected 
(Fig. 3-5B). These findings confirm the specificity of MV V to the RHD of p65. 
3.6 Binding of MV V to p65 is mediated via both N- and C-
terminal domains of the RHD of p65 
The RHD of p65 can be further divided into the N-terminal domain (NTD) responsible 
for DNA binding and the C-terminal domain (CTD) that mediates dimerization, nuclear 
translocation and IκB binding (Zheng et al., 2011). Figure 3-6A shows the PDB structure 
1IKN of the mouse p65/p50/IκBα complex (Huxford et al., 1998). The structure was 
displayed and colored using the PyMOL software (version 0.99rc6). The NTD of p65 is 
displayed in red and the CTD in blue. Associated with the CTD is p50 (light green) and 
IκBα (yellow). 
To define the interaction site of p65 with MV V more precisely, the flag-tagged NTD 
(aa1-180) and CTD (aa181-309) fragments of p65 were constructed (Fig. 3-6A). 
p65-RHD-flag (aa1-309) was used as positive control. CoIP experiments were 
performed expressing the flag-tagged p65 fragments and MV V in HEK-293T cells. MV 
V coprecipitated in small amounts with flag-p65-NTD and with a higher extent with a 
p65-CTD-flag (Fig. 3-6B). The amount of MV V copurified with the entire p65 RHD-flag 
was even higher. However, coexpression of flag-p65-NTD and p65-CTD-flag resulted in 
an increased level of co-purified MV V even though the amounts of transfected 
plasmids encoding for the two p65 fragments were adjusted to the transfected 
amount of single plasmids. These findings suggest that MV V binds to the NTD as well 
as to the CTD of p65-RHD and that this binding is stabilized when both domains are 
coexpressed.  
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Figure 3-6 Binding of MV V to p65 is mediated via both the N- and the C-terminal domain of the RHD of p65 
(A) Crystal structure of mouse p65 in complex with mouse p50 and human IκBα (1IKN.pdb) visualized and colored 
using PyMOL software. The NTD of the RHD of p65 (residues 19-180) is depicted in red, the CTD (residues 181-304) 
in blue. The yellow structure resembles the ankyrin repeats of IκBα (residues 67-302) and p50 (residues 245-363) is 
shown in light green. HEK-293T cells were used to coexpress MV V (B) or p50 (C) and flag-p65-NTD (aa1-180), p65-
CTD-flag (aa 181-309) or p65 RHD-flag (aa1-309). CoIP assays were performed using anti-flag M2 affinity gel. The 
purified proteins were stained with the indicated antibodies. A representative experiment out of three is shown.  
To ensure that the CTD of p65 is functional when expressed separately we had a look 
on its ability to bind to p50 and IκBα using CoIP experiments. Therefore the flag-tagged 
p65 fragments were coexpressed with p50 in HEK-293T cells. Immunoprecipitation of 
the flag-tagged constructs and subsequent immunoblotting revealed that p50 
coprecipitated with comparable affinity with p65-CTD-flag alone and with coexpressed 
flag-p65-NTD/p65-CTD-flag, as well as with the complete p65-RHD-flag (Fig. 3-6C right, 
upper panel). However, binding efficiency of IκBα to p65-CTD-flag and coexpressed 
flag-p65-NTD/p65-CTD-flag was reduced compared to p65-RHD-flag (Fig. 3-6C right, 
middle panel). This indicates that p65-CTD-flag is functional in terms of p50 but not of 
IκBα binding. Nevertheless, the finding that MV V interacts with both domains of p65-
RHD is yet valid, since coexpression of both domains enhances the binding affinity of 
MV V.  
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3.7 Binding of MV V to p65 does not compete with binding of 
p50 or IκBα to p65 
As MV V was shown to bind to p65, but not to p50 or IκBα this raises the question if 
the interaction of V and p65 affects the composition of the NF-κB complex 
(p65/p50/IκBα). To investigate this issue I performed Co-IP experiments with flag-p65, 
p50, IκBα and MV V. Flag-p65 was immunoprecipitated using α-flag M2 affinity gel and 
co-purification of p50 or endogenous IκBα was assessed in the presence or the 
absence of MV V. Flag-p65 was able to pull down equivalent levels of p50 (Fig. 3-7; first 
right panel) and IκBα (Fig. 3-7; second right panel) matter if MV V was present or not. 
The level of co-purified MV V was also equal irrespective whether p50 was expressed 
or not (Fig. 3-7; third right panel). This indicates that binding of p50, IκBα and MV V to 
p65 are independent of each other and that binding of MV V to p65 does not influence 
the composition of the NF-κB complex. 
 
Figure 3-7 Binding of MV V to p65 does not compete with binding of p50 or IκBα to p65 
HEK-293T cells were used to express flag-p65 in combination with p50 and V or only with one of those together 
with empty vector EV (2 µg each). After 24 h cells were lysed under native conditions and flag-tagged proteins were 
pulled down using anti-flag M2 affinity gel. Binding of p50 or IκBα to flag-p65 in the presence of MV V was visualized 
by Western blotting using the indicated antibodies. Depicted is a representative experiment out of three repeats. 
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3.8 MV V prevents nuclear translocation of p65 
The MV V protein was shown to exhibit a cytoplasmic distribution (Wardrop and 
Briedis, 1991). Together with the finding that it interacts with the RHD of p65, which 
comprises the NLS of p65, the question rises whether binding of V to p65 might 
interfere with trafficking of this NF-κB subunit. In order to address this hypothesis, 
HEp2 cells were transfected with a flag-MV V encoding plasmid, or empty vector to 
perform immunofluorescence (IF) experiments (done by Christian Pfaller).  The cells 
were stimulated with 10ng/ml TNFα 30 min prior to fixation, followed by 
immunostaining of p65 and flag-tagged MV V. The subcellular distribution of the 
proteins was assessed using a laser scanning confocal microscope. 
 
Figure 3-8 MV V prevents nuclear translocation of p65 
HEp2 cells were transfected with a vector for flag-MV V or empty vector (EV) (500 ng each). 24 h post 
transfection cells were either treated with 10 ng/ml TNFα for 30 min (+) or left untreated (-). Subsequently, cells 
were fixed and stained using rabbit α-p65, mouse anti-Flag-M2 primary antibodies, and anti-rabbit Alexa 488 or α-
mouse tetramethylrhodamine  secondary antibodies, respectively. Images were acquired by confocal laser scanning 
microscopy and show representative sections. Green: p65 (stained with specific antibody); red: flag-MV V (stained 
with α-FLAG® M2); blue: ToPro3 nuclear staining; open arrow: not flag-MV V expressing cell; closed arrow: flag-MV 
V expressing cell. Depicted is a representative experiment out of three repeats. Adapted from (Schuhmann et al., 
2011). 
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In unstimulated cells transfected with empty vector, p65 is located predominantly in 
the cytoplasm (Fig. 3-8; upper panel), however TNFα treatment resulted in almost 
complete translocation of p65 from the cytoplasm to the nucleus (Fig. 3-8; middle 
panel). In contrast, accumulation of p65 in the nucleus upon TNFα stimulation in cells 
expressing flag-MV V was severely impaired (Fig. 3-8; lower panel; closed arrows), 
while cells failing to express detectable flag-MV V showed a normal nuclear 
accumulation of p65 (Fig. 3-8; lower panel; open arrows). This demonstrates that the 
presence of MV V in cells prevents the nuclear accumulation of the NF-κB-subunit p65 
and thereby precludes its transcriptional activity. 
3.9 Nuclear translocation of p65 upon TNFα treatment in the 
presence of MV P and C 
Even though MV P and C do not bind to p65 they inhibit canonical NF-κB activation. To 
test if they somehow interfere with the nuclear translocation of p65, IF studies with 
flag-tagged MV P gene products were accomplished. Therefore HEp2 cells were 
transfected with flag-MV V as positive control or flag-MV P, C, or empty vector. 30 min 
prior to fixation the cells were treated with TNFα and the proteins were 
immunostained with antibodies against p65 or the flag-epitope. The NF-κB subunit p65 
is located in the cytoplasm in unstimulated cells (Fig. 3-9A), but translocates to the 
nucleus upon TNFα treatment (Fig. 3-9B) in cells transfected with empty vector. In cells 
expressing flag-tagged MV V the TNFα-stimulated nuclear translocation of p65 was 
blocked, and p65 was retained in the cytoplasm (Fig. 3-9C) as observed before 
(Fig. 3-8). Flag MV P expressing cells showed p65 in the nucleus as well as in the 
cytoplasm suggesting a potential inhibition of p65 nuclear accumulation (Fig. 3-9D). In 
contrast to MV P and V, MV C is located in the nucleus and cells expressing flag-MV C 
showed no retention of p65 in the cytoplasm (Fig. 3-9E). To determine nuclear 
translocation of p65 more precisely, the nuclear localization of p65 was quantified 
(Fig. 3-9F). It was discriminated between cells expressing the appropriate MV protein 
(red bars) and those that failed to express (gray bars). The quantification revealed that 
nuclear localization of p65 upon TNFα treatment was only seen in 25% of flag-MV V 
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expressing cells, while 60% of cells expressing flag-MV P and nearly 80% of flag-MV C 
expressing cells showed p65 staining within the nucleus (Fig. 3-9F). In cells that failed 
to express MV proteins at least 80% show nuclear localization of p65 upon TNFα 
treatment. These findings suggest that MV P and V inhibit NF-κB activity upstream of 
the nuclear translocation of p65, whereas MV C probably acts in the nucleus. The 
difference in the degree of inhibition of MV P and V to inhibit p65 translocation was 
also reflected in the previous NF-κB-dependent reporter gene assays. 
 
Figure 3-9 Nuclear translocation of p65 upon TNFα treatment in the presence of MV P and C 
(A-E) Immunofluorescence in HEp-2 cells transfected with flag-tagged MV P, V, C or empty vector (EV) (500ng each). 
Cells were stimulated 24h p.t. by addition of 10 µl/well of TNFα (+) or not (-), and fixed 30 min later to perform 
immunofluorescence staining using rabbit α-p65, mouse anti-Flag-M2 primary antibodies, and anti-rabbit Alexa 488 
or α-mouse tetramethylrhodamine antibodies, respectively. Nuclei were stained with TO-PRO-3 iodide. Images 
were acquired by confocal laser scanning microscopy, and show representative sections. Flag staining is visualized in 
red, p65 staining in green, and TO-PRO-3 iodide staining in blue. (F) p65 nuclear translocation rate was quantified. 
Cells failed to express the transfected flag-construct were counted separately and termed non-expressing (gray 
bars). Cells which expressed the indicated flag-tagged measles protein were named expressing and are displayed as 
red bars. Values given are averages and standard-deviations of results from five independent images.  
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3.10  MV V does not directly bind to the NLS of p65 or interfere 
with importin α 5 binding to p65 
The nuclear import of p65 is mediated via members of the importin α family, namely 
importin α 3, 4, and 5 (Fagerlund et al., 2005; Fagerlund et al., 2008). To further clarify 
the underlying mechanism of MV V mediated inhibition of p65 nuclear translocation, 
the question whether MV V targets the NLS of p65 was assessed, and furthermore it 
was tested if MV V interferes with binding of importin α to p65.  
First of all the binding of p65 to importin α 3, 4, and 5 should be confirmed with our 
conditions. Therefore the HA-tagged importin α isoforms were expressed from 
transfected plasmids with flag-tagged p65 in HEK-293T cells. Extracts were purified 
using α-flag M2 affinity gel and precipitates were subjected to SDS-PAGE and analyzed 
by immunoblotting using antibodies specific for the HA- and the flag-epitope. As 
expected, all importin α subunits were copurified with flag-p65, however, importin α 5 
showed the strongest affinity (Fig. 3-10A).  
In order to check if MV V binds directly to the nuclear translocation signal (NLS) of p65 
two mutants of p65 were constructed. A deletion mutant (p65 1-300) lacking the NLS 
that is located at amino acid position 301 to 304, as well as a mutant with a mutated 
NLS (p65 NLS-) according to Fagerlund et al. (301AAA) (Fagerlund et al., 2005). Binding 
of flag-MV V to the mutants was assessed by CoIP experiments. As positive control full 
length p65 was included as well as the REL homology domain of p65 (p65 RHD), which 
comprises the NLS and spans aa 1 to 309. Immunoprecipitated flag-MV V displayed 
interaction with all p65 constructs even those lacking a functional NLS indicating that 
the binding of MV V to p65 is not directed to its NLS (Fig. 3-10B).  
Although MV V binds not directly to the NLS of p65, but to the RHD it might that MV V 
competes with importin α 5 for binding to p65. To test for competition in binding, the 
association of flag-p65 and HA-importin α 5 was challenged by the presence of MV V 
and vice versa in CoIP experiments against the flag-tag. Irrespective of the presence of 
MV V, HA-importin α 5 was bound to flag-p65. Furthermore, MV V co-precipitated with 
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Indeed, Ig-MV VCTD was sufficient for co-precipitation of p65 with a binding affinity 
comparable to that of full length Ig-MV V, while the other constructs did not reveal 
interaction with the NF-κB subunit (Fig. 3-11A). To clarify whether binding of the small 
VCTD is also sufficient for inhibition of NF-κB transcriptional activity, p65 and p50 were 
overexpressed in HEK-293T cells along with the Ig-tagged constructs and the reporter 
system. A similar and dose-dependent reduction of NF-κB-dependent luciferase 
expression confirmed that binding of VCTD is sufficient for inhibition (Fig. 3-11B). In 
contrast, expression of the C-terminal portion of the P protein had no considerable 
effect on p65/p50 mediated luciferase activity. In summary, the C-terminal domain of 
the V Protein is sufficient for p65 binding and inhibition of p65/p50 mediated NF-κB 
activity. 
3.12 Mutational analysis of MV V 
The CTD of MV V is a 68 aa long cysteine-rich domain (Fig. 3-12A, green marked). 
Seven cysteine residues form together with a histidine two zinc fingers that are named 
loop 1 and 2 (Fig. 3-12B) (Liston and Briedis, 1994). Homology modeling of the MV VCTD 
was accomplished using the crystal structure of PIV5 V (2B5L.pdb (Li et al., 2006)) 
(done by Johannes Söding, Gene Center). The resulting structure illustrates both zinc 
fingers that were colored using the PyMOL software. Loop 1 is displayed in orange, 
loop 2 in blue (Fig. 3-12C). 
In addition to binding to p65, the CTD of the V protein was shown to interact with a set 
of molecules important for the innate immune response, among them MDA5, STAT2 
and IRF7 (Goodbourn and Randall, 2009). In order to discriminate the different binding 
sites and functions located within the VCTD a subset of MV V mutants were generated 
and tested. It was already published that aa 233R and 235E are crucial for MDA5 
binding(Ramachandran and Horvath, 2010) and it was shown in our lab that a MV V 
mutant (MV VdIRF7) that has four amino acid exchanges to alanine in the loop2 region 
(259AAAA) failed to bind to IRF7 anymore (Pfaller, 2009). The MDA5 deficient mutants 
MV VdMDA5(1) (R233A) and MV VdMDA5(2) (E235A) were assessed together with MV VdIRF7 
and MV V for p65, IRF7 and MDA5 binding in CoIP experiments (Fig. 3-12D).  
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Figure 3-12 Mutational analysis of MV V 
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 (A) Amino acid sequence of the cyctein rich- C-terminal region of MV V (aa230- 299). The histidine and all cycteins 
residues are highlited by a blue box. (B) These residues coordinate two zinc ions building two zinc fingers.               
(C) Homology modeling of MVCTD was carried out with the crystal strucutre of PIV5 V as template and displayed 
with the PyMOL software. Loop1 is colored red, loop2 blue. Different MV V mutants were generated. The inserted 
mutations are displayed (A+B). (D + E) CoIP experiments with flag-p65, flag-IRF7, or flag-MDA5 and MV V mutants 
were performed as described above. Purified proteins were visualized with α-flag and α-MV VCTD antibodies. NF-κB 
dependent luciferase assays were performed as described above with ΔRIG-I (F) or MDA5 (G) as stimulus and 
different MV V mutants. (H) IFNβ promoter activity was measured in dual luciferase assays transfecting HEK-293T 
cells with p125-luc (100 ng) and pRL-CMV (10 ng) together with plasmids encoding for MDA5 and MV V mutants. 
IFNβ-promoter driven luciferase activity was determined 24h post transfection. The depicted values are means of 
two independent experiments and their standard deviation is displayed by error bars. Depicted is a representative 
experiment out of two repeats. 
 
Both MDA5 deficient mutants showed a reduced binding to flag-MDA5 while the 
binding affinity of the IRF7 deficient mutant to flag-MDA5 was similar to the affinity of 
parental MV V. The IRF7 deficient mutant as well as MV VdMDA5(1) exhibited reduced 
binding affinity to flag-IRF7, whereas binding of MV VdMDA5(2) was comparable to 
binding of MV V to flag-IRF7. In the CoIP assays with flag-p65, MV VdIRF7, and MV 
VdMDA5(2) showed reduced binding to the NF-κB subunit compared to MV V. However, 
none of the mutants completely failed to interact with the signaling molecules. To sum 
up, the binding sites of different signaling molecules within the MV VCTD cannot be 
clearly discriminated from each other. While for MDA5 binding only residues in loop1 
seem to be relevant, binding to p65 and IRF7 is affected by mutations within loop 1 
and 2, suggesting that binding of p65 and IRF7 to MV VCTD involves two independent 
sites located at loop 1 and 2. 
To search for mutants that completely lost their binding affinity to p65 three more 
mutants were generated. Therefore, either loop 1 (MV VΔloop1) or loop 2 (MV VΔloop2) 
was substituted to two glycine residues (Fig. 3-12A). In addition, a mutant 
(MV VdMDA5(1/2)) was cloned were both aa relevant for MDA5 binding were substituted 
to alanine (R233A, E235A). CoIP experiments with flag-p65 and the mutants displayed 
nearly no binding of all mutants to the NF-κB subunit (Fig. 3-12E), however, the CoIP 
efficiency was much lower than in Fig. 3-12D. Together with the results from the 
repeat experiments I would assume that the binding affinity of all mutants to p65 is 
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reduced but not completely lost, as already seen in Fig. 3-12D with exception of MV 
VdMDA5(1). Next, it was examined whether the reduced binding affinity to p65 of the 
mutants is also reflected in an extenuated capacity to inhibit NF-κB signaling. 
Therefore, NF-κB-dependent dual luciferase assays were performed using ΔRIG-I as 
stimulus and the different mutants (MV VΔloop1; MV VΔloop2; MV VdMDA5(1/2); MV VdIRF7) as 
inhibitor. Parental MV V was used as a reference. All mutants displayed an inhibitory 
capacity similar to that of MV V (Fig. 3-12F). In addition, inhibition of MDA5-dependent 
activation of either NF-κB (Fig. 3-12G) or IFNβ promoter (Fig. 3-12H) was tested in 
further reporter gene assays. To measure IFNβ promoter activity, a plasmid encoding 
for firefly luciferase under the control of the IFNβ promoter (p125-luc) was applied 
instead of the NF-κB reporter plasmid (Yoneyama et al., 1996). The capacities of the 
mutants to suppress NF-κB activation (Fig. 3-12G) or IFNβ-promoter activation 
(Fig. 3-12H) were quite similar. Solely, MV VdIRF7 inhibited IFNβ promoter activation 
more potent. However, these findings revealed that reduced binding to p65 was not 
sufficient to abrogate efficient inhibition of NF-κB activation. Thus, no mutants that are 
defective in the blockade of NF-κB signaling could be identified so far. Possibly, 
combinations of mutants involving the identified aa at loop 1 (R233A,E235A) and 2 
(259AAAA) would be necessary to lose MV V mediated inhibition of NF-κB activity. 
3.13 The V protein of the measles wild type isolate D5 inhibits 
NF-κB activity and binds to p65 
In the previous experiments I used MV proteins derived from the Schwarz strain 
(genotype A), a life attenuated vaccine obtained by multiple passaging on chicken 
embryo fibroblasts (Schwarz, 1962). To check if vaccine and wt measles V proteins 
differ in their ability to interfere with NF-κB activity, a wt strain obtained from the 
Robert Koch Institute in Berlin (genotype D5 – MVi/Berlin.DEU/04.08[D5]) was used to 
generate an expression plasmid coding for the V protein of wt MV. Sequencing and 
subsequent sequence alignment with the Schwarz V revealed that there are only 13 aa 
substitutions within the PVNTD and no mutation was found in the C-terminal domain 
(done by Christian Pfaller) (Fig. 3-13A). NF-κB-dependent luciferase assays in HEK-293T 
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cells illustrated that ΔRIG-I as well as p65/p50-mediated NF-κB activation was 
suppressed by both V proteins to the same degree (Fig. 3-13B and C). Furthermore, it 
was shown that binding to the NF-κB subunit p65 is also conserved between the V 
proteins of both virus strains using CoIP experiments (Fig. 3-13D). These results 
indicate that the capacity to suppress NF-κB activity and the ability to bind to p65 of wt 
and Schwarz-derived V proteins are equal. 
 
Figure 3-13 The V protein of the measles wild type isolate D5 inhibits NF-κB activity and binds to p65 
(A) Sequence alignment of the amino acid sequence of V proteins of the Schwarz strain and the wild type isolate D5. 
The sequence alignment was generated using Clustal W2 and Jalview. NF-κB-dependent luciferase assays in HEK-
293T cells were performed using ΔRIG-I (B) or p65/p50 (C) as stimulus and increasing amounts of V proteins of the 
Schwarz strain (MV V) or the wild type D5 isolate (MV Vwt) were coexpressed. (D) HEK-293T cells were cotransfected 
with vectors encoding flag tagged p65 or an empty vector (EV) and the V protein of the Schwarz strain or the D5 
wild type isolate. Flag-tagged proteins were pulled down using Flag M2 Matrix. The purified proteins were stained 
on Western blots with α-MV VCTD and α-flag antibodies. 
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3.14 CDV V and NiV V act like MV V and suppress classical NF-κB 
activity 
Since the C-terminal domains of the V proteins of the Paramyxovirinae subfamily 
members show significant conservation it was tested if the NF-κB inhibiting potential 
of the MV V protein is also conserved among paramyxoviruses. Therefore, I generated 
expression plasmids for flag-tagged paramyxovirus V proteins. We employed the V 
protein of the canine distemper virus (CDV), another member of the Morbillivirus 
genus, the V protein of the Nipah virus (NiV) of the Henipavirus genus and the V 
protein of the parainfluenza virus type 5 (PIV5) that belongs to the Rubulavirus genus 
(Fig. 3-14A; framed). To illustrate the conservation of the VCTD an amino acid sequence 
alignment of V proteins of MV (AF266291.1), CDV (AF259549.1), NiV (AF212302.2) and 
PIV5 (AF052755.1) was performed with the help of ClustalW2 and Jalview software. 
(Fig. 3-14B). 
The capacity of V proteins of CDV, NiV and PIV5 to interfere with NF-κB activation was 
compared to the NF-κB inhibiting potential of MV V using NF-κB-dependent luciferase 
assays. NF-κB was activated by applying different stimuli. Activation of the RIG-I 
pathway was achieved by overexpression of ΔRIG-I (Fig. 3-14C). Cells expressing only 
ΔRIG-I showed high induction of the NF-κB dependent luciferase activity, whereas the 
coexpression of the V proteins of MV, NiV and CDV decreased NF-κB activation in a 
dose dependent manner. The inhibitory potential of these V proteins appeared to be 
similar. In contrast to that, coexpression of PIV5 V had no effect on RIG-I mediated NF-
κB activation. However, referring to the Western blot of the viral proteins, it becomes 
obvious that the V protein of PIV5 was much lower expressed than the V proteins of 
MV, CDV and NiV.Activation of the TLR pathway was stimulated by overexpression of 
MyD88 (Fig. 3-14B). Consistently, the V proteins of MV, NiV and CDV suppressed NF-κB 
activity with a similar potency, while PIV5 V did not show any inhibitory effect. The 
Western blot illustrates again that PIV5 V was hardly expressed, whereas the V 
proteins of MV, NiV and CDV showed similar expression levels.  
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Figure 3-14 CDV V and NiV V act like MV V and suppress classical NF-κB activity 
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(A) The Paramyxoviridae family is divided into two subfamilies. The Paramyxovirinae subfamily comprises five 
genera: Respiroviruses, Rubulaviruses, Henipaviruses, Morbilliviruses and Avulaviruses, while the Pneumovirinae 
subfamily consists of two genera, namely the Pneumoviruses and the Metapneumoviruses. Abbreviations: Sendai 
virus (SeV), human parainfluenza viruses (HPIV), bovine parainfluenza virus 3 (BPIV3), mumps virus (MuV), simian 
virus 5 (SV5), hendra virus (HeV), nipah virus (NiV), measles virus (MeV), canine distemper virus (CDV), rinderpest 
virus (RPV), phocine distemper virus (PDV), newcastle disease virus (NDV), avian paramyxoviruses (APMVs), human 
respiratory syncytial virus (HRSV), bovine respiratory syncytial virus (BRSV), human metapneumovirus (HMPV) and 
turkey rhinotrachetis virus (TRTV).  Adapted from (Goodbourn and Randall, 2009). (B) Sequence alignment of 
different Paramyxovirinae V proteins: MV V: V protein of the Schwarz strain of measles virus; CDV V: V protein of 
canine distemper virus; NiV V: V protein of Nipah virus; PIV5 V: V protein of parainfluenza virus 5; The sequence 
alignment was generated using Clustal W2 and Jalview. Increasing amounts (200 ng, 400 ng, 600 ng) of vectors 
encoding the V proteins of MV, CDV, NiV and PIV5 were cotransfected into HEK-293T cells with 200 ng of an 
expression plasmid for ΔRIG-I (C), MyD88 (D), or 100 ng of each p50 and p65 (E) and the NF-κB-dependent reporter 
system (100 ng p55A2, 10 ng pRL-CMV). After 24 h, cells were lysed and NF-κB activity was determined by a dual-
luciferase assay. Values given are averages and standard-deviations of results from two independent experiments. 
Expression of the viral proteins was assessed by Western blotting using an α-flag antibody. 
To test whether the V proteins of NiV, CDV and PIV5 can block NF-κB activation 
downstream of the IKK complex as it was demonstrated for MV V, the NF-κB 
dependent luciferase assay was applied using overexpression of the p50/p65 dimer as 
stimulus. To exclude upstream activation of NF-κB, Ig-NBD was included as a negative 
control again. V proteins of MV, NiV and CDV inhibited NF-κB activity, while PIV5 V did 
not (Fig. 3-14C). However, PIV5 V was again only weakly expressed, in contrast to the 
other viral proteins. Upstream activation could be excluded, since Ig-NBD did not 
inhibit p50/p65 dependent NF-κB activity. 
Taken together, these findings revealed that the inhibitory potential of the V proteins 
of CDV and NiV is similar to that of MV V. 
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3.15 The Rel homology domain of p65 is also bound by CDV V and 
NiV V 
To test if the different paramyxovirus V proteins can also bind the NF-κB subunit p65, 
Co-IP experiments were performed. Therefore, HEK-293T cells were used to coexpress 
flag-tagged V proteins together with p65. The flag-tagged proteins and their 
interaction partners were purified from the cell lysate using Flag-M2 Matrix and 
subjected to immunoblotting. p65 was copurified with MV V, CDV V, and NiV V but not 
with PIV5 V (Fig. 3-15A). Notably, the expression levels of flag-PIV5 V was again lower. 
Since it was shown that MV V specifically binds to the rel homology domain of p65, the 
other V proteins were assessed for their binding affinity to this domain. V proteins of 
CDV and NiV clearly associated with the RHD of p65 whereas PIV5 V showed no 
interaction (Fig. 3-15B). These findings indicate that not only the NF-κB inhibitory 
potential of the V proteins of MV, CDV, and NiV is conserved but also their binding 
affinity to the RHD of p65 and that PIV5 V does not bind to p65 and therefore cannot 
interfere with NF-κB activation. 
 
Figure 3-15 The Rel homology domain of p65 is also bound by CDV V and NiV V 
HEK-293T cells were cotransfected with vectors encoding the indicated flag tagged constructs or an empty vector 
(EV) and full length p65 (A) or RHD-p65 (B). Flag-tagged proteins were pulled down using Flag M2 Matrix. The 
purified proteins were stained with α-p65 and α-flag antibodies on Western blots. 
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3.16 Binding of P gene products to other NF-κB subunits 
Besides p65 and p50, the main subunits of the classical NF-κB signaling cascade, 
additional dimers composed of other NF-κB subunits exist. RelB and p100/p52 are the 
key players of the alternative NF-κB pathway, which is involved in adaptive immune 
responses (Bonizzi and Karin, 2004). The NF-κB subunit c-Rel plays an important role in 
controlling B-cell proliferation, survival, and oncogenesis (Gilmore et al., 2004). Since 
MV infection in vivo can result in immunosuppression of the host that also involves the 
adaptive immune system (Griffin, 2010), it was checked if any of the MV P gene 
products can interfere with these NF-κB subunits. CoIP experiments with flag-tagged 
MV P, V, and C together with RelB, c-Rel, p100 and p52 were accomplished. Like p65, 
RelB exhibited binding affinity exclusively to flag-MV V (Fig. 3-16A). Notably, an 
additional 55 kDa band was seen with the α-RelB antibody directed to the C-terminus 
of RelB if MV V was present. Weak binding of c-Rel was observed to both flag-MV P 
and V (Fig. 3-16B). For p100, the precursor of p52, no interaction with any of the P 
gene products was observed (Fig. 3-16C), whereas the processed p52 associated with 
both flag-MV P and V, however, with weaker affinity to flag-MV V (Fig. 3-16D). To 
further validate these findings CoIP experiments were performed the other way 
around using flag-tagged NF-κB subunits for co-precipitation of untagged MV proteins. 
Here, flag-p65 and -p50 were included as positive and negative controls and 
references. The experiments copurifying MV P revealed only binding to flag-p52. The 
weak association of c-Rel with flag-MV P was not confirmed (Fig. 3-16E). A very weak 
band of MV P was observed with flag-p65 as already descripted in chapter 3.5. CoIP 
assays with the flag-tagged NF-κB subunits and MV V prove the binding of MV V to p65 
and p52, however, binding of V to flag-RelB and flag-c-Rel was not observed 
(Fig. 3-16F). But notably, coexpression of MV V and RelB resulted in very low 
expression levels of V (Fig. 3-16F) and this was also seen for MV P (Fig. 3-16E).  
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Figure 3-16 Binding of P gene products to other NF-κB subunits 
Lysates of HEK-293T cells expressing flag-tagged MV P, V, or C and RelB (A), c-Rel (B), p100 (C) or p52 (D) were 
purified with anti-flag M2 affinity gel. Purified proteins were visualized by Western Blooting using antibodies 
specific for the overexpressed NF-κB subunits or the flag epitope. CoIPs with flag-tagged p65, RelB, c-Rel, p50 or p52 
and MV P (E) or MV V (F) were stained with α-PVNTD or α-VCTD and the α-flag antibody. 
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Thus binding of RelB and MV V could not be confirmed but is still conceivable. The 
binding capacity of MV V to p65 was much more prominent than to p52, indicating 
that the main binding partner among the NF-κB subunits of MV V is p65. Furthermore, 
these results indicate that there is an interaction of MV P and V with the alternative 
NF-κB subunit p52. Binding of flag-MV V to RelB, and probably a processed form of 
RelB, suggests also an interaction of V and RelB in cells. 
3.17 Inhibition of the alternative NF-κB pathway 
In order to examine if binding of MV P and V to p52 and the supposed binding of MV V 
to RelB result in inhibition of the alternative NF-κB signaling pathway, NF-κB-
dependent luciferase assays were implemented. The alternative pathway was 
stimulated by overexpressing NIK, a kinase involved in the alternative signaling 
cascade. Cells overexpressing NIK without any viral protein showed high induction of 
NF-κB-dependent luciferase activity. However, the presence of MV P, V, and C caused a 
similar inhibition pattern as seen for the classical pathway (Fig. 3-17A). Since it is 
known that stimulation of the alternative signaling is not exclusive but also leads to 
activation of the classical NF-κB subunits, the observed suppression pattern might 
result from inhibition of p65 activity. To exclude activation of p65, alternative NF-κB 
activation was induced expressing directly the alternative subunits. RelB/p52-mediated 
induction was not very prominent (less than 10-fold), but this was also seen in other 
studies. Solely MV V coexpression exhibited a very slight suppressive effect on 
RelB/p52 mediated-NF-κB activation (Fig. 3-17B). Last, the effect of MV P, V, and C on 
c-Rel mediated NF-κB activation was investigated. Again, NF-κB activation was quite 
poor and there was no inhibitory capacity displayed by any of the MV P gene products 
(Fig. 3-17C). These results suggest that the assumed binding to RelB and c-Rel or the 
binding to p52 of MV P and V do not result in substantial suppression of NF-κB 
activation mediated by these subunits. However, it still remains to be investigated if 
there is any suppressive effect of the viral gene products upstream of RelB, p52 and 
c-Rel. 
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Figure 3-17 Inhibition of the alternative NF-κB pathway 
NF-κB dependent luciferase activity was measured in HEK-293T cells transfected with 200 ng of plasmids encoding 
for NIK (A), RelB/p52 (B) or crel (C), increasing amounts (200 ng, 400 ng, 600 ng) of vectors for MV P, V, or C and the 
NF-κB-dependent reporter system. The bars represent the means and the error bars the standard deviation of two 
independent experiments. Depicted is a representative experiment out of three repeats. Expression of the viral 
proteins was assessed by Western blotting using either α-flag (A) or α-PVNTD, α-VCTD, or α-MV C (B+C) antibodies. 
 
3.18 Generation and characterization of recombinant viruses MV-
vac2, MV-MCS, MV-VKO, MV-VKO+V 
To investigate the biochemical results obtained so far in the viral context, recombinant 
measles viruses were rescued. Therefore, different full-length constructs of the MV 
genome were cloned (Fig. 3-18A). The sequence of the Schwarz MV anti-genome from 
the pB(+)MVvac2 plasmid (del Valle et al., 2007) was cloned into the backbone of the 
rescue plasmid pBS-HHrz/Hdrz(sc) which was shown to significantly improve virus 
rescue efficiency (Ghanem et al., 2012). Virus rescued from this plasmid is referred to 
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as MV-vac2. To enable insertion of an additional gene, a plasmid where a multiple 
cloning site (MCS) flanked by the 5‘-UTR and the 3’-UTR of the P gene was inserted 
between the P and the M gene was constructed (done by Christian Pfaller). The 
corresponding virus is named MV-MCS. For a virus deficient in V protein expression 
(MV-VKO) a point mutation within the V editing site was inserted in the MV-MCS full 
length plasmid to destroy V mRNA production (Radecke and Billeter, 1997; Schneider 
et al., 1997). The introduced point mutation is silent for the P and C protein. The V ORF 
with mutated editing site was inserted into the MCS of the MV-VKO full length plasmid 
such that the expression of the V protein is restored in the recombinant virus MV-
VKO+V.  
To characterize the recombinant viruses on protein level A549 cells were infected at an 
MOI of 1 for 24 or 48h or mock-treated with supernatant of Vero cells lysed by freeze-
thaw. Lysates of the infected cells were subjected to SDS-PAGE followed by Western 
blotting using α-MV N, α-MV PNTD, α-MV VCTD, α-MV C and α-actin antibodies. All 
viruses expressed comparable ratios of the MV N, P, and C proteins. In case of 
infection with MV VKO no expression of the V protein was detected illustrating that 
knock out (KO) of V was successful (Fig. 3-18B).  
The recombinant viruses were further characterized with respect to their growth 
kinetics on IFN incompetent Vero cells and IFN competent A549 cells. Therefore, Vero 
or A549 cells were infected at an MOI 0.01. Infectious titers were determined 6 h, 24 
h, 48 h, 72 h, and 96 h p.i. The viruses showed similar growth kinetics on Vero cells 
(Fig. 3-18C) as well as on A549 cells (Fig. 3-18D). Surprisingly, even the KO of the V 
protein did not influence the growth of the virus on IFN competent cells. 
To sum up, the MV-VKO virus appears to be indistinguishable from the other viruses in 
regards of growth and protein expression in Vero and A549 cells. 
Results 90 
 
Figure 3-18 Generation and characterisation of recombinant viruses MV-vac2, MV-MCS, MV-VKO, MV-VKO+V 
(A) Overview of the full length plasmid used to generate the recombinant viruses MV-vac2, MV-MCS, MV-VKO and 
MV-KO+V. The Schwarz measles virus antigenome is cloned in the pBluescript vector (pBS(+)) containing a T7 
promoter and a T7 terminator and flanked by ribozyme sequences. The hammerhead ribozyme (HHrz) and Hepatitis 
delta virus antigenomic ribozyme (HdRz)  were used to enable 5’ or 3’ processing, respectively. (B)A549 cells were 
infected (MOI=1) with the indicated viruses and lysed 24h or 48h p.i.. Western blot analysis was carried out and α-
MV N (abcam/millipore), α-MV PVNTD, α-MV VCTD, α-MV C (FEA/10/1)  and α-actin were used to detect expression of 
the indicated proteins. A representative experiment out of four is shown. (C) Vero cells were infected (MOI=0.01) 
with the indicated viruses, 1h p.i. the cells were washed and frozen at 6h, 24h, 48h, 72h and 96h p.i.. Virus titers 
were determined by titration on Vero cells. Shown is the average and standard deviation of two independent 
experiments. (D) A549 cells were infected at an MOI of 0.01, 1h p.i. cells were washed and frozen at the indicated 
time points. Titration of the viral titers was carried out on Vero cells. The average and standard deviation of three 
independent experiments is shown. 
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3.19 NF-κB activation upon infection with MV-MCS, MV-VKO, MV-
VKO+V 
The recombinant viruses were used to determine if the inhibitory effects proven for 
the MV V protein are also found in the viral context. Thus, HEK-293T cells were 
transfected with the dual NF-κB-reporter system, infected 6h p.t. with MV-MCS, MV-
VKO, MV-VKO+V at an MOI of 1 or mock-treated with supernatant of frozen Vero cells 
and lysed 24h later. MV-VKO was expected to induce NF-κB activity more prominent 
than MV-MCS and MV-VKO+V, since one of the NF-κB inhibitors is knocked out in MV-
VKO. Surprisingly, analysis of NF-κB dependent luciferase activity displayed that MV-
MCS infection activated NF-κB slightly (3 fold), infection with MV-VKO resulted in only 
6 fold induction of NF-κB activity whereas MV-VKO+V infected cells showed 15 fold 
induction (Fig. 3-19A). Furthermore, Western blotting revealed that infection with MV-
VKO was slightly enhanced. Using quantitative real-time RT-PCR as an additional 
readout, mRNA levels of different NF-κB dependent genes were analyzed upon 
infection. A549 cells were infected with the indicated viruses at an MOI of 1 or mock-
treated, RNA was isolated 24h p.i. and reverse transcribed into cDNA. Quantitative PCR 
was accomplished using IL-6, RANTES, IFNβ, or MV N primers. Levels of IL-6 mRNA 
were about 600 fold induced in MV-MCS and MV-VKO infected cells, while infection 
with MV-VKO+V resulted in even 1200 fold induction (Fig. 3-19B). A similar expression 
pattern was found with RANTES mRNA levels. Induction by MV-MCS and MV-VKO was 
comparable (around 2000 fold) whereas MV-VKO+V induced twice as much (Fig. 3-
19C). In contrast, IFNβ mRNA levels were equivalent for all viruses (Fig. 3-19D). Levels 
of MV N mRNA were checked as infection control and two fold increased levels for 
MV-VKO+V revealed that infection with this virus was higher (Fig. 3-19E). This is also 
reflected in the Western blot control (Fig. 3-19F). Increased infection rate with MV-
VKO+V might explain the increased levels of IL-6 and RANTES with this virus. In sum, 
these experiments do not reveal a major impact of the presence of V on NF-κB 
activation in HEK-293T and A549 cells 24h post infection. 
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Figure 3-19 NF-κB activation upon infection with MV-MCS, MV-VKO, MV-VKO+V 
(A) NF-κB activity was determined on HEK-293T cells transfected with the NF-κB reporter system (p55A2/pRL-CMV) 
by dual luciferase assays. 6h post transfection cells were infected with the indicated viruses at an MOI of 1 and 
lysed 24h later to determine luciferase activities. Values shown are average and standard deviations of two 
independent experiments. Expression of viral proteins was assessed by Western blotting. (B-F) Real-time RT-PCRs 
for NF-κB-dependent genes in HEK-293T cells infected with the indicated viruses at an MOI of 1. 24h p.i. cells were 
lysed and subjected to real-time RT-PCR using primer specific for IL-6 (B), RANTES (C), IFNβ (D), or MV N (E) as 
infection control. Values given are average and standard deviation of two independent experiments. Shown are 
representative experiments out of two repeats. To control infection on the protein level A549 cells were infected in 
parallel and lysates were subjected to Western blotting. Protein levels were visualized using antibodies specific for 
MV N, P, V, or C. 
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4 Discussion 
NF-κB is a ubiquitously expressed transcription factor that mediates a wide variety of 
cellular responses, ranging from proliferation, differentiation, and cell survival to 
cytokine production and other proinflammatory processes thereby regulating innate as 
well as adaptive immune responses. The primary result of NF-κB activation by 
triggering of PRRs during innate immune responses is the expression of chemokines 
and pro-inflammatory cytokines, such as IL-6 or TNFα. The role of NF-κB for IFNβ 
expression is highly discussed. Early studies on the activation of the IFN-β promoter, 
which contains NF-κB, AP1, and IRF binding sites, implicated NF-κB as a key mediator 
of virus-induced IFN-β expression (Lenardo et al., 1989; Thanos and Maniatis, 1995). 
However, infection of NF-κB knockout mouse embryonic fibroblasts (MEFs) with 
Sendai virus initially suggested the lack of an essential role for NF-κB in virus induced 
IFN-β expression (Wang et al., 2007), but the same group then showed that NF-κB is 
crucial during the early phase of virus infection (Wang et al., 2010). The important role 
of NF-κB during infections in general is emphasized by reports showing that mice 
lacking different NF-κB family members become more susceptible to various viral, 
bacterial, and parasitic infections (Rahman and McFadden, 2011). However, all these 
studies were conducted in mice, and therefore the role of NF-κB in human IFN-
expression needs to be evaluated. 
In this study, it was shown that P gene products of the immunosuppressive measles 
virus, including the essential P protein, and the ‘accessory’ proteins V and C, interfere 
with activation of NF-κB in human epithelial cells. MV P, V, and C, which are 
established MV virulence factors, were found to individually suppress NF-κB-
dependent reporter gene expression in response to activation of TNF receptor, RLRs, 
or TLRs. While the V protein exhibited the most potent inhibitory capacity, MV P and C 
proteins suppressed NF-κB activation more moderately. As indicated by reporter gene 
assays involving overexpression of the IKK complex, which phosphorylates IκBα to 
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liberate NF-κB, V protein targets a downstream step in the signaling cascade. CoIP 
experiments revealed that V specifically binds to the RHD of the NF-κB subunit p65 but 
not of p50, which constitute the main dimers involved in the classical NF-κB signaling. 
As observed by confocal microscopy, the presence of MV V abolished nuclear 
accumulation of p65 upon TNFα stimulation. Notably, the short C-terminal domain of 
the V protein that is also involved in binding STAT2, IRF7, and MDA5, was sufficient for 
interaction with p65 and for preventing reporter gene activity (Schuhmann et al., 
2011). This highlights VCTD as a cellular hub for innate immune signaling molecules. 
Mutational analysis of the V protein revealed that p65, IRF7, and MDA5 recognize 
common binding sites at the C-terminal domain of V. Besides binding of MV V to the 
classical NF-κB subunit p65, CoIP experiments indicated MV V binding to the 
alternative NF-κB subunits RelB and p52. Notably, MV P, which does not bind to the 
classical subunits, was found to bind to p52 as well. These findings reveal NF-κB as a 
key target of MV and stress the importance of the V protein as the major viral 
immune-modulatory factor.  
4.1 Inhibition of NF-κB by MV P and C 
Overexpression of the MV P and C protein resulted in suppression of classical NF-κB 
activation upon different stimuli, like TNFα, ΔRIG-I, IPS-1, MyD88, and TRIF (Fig. 3-1 
and 3.2) in reporter gene assays. Immunofluorescence experiments with flag-tagged P 
revealed that MV P interferes with nuclear accumulation of the NF-κB subunit p65 to 
some extent. 40% of cells expressing flag-MV P showed no nuclear p65 upon TNFα 
stimulation (Fig. 3-9) even though P was not found to interact with p65 in CoIP 
experiments (Fig. 3-4). This partial inhibition of nuclear translocation correlates well 
with the partial inhibition of NF-κB activation seen in the reporter gene assays. Taken 
together and in view of the fact that the P protein itself is located in the cytoplasm, an 
inhibitory mechanism upstream of p65 translocation is indicated. In monocytes but not 
in epithelial cells, MV P was previously shown to directly activate the expression of the 
ubiquitin-modifying enzyme A20, a potent inhibitor of the classical NF-κB pathway 
(Yokota et al., 2008). MV P was reported to indirectly interact with a negative 
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regulatory motif in the A20 gene promoter and thereby the suppression of A20 
expression is released. It was already revealed before that MV P has transactivating 
properties due to the acid-rich PVNTD (Chen et al., 2003), however, how P reaches the 
nucleus is not known. Importantly, upregulation of the NF-κB inhibitor A20 was not 
observed in HEK-293T cells with any of the MV proteins (data not shown), excluding 
the possibility of a contribution of this recently described mechanism (Yokota et al., 
2008). Besides the potential of P to inhibit the classical NF-κB signaling pathway, P 
might have the capacity to suppress the alternative pathway as well. MV P was able to 
interact with p52 (Fig. 3-16) and to inhibit NF-κB-dependent reporter gene expression 
mediated by NIK, a kinase involved in the alternative NF-κB pathway (Fig. 3-17A). 
However, stimulation of NF-κB by RelB/p52 was apparently not impeded by P 
(Fig 3-17B). Thus, further investigations must be implemented to clarify if P interferes 
with alternative NF-κB signaling.  
In contrast to the P protein, MV C, which was shown to shuttle between the nucleus 
and the cytoplasm (Nishie et al., 2007), is mainly located in the nucleus in the steady 
state and does not interfere with nuclear translocation of p65 (Fig. 3-9). These findings 
suggest that MV C protein suppresses classical NF-κB activation within the nucleus by a 
so far unknown mechanism in analogy to the nuclear blockage of IFNβ induction 
(Sparrer et al., 2012). Notably, infection with a MV engineered to prevent expression 
of the C protein efficiently activates NF-κB in comparison to infection with the parental 
MV (McAllister et al., 2010). This indicates that the C protein plays a pivotal role to 
inhibit NF-κB activation during MV infection even though the direct capacity to 
suppress NF-κB in my in vitro studies was only moderate.  
4.2 Inhibitory mechanism of MV V  
In all conducted reporter gene assays, the NF-κB inhibitory capacity of the V protein 
was the most pronounced irrespective of the stimulus (Fig. 3-2, 3-2, 3-3). Specifically, 
in cells stimulated by overexpression of ΔRIG-I the inhibitory capacity of MV V 
appeared to be particularly pronounced (Fig. 3-2A). Interestingly, it was recently found 
that V binds to LGP2 which builds a complex with RIG-I in the presence of V and this 
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complex cannot be activated by RIG-I ligands (Childs et al., 2012). However, the 
inhibitory effect of LGP2 is operating at the level of RIG-I activation and is dependent 
on the helicase domain of RIG-I. Since I stimulated only with the CARD domains of RIG-
I, the strong inhibition of NF-κB activity cannot be explained by the interplay of V and 
RLRs. Therefore, I suggest that binding of MV V to the downstream transcription factor 
p65 is the major mechanism for suppression of RLR-mediated NF-κB activation.  
MV V was the only P gene product that substantially interacted with the NF-κB subunit 
p65 as revealed with CoIP studies (Fig. 3-4) as well as with IF images which suggested 
co-localization of MV V and p65 (Fig. 3-8). The V protein of an MV wild type isolate 
(genotype D5) bear some point mutations in its PVNTD, which is the common domain of 
P and V, while the sequence of the unique VCTD, which is responsible for p65 binding, is 
completely conserved in the wild-type isolate and the Schwarz strain. Consistent with 
this fact, binding of wild-type V to p65 and similar levels of inhibition of NF-κB-
dependent reporter gene activity were observed (Fig. 3-13). 
Binding of MV V to p65 might interfere with posttranslational modifications (PTMs) of 
p65, which are not essential for NF-κB activation, but regulate the transcriptional 
efficiency of p65 by affecting the localization, stability and ability of p65 to interact 
with DNA and transcriptional cofactors (Huang et al., 2010). Numerous regulatory 
PTMs of p65 have been reported so far, such as phosphorylation, acetylation, and 
ubiquitination. Phosphorylation of serine (S) 276 within the RHD of p65 by protein 
kinase A (PKA) promotes the interaction of p65 with the transcriptional coactivators 
CREB-binding protein (CBP) and p300 (Zhong et al., 1998). This enhances the activation 
of a subset of NF-κB target genes (Dong et al., 2008). Western Blot analysis of the 
phosphorylation state of p65 at S276 using an antibody for P-p65 S276 revealed no 
difference in the absence or presence of MV V (data not shown). However, there are 
concerns regarding the specificity of commercially available α-P-S276-p65 antibodies, 
since they were found to react with other PKA-regulated proteins, but do not detect 
S276-phosphorylation of p65 via Western Blotting (Spooren et al., 2010). Besides this 
phosphorylation within the RHD, a variety of phosphorylation sites within the TAD 
have been demonstrated (Hayden and Ghosh, 2012). Since MV V was shown to 
interact with the RHD of p65 (Fig. 3-5), these phosphorylation events will probably not 
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contribute to the inhibition seen in the presence of the V protein. Interestingly, 
ubiquitination of p65 was associated with the regulation of p65 localization (Maine et 
al., 2007). Ubiquitination seems to favor p65 localization in the cytoplasm, however 
MV V binding to p65 did not mediate ubiquitination of p65 as analyzed by Western 
blotting using an antibody against ubiquitin (data not shown).  
Another consequence of MV V binding to p65 could be the disruption of the 
NF-κB/IκBα complex. However, I could demonstrate that binding of V does not prevent 
IκBα or p50 binding to p65 (Fig. 3-7). This is also supported by the finding that MV V 
binds to both NTD and CTD of p65 RHD in contrast to IκBα and p50, which bind only to 
the CTD of p65 RHD (Fig. 3-6). Since MV V retains p65 in the cytoplasm upon TNFα 
treatment (Fig. 3-8, 3-9), I assumed that binding of V to p65 leads to the inhibition of 
p65 translocation. Upon stimulation, p65 is imported into the nucleus by a subset of 
importin α isoforms, namely importin α 3, 4, and 5 (Fagerlund et al., 2005; Fagerlund 
et al., 2008). I found that p65 interacts most efficiently with the importin α 5 subunit 
(Fig. 3-10A). In unstimulated cells, IκBα shields the NLS thereby preventing binding of 
the importin subunits (Hinz et al., 2012). Upon stimulation, IκBα is degraded in 
presence and absence of V (data not shown) and importin α molecules can recognize 
the liberated NLS of p65, bind to p65 and associate with importin β to form a trimeric 
complex. Subsequently, importin β mediates docking of the complex to the 
cytoplasmic side of the nuclear pore complex (NCP) leading to translocation of the 
complex through the NCP (Funasaka and Wong, 2011).  
Here I found that the inhibition of the translocation is not due to direct binding of V to 
the NLS of p65 (Fig. 3-10B). Furthermore, it could be excluded that the V protein 
competed with importin α 5 binding to p65 (Fig. 3-10C). However, weak binding of MV 
V to importin α 5 was observed in some experiments (data not shown), which might 
indicate that the retention of p65 in the cytoplasm in the presence of V might be due 
to interference of MV V with the import machinery. Since STAT1 and STAT2 are also 
cargos of importin α 5 (Fagerlund et al., 2002) and their nuclear translocation is 
inhibited by MV V as well (Palosaari et al., 2003), this common hub of signaling 
molecules might be a general target for MV V. However, preliminary data (not shown) 
suggest that nuclear translocation of heterogeneous nuclear ribonucleoprotein 
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complex C1/C2 (hnRNP C1/C2), an additional importin α 5 cargo (Shabman et al., 
2011), was not inhibited in the presence of V contradicting the idea of a general 
inhibition of importin α 5 mediated nuclear import. Furthermore, the inhibition of 
STAT1 translocation by V is probably rather due to inhibition of JAK1 mediated 
phosphorylation (Caignard et al., 2007) than to interference of V with importin α 5.  
The idea that MV V interferes with the import machinery in general is in turn 
supported by a study using mass spectrometry to identify interaction partners of the V 
protein, which identified different components of the nuclear pore such as nuclear 
pore complex protein 93 (NUP93) and NUP205 as well as importin α 1, importin β to 
interact with MV V (Komarova et al., 2011). Although the study could confirm well 
known interaction partners of the V protein such as STAT1 and STAT2, other 
interaction partners like LGP2, IKKα, IRF7, or JAK1 as well as p65 were not found in the 
mass spectrometry dataset. Nevertheless, possible interactions with proteins of the 
import machinery should be further investigated. NUP93 and NUP205 are part of the 
nucleoporin complex and required for correct nuclear pore assembly (Grandi et al., 
1997). Although NUP93 and NUP205 are not involved in the transfer of the 
cargo/importin complex through the NCP (Shah et al., 1998), interaction of MV V with 
both proteins, which are localized to central channel of the pore and the nuclear 
basket, might eventually block the channel. However, this would result in a general 
blockage of nuclear import, which is not observed upon expression of MV V. On the 
contrary, the blockage of the nuclear import by V is even very specific. So, it might 
rather be the importins, which are interesting targets for V mediated specific nuclear 
import inhibition. Although V could not compete with binding of importin α 5 to its 
cargo p65 (Fig. 3-10C), it might interfere with downstream events of the import 
machinery, like importin β binding. 
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4.3 MV V binds a variety of cellular proteins but with specificity 
Besides binding to p65, MV V was shown to interact with a variety of cellular proteins. 
Interestingly, these interactions seem to be very specific, since MV V binds only to 
selected members of a protein family. Here, it was revealed that the V protein 
interacts with the NF-κB subunits p65 and p52, but not with p50 or p100, the precursor 
of p52 (Fig. 3-4 and 3-16). Especially, p52 and p50 are highly conserved, which 
highlights the high specificity of V to interact with defined molecules. Since it was 
shown that p50 homodimers, which are lacking the TAD to mediate gene transcription, 
repress a subset of IFN-inducible genes (Cheng et al., 2011), it might be a strategy of 
the virus to refrain from targeting the inhibitory p50 dimer. 
It is also known that MV V binds to the RLRs MDA5 and LGP2, but not to the closely 
related RIG-I (Childs et al., 2012; Childs et al., 2007). Furthermore, MV V interacts with 
IKKα, but not with IKKβ or IKKi (Pfaller and Conzelmann, 2008). Besides its dual role in 
the canonical as well as alternative NF-κB signaling pathway, IKKα is also involved in 
the activation of IRF7 through TLR7/8/9. In vitro kinase assays showed that the IKKα-
dependent phosphorylation of IRF7 was diminished in the presence of MV V, whereas 
the phosphorylation of the NF-κB inhibitor IκBα by IKKα was not altered (Pfaller and 
Conzelmann, 2008). Thus, binding of MV V to IKKα suppresses IRF7 activation but does 
not affect activation of NF-κB. This displays another layer of specificity of MV V 
mediated modulation of the immune system. In the same study it was revealed that 
the transcription factor IRF7 is bound by MV V. However, no interaction with IRF3 
could be detected in their study. This is consistent with the finding that the V proteins 
of PIV5 and related rubulaviruses, but not MV V, targets the IRF3 rather than the IRF7 
signaling pathway, by binding to IKKi, which prevents IRF3 activation and RLR-
dependent IFNβ induction (Lu et al., 2008). In contradiction with this findings, it was 
recently suggested that V proteins of different paramyxoviruses, including MV V, 
inhibit IRF3 signaling by binding to IRF3 (Irie et al., 2012). However, this binding could 
not be verified in my experiments (data not shown), speaking for the specificity for the 
V protein to IRF7 as found before (Lu et al., 2008; Pfaller and Conzelmann, 2008). 
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All these interactions with V are mediated via its unique C-terminal domain, which 
turns out to be a hub for specific binding of numerous cellular proteins. This includes 
not only targets of the innate immunity but also proteins related to proliferation and 
cell death, like p53 family member p73, which down regulates expression of the 
proapoptotic target gene PUMA and might therefore function as a viral antiapoptotic 
factor (Cruz et al., 2006). 
Taken together, all these specific interactions of MV V with cellular proteins might 
contribute to the fine regulation and modulation of the immune system by MV, 
emphasizing the important role of the V protein for MV-mediated immune escape.  
4.4 Interactions of V with cellular molecules are often 
conserved among paramyxoviruses 
Most of the interactions of MV V with the cellular proteins are conserved among V 
proteins of other paramyxoviruses such as the interactions with MDA5, IKKα, and IRF7 
(Andrejeva et al., 2004; Kitagawa et al., 2011). Indeed, an interaction of p65 with the V 
proteins of CDV and NiV was found here (Fig. 3-15). However, no interaction was 
detected with PIV5 V, which might be either the consequence of the low expression 
levels of PIV5 V in all reporter gene assays, or PIV5 V fails to interact with p65 due to 
its nuclear localization within the cell (Precious et al., 1995). Interestingly, the V 
protein of PIV5 was reported to suppress NF-κB activation only upon triggering with 
synthetic dsRNA or upon viral infection, whereas inhibition of LPS- or TNFα-dependent 
NF-κB activity was not observed (Lin et al., 2007; Poole et al., 2002). This is in 
accordance with my NF-κB reporter gene experiments where expression of PIV5 V was 
ineffective in preventing NF-κB activity induced by ΔRIG-I, MyD88, or p65/p50 
(Fig. 3-14). Thus, it is likely that NF-κB inhibition and p65 binding is not generally 
conserved among members of the Paramyxoviridae family, but that the immune-
modulatory strategies of MV to inhibit NF-κB activation are applied by a selected 
subset of paramyxoviruses, as proven for the highly related CDV and the more distinct 
NiV.  
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This emphasizes the broad usage of the revealed NF-κB inhibitory mechanism and 
therefore it helps to understand the complex and multifaceted mechanisms, which are 
applied by paramyxoviruses to circumvent innate immune responses. 
4.5 p65 shares binding sites at the C-terminal domain of V with 
MDA5 and IRF7 
Intriguingly, numerous interactions of V with cellular proteins, such as MDA5, LGP2, 
STAT2, or IRF7 are mediated via the 68 aa long C-terminal domain of V. And it was also 
MV VCTD, which was shown to mediated interaction with p65 (Fig. 3-11).  
Since MV V interferes with different steps of the signaling cascades it is important to 
reveal the aa of motifs which are responsible for each interaction in order to be able to 
discriminate the resulting effects. Responsible aa for MV V binding to MDA5 were 
already identified in two independent studies (Ramachandran and Horvath, 2010; 
Takaki et al., 2011). Ramachandran and Horvath identified two aa (233R and 235E) as 
important for MDA5 interaction and interference by site-directed mutagenesis. In 
contrast, Takaki et al. recognized 272C to be critical for interaction with MDA5 due to 
sequence alignment of different MV strains. However, mutation of 272C or of any 
other cysteine might destroy the zinc finger structure of VCTD and affect other 
interactions as well. Therefore, the 233 and 235 mutations, located within the first 
loop, are probably more promising for dissecting V protein functions. The aa 246F and 
248D, which are important to mediate the interactions with STAT2 are also found 
within the first loop (Ramachandran et al., 2008). Residues mediating binding to IRF7 
were identified to be localized within the second loop. A stretch of four amino acids 
(aa 259-262) seems to be important for IRF7 binding and substitution of these residues 
against alanine resulted in decreased binding to the transcription factor (Pfaller, 2009). 
It could be revealed here, that aa responsible for MDA5 binding as well as for IRF7 
binding are also important for p65 binding (Fig. 3-12D). Specifically, mutants either 
lacking loop 1 or 2 were compromised to interact with p65 to the full range 
(Fig. 3-12E), however could still interfere to some degree with NF-κB or IFN promoter 
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activity (Fig. 3-12F-H). This indicates that, in case of p65 binding, both regions loop 1 
and 2 are involved in the interaction and that one of them might be enough for 
inhibition. Since binding of V to p65 was reduced rather than completely lost, the 
reduced binding is obviously sufficient for inhibition. It seems that both IRF7 and 
MDA5 binding domains overlap with the p65 binding site to MV V (Fig. 3-12D). For that 
reason, it might be possible that MV V rather binds a common hypothetical adaptor 
protein of the cellular interaction partners. Thus, the interaction at least of some 
cellular proteins with MV V might be indirect. So far, a direct binding of MV V was only 
shown for STAT1, JAK1, and MDA5 using a yeast two-hybrid approach (Caignard et al., 
2007). However, if binding of all cellular proteins is direct, the different interaction 
partners of V might compete for their common binding sites, which might be another 
layer of regulation applied by the V protein. 
 
4.6 Relevance of the P gene products for the alternative 
pathway 
In contrast to the classical NF-κB signaling pathway, which plays a major role in innate 
immune processes, the alternative pathway is rather thought to be involved in the 
regulation of the adaptive immune system. For example, mice deficient in p52 present 
defects in humoral responses and splenic microarchitecture (Franzoso et al., 1998). 
RelB deficient mice have a lack of bone marrow-derived DCs (Lo et al., 1992) and 
decreased T cell responses upon vaccinia virus infections, which leads to impaired 
clearance of the virus (Freyschmidt et al., 2007). Furthermore, it was shown that RelB-
deficient mice are more susceptible for influenza A virus infection (Castiglioni et al., 
2008). This highlights the important function of the alternative NF-κB pathway during 
viral infections.  
Here, I could show that both MV P and V interact with the alternative NF-κB subunit 
p52, but not with its precursor p100 (Fig. 3-16). This indicates that in the full-length 
protein the binding sites for MV V or P are shielded by the inhibitory C-terminus of 
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p100, which gets degraded upon stimulation of the alternative pathway. This specific 
binding might be an additional mechanism applied by MV to counteract immune 
responses. An interaction of MV V and RelB, however, was indicated in a certain 
setting of experiments only. When V was coexpressed with untagged RelB, an 
additional 55 kDa band was always co-precipitated with flag-MV V using an antibody 
directed against the C-terminus of RelB for visualization. This might be due to an N-
terminal cut of RelB, as it is seen upon 12-O-tetradecanoylphorbol-13-
acetate/ionomycin treatment of EL-4 T-cells, where RelB was shown to be N-terminally 
processed followed by degradation of RelB (Marienfeld et al., 2001). The N-terminal 
processing is also supported by the finding that the additional band was not observed 
when MV V was coexpressed with an N-terminal flag-tagged RelB. It might be possible 
that RelB processing is supported by the V protein. Besides binding to the alternative 
NF-κB subunits, the capacity of the P gene products to suppress NIK-mediated NF-κB 
signaling was also demonstrated (Fig. 3-17). Triggering of the alternative pathway also 
activates the classical NF-κB subunits. Although V interactions with the alternative 
subunits RelB and p52 suggest points of interference, it cannot be excluded that the 
inhibitory effect on NIK-mediated NF-κB activity observed in reporter gene assays is 
primarily due to inhibition of the classical pathway. The finding that RelB/p52-
mediated NF-κB activation cannot be inhibited by any of the P gene products argues in 
favor of an only minor role of the P gene products to suppress alternative NF-κB 
signaling downstream of the NF-κB subunits. However, they might target the signaling 
cascade just upstream of p52 and RelB. For example IKKα targeting of MV V might be 
involved in modulation of alternative signaling. It was shown that MV V interaction 
with IKKα does not interfere with phosphorylation of IκBα in vitro (Pfaller and 
Conzelmann, 2008), argues against an involvement of the interaction of V and IKKα to 
inhibit classical NF-κB signaling, but its role in suppression of the alternative pathway 
should be further analyzed. 
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4.7 Role of the V protein during MV infection 
To characterize the relevance of the V protein in a viral context, suitable cDNAs were 
constructed and recombinant viruses were rescued including the parental virus with an 
additional MCS, the VKO virus and the VKO virus with an ORF for the V protein within 
the MCS. The viruses were shown to grow with similar growth kinetics on Vero as well 
as on A549 cells (Fig. 3-18C+D). At least for infection of the IFN-competent A549 cells 
one could expect a growth defect of the virus deficient in V expression, due to the lack 
of V-mediated IFN-inhibiting activities, such as suppression of IFN-expression as a 
result of MDA5 or IRF3 binding (Andrejeva et al., 2004; Irie et al., 2012). However, also 
the finding that the mRNA levels of IFNβ upon infection were comparable for all 
viruses point in a direction that IFN inhibition by MV is sufficient in the viral context 
even in the absence of V (Fig. 3-19D). Similar results were obtained in a study where 
macaques were infected with viruses either deficient in V or C expression. Infection of 
the animals with the viruses revealed that the V protein had no effect on IFNβ 
induction in vivo, since no significant difference of IFNβ mRNA levels in PBMCs was 
seen between infection with the VKO or the parental virus, whereas the C deficient 
virus showed enhanced IFNβ induction (Devaux et al., 2008). Furthermore, this study 
showed that expression of IFN-stimulated genes (ISG), like MxA or OAS (2,5-oligo-
adenylate synthetase) was also not altered whether the V protein was present or not 
during infections. This is contradictory to the findings in cultivated cells, where MV V 
was shown to counteract STAT signaling at multiple steps and subsequently suppress 
ISG expression (Caignard et al., 2007; Ohno et al., 2004; Palosaari et al., 2003; 
Ramachandran et al., 2008). These findings may indicate that effects seen by studies 
overexpressing the V protein are only conditionally transferable to the situation of a 
viral infection. The effects of the V protein might be compensated by the P or the C 
protein, since they have been shown to have similar functions. For example, the C 
protein was shown to inhibit IFN induction as well (Sparrer et al., 2012) and inhibition 
of STAT signaling via STAT1 binding is mediated by the common N-terminal domain of 
the P and V protein (Devaux et al., 2007). So, a loss of the V protein in the viral context 
Discussion 105 
may lead to a more pronounced role of either the P or the C protein and therefore 
compensate the effect normally mediated by the V protein. 
As far as NF-κB inhibition is concerned, infection of epithelial cells with the viruses 
revealed that there were also nearly no effect of the V protein on the induction of the 
NF-κB dependent genes IL-6 and RANTES, as both viruses, the VKO virus and the 
parental one, induced comparable levels of the respective mRNAs (Fig. 3-19B+C). The 
advanced induction of IL-6 and RANTES mRNA levels due to infection with the VKO+V 
virus is probably caused by an increased initial infection kinetics, which is reflected by 
the increased mRNA and protein levels of the MV N protein (Fig. 3-19E+F). The NF-κB 
reporter gene assays in HEK-293T cells showed also no difference in NF-κB activation 
comparing infections with the V deficient virus to the parental one (Fig. 3-19A). The 
enhanced induction seen with the rescued VKO virus (VKO+V) is very surprising and 
cannot be explained by the initial infection rate, as the Western blots show similar 
levels of the N protein.  
In contrast to IFNβ and ISG expression, the levels of the NF-κB dependent genes TNFα 
and IL6 were increased upon infection of macaques with the VKO virus in comparison 
to the parental one (Devaux et al., 2008). This strongly suggests that the NF-κB 
inhibitory capacity of the V protein is of importance in in vivo infections, although I 
could not detect any effect of V on NF-κB dependent genes in infections of cultured 
cell lines. This difference might result from the different cell types which were studied, 
since I used epithelial cell lines, whereas the in vivo study investigated primary PMBCs 
from infected macaques. Thus, the inhibitory effect of V on NF-κB activity in the viral 
context can be either cell type specific or solely observed in vivo. 
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4.8 Future prospects 
The biochemical data obtained in this study identify multiple targets within NF-κB 
signaling pathways for the MV P gene products. A very prominent inhibition of the 
classical pathway was seen with the V protein, which binds to the NF-κB subunit p65 
and retains it in the cytoplasm. The exact mechanism how this is achieved should be 
further investigated and studies on the modulation of the import machinery might be a 
very promising option. In particular, it would be very interesting to see if MV V 
interacts with a common hub of different signaling molecules. In addition, in vitro 
binding assays would bring further knowledge into the overall organization of the 
different inhibitory mechanisms mediated by the small 68 aa long MV VCTD.  
Clarification of the inhibitory mechanism of MV P and C would help to understand 
different aspects of NF-κB inhibition during MV infections. The compensatory 
mechanism which might be applied by the C protein in a virus which lacks the V 
protein could be investigated by generation of a virus defective in V and C expression. 
The role of MV P within the alternative signaling is of particular interest for clarification 
of the inhibitory mechanism applied by MV P, since it interacted solely with the 
alternative NF-κB subunit p52. However, P deficient virus is not viable, such that these 
studies would require first identification of relevant P domains by mutagenesis. 
The role of the inhibitory capacity of the V protein in the viral context should be 
further investigated. Thereby it would be very interesting to see whether, infection of 
cultured cells other than epithelial cells with VKO virus leads to an upregulation of NF-
κB dependent genes. PBMCs are here of special interest, since an effect in these cells 
was already observed in vivo. If the inhibitory effect of the V protein in vivo can be 
further confirmed, it might be worthwhile to check if the oncolytic efficiency, which 
was extensively utilized for MV (Galanis, 2010), can be enhanced by controlling NF-κB 
activity, which was shown to be constitutively active in cancer cells (DiDonato et al., 
2012). 
 
References 107 
5 References 
Andrejeva, J., K.S. Childs, D.F. Young, T.S. Carlos, N. Stock, S. Goodbourn, and R.E. 
Randall. 2004. The V proteins of paramyxoviruses bind the IFN-inducible RNA 
helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl 
Acad Sci U S A. 101:17264-17269. 
Arimoto, K., H. Takahashi, T. Hishiki, H. Konishi, T. Fujita, and K. Shimotohno. 2007. 
Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc 
Natl Acad Sci U S A. 104:7500-7505. 
Beckford, A.P., R.O. Kaschula, and C. Stephen. 1985. Factors associated with fatal 
cases of measles. A retrospective autopsy study. South African medical journal 
= Suid-Afrikaanse tydskrif vir geneeskunde. 68:858-863. 
Bellini, W.J., G. Englund, S. Rozenblatt, H. Arnheiter, and C.D. Richardson. 1985. 
Measles virus P gene codes for two proteins. J Virol. 53:908-919. 
Berghall, H., J. Siren, D. Sarkar, I. Julkunen, P.B. Fisher, R. Vainionpaa, and S. 
Matikainen. 2006. The interferon-inducible RNA helicase, mda-5, is involved in 
measles virus-induced expression of antiviral cytokines. Microbes and infection 
/ Institut Pasteur. 8:2138-2144. 
Bieback, K., E. Lien, I.M. Klagge, E. Avota, J. Schneider-Schaulies, W.P. Duprex, H. 
Wagner, C.J. Kirschning, V. Ter Meulen, and S. Schneider-Schaulies. 2002. 
Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 
signaling. J Virol. 76:8729-8736. 
Bonizzi, G., and M. Karin. 2004. The two NF-[kappa]B activation pathways and their 
role in innate and adaptive immunity. Trends in Immunology. 25:280-288. 
Brzózka, K., S. Finke, and K.K. Conzelmann. 2005. Identification of the rabies virus 
alpha/beta interferon antagonist: phosphoprotein P interferes with 
phosphorylation of interferon regulatory factor 3. J Virol. 79:7673-7681. 
Brzózka, K., S. Finke, and K.K. Conzelmann. 2006. Inhibition of interferon signaling by 
rabies virus phosphoprotein P: activation-dependent binding of STAT1 and 
STAT2. J Virol. 80:2675-2683. 
Bunting, C.H. 1950. The giant-cells of measles. The Yale journal of biology and 
medicine. 22:513-519. 
Caignard, G., M. Guerbois, J.L. Labernardiere, Y. Jacob, L.M. Jones, F. Wild, F. 
Tangy, and P.O. Vidalain. 2007. Measles virus V protein blocks Jak1-mediated 
phosphorylation of STAT1 to escape IFN-alpha/beta signaling. Virology. 
368:351-362. 
References 108 
Campbell, H., N. Andrews, K.E. Brown, and E. Miller. 2007. Review of the effect of 
measles vaccination on the epidemiology of SSPE. International journal of 
epidemiology. 36:1334-1348. 
Castiglioni, P., D.S. Hall, E.L. Jacovetty, E. Ingulli, and M. Zanetti. 2008. Protection 
against Influenza A Virus by Memory CD8 T Cells Requires Reactivation by 
Bone Marrow-Derived Dendritic Cells. The Journal of Immunology. 180:4956-
4964. 
Cathomen, T., B. Mrkic, D. Spehner, R. Drillien, R. Naef, J. Pavlovic, A. Aguzzi, M.A. 
Billeter, and R. Cattaneo. 1998. A matrix-less measles virus is infectious and 
elicits extensive cell fusion: consequences for propagation in the brain. EMBO 
J. 17:3899-3908. 
Cattaneo, R., K. Kaelin, K. Baczko, and M.A. Billeter. 1989. Measles virus editing 
provides an additional cysteine-rich protein. Cell. 56:759-764. 
Cattaneo, R., G. Rebmann, K. Baczko, V. ter Meulen, and M.A. Billeter. 1987. Altered 
ratios of measles virus transcripts in diseased human brains. Virology. 160:523-
526. 
Chen, M., J.C. Cortay, and D. Gerlier. 2003. Measles virus protein interactions in yeast: 
new findings and caveats. Virus Research. 98:123-129. 
Cheng, C.S., K.E. Feldman, J. Lee, S. Verma, D.-B. Huang, K. Huynh, M. Chang, J.V. 
Ponomarenko, S.-C. Sun, C.A. Benedict, G. Ghosh, and A. Hoffmann. 2011. 
The Specificity of Innate Immune Responses Is Enforced by Repression of 
Interferon Response Elements by NF-{kappa}B p50. Sci. Signal. 4:ra11-. 
Childs, K., R. Randall, and S. Goodbourn. 2012. Paramyxovirus V Proteins Interact 
with the RNA Helicase LGP2 To Inhibit RIG-I-Dependent Interferon Induction. 
Journal of Virology. 86:3411-3421. 
Childs, K., N. Stock, C. Ross, J. Andrejeva, L. Hilton, M. Skinner, R. Randall, and S. 
Goodbourn. 2007. mda-5, but not RIG-I, is a common target for paramyxovirus 
V proteins. Virology. 359:190-200. 
Cruz, C.D., H. Palosaari, J.-P. Parisien, P. Devaux, R. Cattaneo, T. Ouchi, and C.M. 
Horvath. 2006. Measles Virus V Protein Inhibits p53 Family Member p73. J. 
Virol. 80:5644-5650. 
Cui, S., K. Eisenacher, A. Kirchhofer, K. Brzozka, A. Lammens, K. Lammens, T. Fujita, 
K.K. Conzelmann, A. Krug, and K.P. Hopfner. 2008. The C-terminal regulatory 
domain is the RNA 5'-triphosphate sensor of RIG-I. Mol Cell. 29:169-179. 
de Swart, R.L., M. Ludlow, L. de Witte, Y. Yanagi, G. van Amerongen, S. McQuaid, S. 
Yuksel, T.B. Geijtenbeek, W.P. Duprex, and A.D. Osterhaus. 2007. 
Predominant infection of CD150+ lymphocytes and dendritic cells during 
measles virus infection of macaques. PLoS Pathog. 3:e178. 
del Valle, J.R., P. Devaux, G. Hodge, N.J. Wegner, M.B. McChesney, and R. Cattaneo. 
2007. A Vectored Measles Virus Induces Hepatitis B Surface Antigen 
Antibodies While Protecting Macaques against Measles Virus Challenge. 
Journal of Virology. 81:10597-10605. 
Dev, A., S. Iyer, B. Razani, and G. Cheng. 2011. NF-κB and Innate Immunity 
References 109 
In NF-kB in Health and Disease. Vol. 349. M. Karin, editor. Springer Berlin Heidelberg. 
115-143. 
Devaux, P., G. Hodge, M.B. McChesney, and R. Cattaneo. 2008. Attenuation of V- or 
C-defective measles viruses: infection control by the inflammatory and 
interferon responses of rhesus monkeys. J Virol. 82:5359-5367. 
Devaux, P., V. von Messling, W. Songsungthong, C. Springfeld, and R. Cattaneo. 
2007. Tyrosine 110 in the measles virus phosphoprotein is required to block 
STAT1 phosphorylation. Virology. 360:72-83. 
DiDonato, J.A., F. Mercurio, and M. Karin. 2012. NF-κB and the link between 
inflammation and cancer. Immunological Reviews. 246:379-400. 
Dong, J., E. Jimi, H. Zhong, M.S. Hayden, and S. Ghosh. 2008. Repression of gene 
expression by unphosphorylated NF-kappaB p65 through epigenetic 
mechanisms. Genes Dev. 22:1159-1173. 
Dorig, R.E., A. Marcil, A. Chopra, and C.D. Richardson. 1993. The human CD46 
molecule is a receptor for measles virus (Edmonston strain). Cell. 75:295-305. 
Fagerlund, R., L. Kinnunen, M. Kohler, I. Julkunen, and K. Melen. 2005. NF-{kappa}B 
is transported into the nucleus by importin {alpha}3 and importin {alpha}4. J Biol 
Chem. 280:15942-15951. 
Fagerlund, R., K. Melén, X. Cao, and I. Julkunen. 2008. NF-κB p52, RelB and c-Rel are 
transported into the nucleus via a subset of importin α molecules. Cellular 
Signalling. 20:1442-1451. 
Fagerlund, R., K. Melén, L. Kinnunen, and I. Julkunen. 2002. Arginine/Lysine-rich 
Nuclear Localization Signals Mediate Interactions between Dimeric STATs and 
Importin α5. Journal of Biological Chemistry. 277:30072-30078. 
Ferreira, C.S., M. Frenzke, V.H. Leonard, G.G. Welstead, C.D. Richardson, and R. 
Cattaneo. 2010. Measles virus infection of alveolar macrophages and dendritic 
cells precedes spread to lymphatic organs in transgenic mice expressing 
human signaling lymphocytic activation molecule (SLAM, CD150). J Virol. 
84:3033-3042. 
Franzoso, G., L. Carlson, L. Poljak, E.W. Shores, S. Epstein, A. Leonardi, A. Grinberg, 
T. Tran, T. Scharton-Kersten, M. Anver, P. Love, K. Brown, and U. Siebenlist. 
1998. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in 
humoral responses, germinal center reactions, and splenic microarchitecture. J 
Exp Med. 187:147-159. 
Freyschmidt, E.J., C.B. Mathias, D.H. MacArthur, A. Laouar, M. Narasimhaswamy, F. 
Weih, and H.C. Oettgen. 2007. Skin inflammation in RelB(-/-) mice leads to 
defective immunity and impaired clearance of vaccinia virus. The Journal of 
allergy and clinical immunology. 119:671-679. 
Fugier-Vivier, I., C. Servet-Delprat, P. Rivailler, M.C. Rissoan, Y.J. Liu, and C. 
Rabourdin-Combe. 1997. Measles virus suppresses cell-mediated immunity by 
interfering with the survival and functions of dendritic and T cells. J Exp Med. 
186:813-823. 
References 110 
Funasaka, T., and R.W. Wong. 2011. The role of nuclear pore complex in tumor 
microenvironment and metastasis. Cancer metastasis reviews. 30:239-251. 
Gack, M.U., Y.C. Shin, C.H. Joo, T. Urano, C. Liang, L. Sun, O. Takeuchi, S. Akira, Z. 
Chen, S. Inoue, and J.U. Jung. 2007. TRIM25 RING-finger E3 ubiquitin ligase is 
essential for RIG-I-mediated antiviral activity. Nature. 446:916-920. 
Galanis, E. 2010. Therapeutic Potential of Oncolytic Measles Virus: Promises and 
Challenges. Clin Pharmacol Ther. 88:620-625. 
Ghanem, A., A. Kern, and K.-K. Conzelmann. 2012. Significantly improved rescue of 
rabies virus from cDNA plasmids. European Journal of Cell Biology. 91:10-16. 
Ghosh, G., V.Y. Wang, D.B. Huang, and A. Fusco. 2012. NF-kappaB regulation: 
lessons from structures. Immunol Rev. 246:36-58. 
Ghosh, S., and M. Karin. 2002. Missing Pieces in the NF-[kappa]B Puzzle. Cell. 
109:S81-S96. 
Ghosh, S., M.J. May, and E.B. Kopp. 1998. NF-kappa B and Rel proteins: 
evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 
16:225-260. 
Giard, D.J., S.A. Aaronson, G.J. Todaro, P. Arnstein, J.H. Kersey, H. Dosik, and W.P. 
Parks. 1973. In vitro cultivation of human tumors: establishment of cell lines 
derived from a series of solid tumors. J Natl Cancer Inst. 51:1417-1423. 
Gilmore, T.D., D. Kalaitzidis, M.-C. Liang, and D.T. Starczynowski. 2004. The c-Rel 
transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 
23:2275-2286. 
Gitlin, L., W. Barchet, S. Gilfillan, M. Cella, B. Beutler, R.A. Flavell, M.S. Diamond, and 
M. Colonna. 2006. Essential role of mda-5 in type I IFN responses to 
polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. 
Proc Natl Acad Sci U S A. 103:8459-8464. 
Goodbourn, S., and R.E. Randall. 2009. The regulation of type I interferon production 
by paramyxoviruses. J Interferon Cytokine Res. 29:539-547. 
Graham, F.L., J. Smiley, W.C. Russell, and R. Nairn. 1977. Characteristics of a human 
cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 36:59-
74. 
Grandi, P., T. Dang, N. Pane, A. Shevchenko, M. Mann, D. Forbes, and E. Hurt. 1997. 
Nup93, a vertebrate homologue of yeast Nic96p, forms a complex with a novel 
205-kDa protein and is required for correct nuclear pore assembly. Mol Biol 
Cell. 8:2017-2038. 
Griffin, D.E. 2010. Measles virus-induced suppression of immune responses. Immunol 
Rev. 236:176-189. 
Griffin, D.E., W.-H. Lin, and C.-H. Pan. 2012. Measles virus, immune control, and 
persistence. FEMS Microbiology Reviews. 36:649-662. 
Griffin, D.E., and B.J. Ward. 1993. Differential CD4 T cell activation in measles. The 
Journal of infectious diseases. 168:275-281. 
References 111 
Hacker, H., V. Redecke, B. Blagoev, I. Kratchmarova, L.C. Hsu, G.G. Wang, M.P. 
Kamps, E. Raz, H. Wagner, G. Hacker, M. Mann, and M. Karin. 2006. 
Specificity in Toll-like receptor signalling through distinct effector functions of 
TRAF3 and TRAF6. Nature. 439:204-207. 
Hall, W.W., and V. Meulen. 1977. Rolyadenylic acid [poly(A)] sequences associated 
with measles virus intracellular ribonucleic acid (RNA) species. J Gen Virol. 
35:487-510. 
Hashiguchi, T., M. Kajikawa, N. Maita, M. Takeda, K. Kuroki, K. Sasaki, D. Kohda, Y. 
Yanagi, and K. Maenaka. 2007. Crystal structure of measles virus 
hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci U S 
A. 104:19535-19540. 
Hashimoto, C., K.L. Hudson, and K.V. Anderson. 1988. The Toll gene of Drosophila, 
required for dorsal-ventral embryonic polarity, appears to encode a 
transmembrane protein. Cell. 52:269-279. 
Hausmann, S., J.B. Marq, C. Tapparel, D. Kolakofsky, and D. Garcin. 2008. RIG-I and 
dsRNA-induced IFNbeta activation. PLoS One. 3:e3965. 
Hayden, M.S., and S. Ghosh. 2012. NF-kappaB, the first quarter-century: remarkable 
progress and outstanding questions. Genes Dev. 26:203-234. 
Hayden, M.S., A.P. West, and S. Ghosh. 2006. NF-kappaB and the immune response. 
Oncogene. 25:6758-6780. 
Hinz, M., S.C. Arslan, and C. Scheidereit. 2012. It takes two to tango: IkappaBs, the 
multifunctional partners of NF-kappaB. Immunol Rev. 246:59-76. 
Honda, K., Y. Ohba, H. Yanai, H. Negishi, T. Mizutani, A. Takaoka, C. Taya, and T. 
Taniguchi. 2005. Spatiotemporal regulation of MyD88-IRF-7 signalling for 
robust type-I interferon induction. Nature. 434:1035-1040. 
Hornung, V., J. Ellegast, S. Kim, K. Brzozka, A. Jung, H. Kato, H. Poeck, S. Akira, K.K. 
Conzelmann, M. Schlee, S. Endres, and G. Hartmann. 2006. 5'-Triphosphate 
RNA Is the Ligand for RIG-I. Science. 314:994-997. 
Huang, B., X.D. Yang, A. Lamb, and L.F. Chen. 2010. Posttranslational modifications 
of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. 
Cell Signal. 22:1282-1290. 
Huxford, T., D.-B. Huang, S. Malek, and G. Ghosh. 1998. The Crystal Structure of the 
I[kappa]B[alpha]/NF-[kappa]B Complex Reveals Mechanisms of NF-[kappa]B 
Inactivation. Cell. 95:759-770. 
Ikegame, S., M. Takeda, S. Ohno, Y. Nakatsu, Y. Nakanishi, and Y. Yanagi. 2010. 
Both RIG-I and MDA5 RNA Helicases Contribute to the Induction of Alpha/Beta 
Interferon in Measles Virus-Infected Human Cells. J. Virol. 84:372-379. 
Ireton, R.C., and M. Gale, Jr. 2011. RIG-I like receptors in antiviral immunity and 
therapeutic applications. Viruses. 3:906-919. 
Irie, T., K. Kiyotani, T. Igarashi, A. Yoshida, and T. Sakaguchi. 2012. Inhibition of 
Interferon Regulatory Factor 3 Activation by Paramyxovirus V Protein. Journal 
of Virology. 86:7136-7145. 
References 112 
Iwasaki, M., M. Takeda, Y. Shirogane, Y. Nakatsu, T. Nakamura, and Y. Yanagi. 2009. 
The matrix protein of measles virus regulates viral RNA synthesis and assembly 
by interacting with the nucleocapsid protein. J Virol. 83:10374-10383. 
Kato, H., O. Takeuchi, E. Mikamo-Satoh, R. Hirai, T. Kawai, K. Matsushita, A. Hiiragi, 
T.S. Dermody, T. Fujita, and S. Akira. 2008. Length-dependent recognition of 
double-stranded ribonucleic acids by retinoic acid–inducible gene-I and 
melanoma differentiation–associated gene 5. The Journal of Experimental 
Medicine. 205:1601-1610. 
Kato, H., O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. Matsui, S. Uematsu, 
A. Jung, T. Kawai, K.J. Ishii, O. Yamaguchi, K. Otsu, T. Tsujimura, C.S. Koh, C. 
Reis e Sousa, Y. Matsuura, T. Fujita, and S. Akira. 2006. Differential roles of 
MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 441:101-
105. 
Kato, S.I., K. Nagata, and K. Takeuchi. 2012. Cell tropism and pathogenesis of 
measles virus in monkeys. Frontiers in microbiology. 3:14. 
Kawai, T., and S. Akira. 2009. The roles of TLRs, RLRs and NLRs in pathogen 
recognition. International Immunology. 21:317-337. 
Kawai, T., K. Takahashi, S. Sato, C. Coban, H. Kumar, H. Kato, K.J. Ishii, O. Takeuchi, 
and S. Akira. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated 
type I interferon induction. Nat Immunol. 6:981-988. 
Kawasaki, T., T. Kawai, and S. Akira. 2011. Recognition of nucleic acids by pattern-
recognition receptors and its relevance in autoimmunity. Immunol Rev. 243:61-
73. 
Kitagawa, Y., M. Yamaguchi, M. Zhou, T. Komatsu, M. Nishio, T. Sugiyama, K. 
Takeuchi, M. Itoh, and B. Gotoh. 2011. A Tryptophan-Rich Motif in the Human 
Parainfluenza Virus Type 2 V Protein Is Critical for the Blockade of Toll-Like 
Receptor 7 (TLR7)- and TLR9-Dependent Signaling. Journal of Virology. 
85:4606-4611. 
Kolakofsky, D., L. Roux, D. Garcin, and R.W. Ruigrok. 2005. Paramyxovirus mRNA 
editing, the "rule of six" and error catastrophe: a hypothesis. J Gen Virol. 
86:1869-1877. 
Komarova, A.V., C. Combredet, L. Meyniel-Schicklin, M. Chapelle, G. Caignard, J.M. 
Camadro, V. Lotteau, P.O. Vidalain, and F. Tangy. 2011. Proteomic analysis of 
virus-host interactions in an infectious context using recombinant viruses. 
Molecular & cellular proteomics : MCP. 10:M110 007443. 
Kumar, H., T. Kawai, and S. Akira. 2011. Pathogen recognition by the innate immune 
system. International reviews of immunology. 30:16-34. 
Lemaitre, B., E. Nicolas, L. Michaut, J.M. Reichhart, and J.A. Hoffmann. 1996. The 
dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent 
antifungal response in Drosophila adults. Cell. 86:973-983. 
Lemon, K., R.D. de Vries, A.W. Mesman, S. McQuaid, G. van Amerongen, S. Yuksel, 
M. Ludlow, L.J. Rennick, T. Kuiken, B.K. Rima, T.B. Geijtenbeek, A.D. 
References 113 
Osterhaus, W.P. Duprex, and R.L. de Swart. 2011. Early target cells of measles 
virus after aerosol infection of non-human primates. PLoS Pathog. 7:e1001263. 
Lenardo, M.J., C.M. Fan, T. Maniatis, and D. Baltimore. 1989. The involvement of NF-
kappa B in beta-interferon gene regulation reveals its role as widely inducible 
mediator of signal transduction. Cell. 57:287-294. 
Leonard, V.H., P.L. Sinn, G. Hodge, T. Miest, P. Devaux, N. Oezguen, W. Braun, P.B. 
McCray, Jr., M.B. McChesney, and R. Cattaneo. 2008. Measles virus blind to its 
epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the 
airway epithelium and is not shed. J Clin Invest. 118:2448-2458. 
Li, T., X. Chen, K.C. Garbutt, P. Zhou, and N. Zheng. 2006. Structure of DDB1 in 
Complex with a Paramyxovirus V Protein: Viral Hijack of a Propeller Cluster in 
Ubiquitin Ligase. Cell. 124:105-117. 
Liao, G., M. Zhang, E.W. Harhaj, and S.C. Sun. 2004. Regulation of the NF-kappaB-
inducing kinase by tumor necrosis factor receptor-associated factor 3-induced 
degradation. J Biol Chem. 279:26243-26250. 
Liljeroos, L., J.T. Huiskonen, A. Ora, P. Susi, and S.J. Butcher. 2011. Electron 
cryotomography of measles virus reveals how matrix protein coats the 
ribonucleocapsid within intact virions. Proc Natl Acad Sci U S A. 108:18085-
18090. 
Lin, Y., M. Sun, S.M. Fuentes, C.D. Keim, T. Rothermel, and B. He. 2007. Inhibition of 
interleukin-6 expression by the V protein of parainfluenza virus 5. Virology. 
368:262-272. 
Liston, P., and D.J. Briedis. 1994. Measles Virus V Protein Binds Zinc. Virology. 
198:399-404. 
Liu, F., Y. Xia, A.S. Parker, and I.M. Verma. 2012. IKK biology. Immunol Rev. 246:239-
253. 
Lo, D., H. Quill, L. Burkly, B. Scott, R.D. Palmiter, and R.L. Brinster. 1992. A recessive 
defect in lymphocyte or granulocyte function caused by an integrated 
transgene. Am J Pathol. 141:1237-1246. 
Loo, Y.M., J. Fornek, N. Crochet, G. Bajwa, O. Perwitasari, L. Martinez-Sobrido, S. 
Akira, M.A. Gill, A. Garcia-Sastre, M.G. Katze, and M. Gale, Jr. 2008. Distinct 
RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol. 82:335-
345. 
Lu, L.L., M. Puri, C.M. Horvath, and G.C. Sen. 2008. Select Paramyxoviral V Proteins 
Inhibit IRF3 Activation by Acting as Alternative Substrates for Inhibitor of IκB 
Kinase ε (IKKε)/TBK1. Journal of Biological Chemistry. 283:14269-14276. 
Ludlow, M., L.J. Rennick, S. Sarlang, G. Skibinski, S. McQuaid, T. Moore, R.L. de 
Swart, and W.P. Duprex. 2010. Wild-type measles virus infection of primary 
epithelial cells occurs via the basolateral surface without syncytium formation or 
release of infectious virus. J Gen Virol. 91:971-979. 
Lund, G.A., D.L. Tyrrell, R.D. Bradley, and D.G. Scraba. 1984. The molecular length of 
measles virus RNA and the structural organization of measles nucleocapsids. J 
Gen Virol. 65 ( Pt 9):1535-1542. 
References 114 
Maine, G.N., X. Mao, C.M. Komarck, and E. Burstein. 2007. COMMD1 promotes the 
ubiquitination of NF-kappaB subunits through a cullin-containing ubiquitin 
ligase. EMBO J. 26:436-447. 
Marienfeld, R., F. Berberich-Siebelt, I. Berberich, A. Denk, E. Serfling, and M. 
Neumann. 2001. Signal-specific and phosphorylation-dependent RelB 
degradation: a potential mechanism of NF-kappaB control. Oncogene. 20:8142-
8147. 
May, M.J., F. D'Acquisto, L.A. Madge, J. Glockner, J.S. Pober, and S. Ghosh. 2000. 
Selective inhibition of NF-kappaB activation by a peptide that blocks the 
interaction of NEMO with the IkappaB kinase complex. Science. 289:1550-
1554. 
May, M.J., R.B. Marienfeld, and S. Ghosh. 2002. Characterization of the Ikappa B-
kinase NEMO binding domain. J Biol Chem. 277:45992-46000. 
McAllister, C.S., A.M. Toth, P. Zhang, P. Devaux, R. Cattaneo, and C.E. Samuel. 2010. 
Mechanisms of Protein Kinase PKR-Mediated Amplification of Beta Interferon 
Induction by C Protein-Deficient Measles Virus. Journal of Virology. 84:380-386. 
Meylan, E., J. Curran, K. Hofmann, D. Moradpour, M. Binder, R. Bartenschlager, and J. 
Tschopp. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is 
targeted by hepatitis C virus. Nature. 437:1167-1172. 
Moss, W.J., and D.E. Griffin. 2006. Global measles elimination. Nat Rev Microbiol. 
4:900-908. 
Moss, W.J., and D.E. Griffin. 2012. Measles. The Lancet. 379:153-164. 
Muhlebach, M.D., M. Mateo, P.L. Sinn, S. Prufer, K.M. Uhlig, V.H. Leonard, C.K. 
Navaratnarajah, M. Frenzke, X.X. Wong, B. Sawatsky, S. Ramachandran, P.B. 
McCray, Jr., K. Cichutek, V. von Messling, M. Lopez, and R. Cattaneo. 2011. 
Adherens junction protein nectin-4 is the epithelial receptor for measles virus. 
Nature. 480:530-533. 
Nakai, M., and D.T. Imagawa. 1969. Electron microscopy of measles virus replication. 
J Virol. 3:187-197. 
Naniche, D., G. Varior-Krishnan, F. Cervoni, T.F. Wild, B. Rossi, C. Rabourdin-Combe, 
and D. Gerlier. 1993. Human membrane cofactor protein (CD46) acts as a 
cellular receptor for measles virus. J Virol. 67:6025-6032. 
Nishie, T., K. Nagata, and K. Takeuchi. 2007. The C protein of wild-type measles virus 
has the ability to shuttle between the nucleus and the cytoplasm. Microbes and 
infection / Institut Pasteur. 9:344-354. 
Noyce, R.S., D.G. Bondre, M.N. Ha, L.T. Lin, G. Sisson, M.S. Tsao, and C.D. 
Richardson. 2011. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell 
receptor for measles virus. PLoS Pathog. 7:e1002240. 
Oeckinghaus, A., M.S. Hayden, and S. Ghosh. 2011. Crosstalk in NF-kappaB signaling 
pathways. Nat Immunol. 12:695-708. 
References 115 
Ohno, S., N. Ono, M. Takeda, K. Takeuchi, and Y. Yanagi. 2004. Dissection of 
measles virus V protein in relation to its ability to block alpha/beta interferon 
signal transduction. J Gen Virol. 85:2991-2999. 
Okada, H., F. Kobune, T.A. Sato, T. Kohama, Y. Takeuchi, T. Abe, N. Takayama, T. 
Tsuchiya, and M. Tashiro. 2000. Extensive lymphopenia due to apoptosis of 
uninfected lymphocytes in acute measles patients. Archives of virology. 
145:905-920. 
Ono, N., H. Tatsuo, Y. Hidaka, T. Aoki, H. Minagawa, and Y. Yanagi. 2001. Measles 
Viruses on Throat Swabs from Measles Patients Use Signaling Lymphocytic 
Activation Molecule (CDw150) but Not CD46 as a Cellular Receptor. Journal of 
Virology. 75:4399-4401. 
Oshiumi, H., M. Miyashita, N. Inoue, M. Okabe, M. Matsumoto, and T. Seya. 2010. The 
Ubiquitin Ligase Riplet Is Essential for RIG-I-Dependent Innate Immune 
Responses to RNA Virus Infection. Cell Host Microbe. 8:496-509. 
Palosaari, H., J.-P. Parisien, J.J. Rodriguez, C.M. Ulane, and C.M. Horvath. 2003. 
STAT Protein Interference and Suppression of Cytokine Signal Transduction by 
Measles Virus V Protein. J. Virol. 77:7635-7644. 
Pfaller, C.K. 2009. Subversion of Toll-like receptor 7/9 signaling by Measles virus − V 
holds the key. PhD thesis. 
Pfaller, C.K., and K.K. Conzelmann. 2008. Measles virus V protein is a decoy substrate 
for IkappaB kinase alpha and prevents Toll-like receptor 7/9-mediated interferon 
induction. J Virol. 82:12365-12373. 
Pichlmair, A., O. Schulz, C.P. Tan, T.I. Naslund, P. Liljestrom, F. Weber, and C. Reis e 
Sousa. 2006. RIG-I-mediated antiviral responses to single-stranded RNA 
bearing 5'-phosphates. Science. 314:997-1001. 
Pichlmair, A., O. Schulz, C.P. Tan, J. Rehwinkel, H. Kato, O. Takeuchi, S. Akira, M. 
Way, G. Schiavo, and C. Reis e Sousa. 2009. Activation of MDA5 requires 
higher-order RNA structures generated during virus infection. J Virol. 83:10761-
10769. 
Plemper, R.K., M.A. Brindley, and R.M. Iorio. 2011. Structural and mechanistic studies 
of measles virus illuminate paramyxovirus entry. PLoS Pathog. 7:e1002058. 
Poole, E., B. He, R.A. Lamb, R.E. Randall, and S. Goodbourn. 2002. The V Proteins of 
Simian Virus 5 and Other Paramyxoviruses Inhibit Induction of Interferon-[beta]. 
Virology. 303:33-46. 
Precious, B., D.F. Young, A. Bermingham, R. Fearns, M. Ryan, and R.E. Randall. 
1995. Inducible expression of the P, V, and NP genes of the paramyxovirus 
simian virus 5 in cell lines and an examination of NP-P and NP-V interactions. 
Journal of Virology. 69:8001-8010. 
Qing, G., Z. Qu, and G. Xiao. 2005. Stabilization of basally translated NF-kappaB-
inducing kinase (NIK) protein functions as a molecular switch of processing of 
NF-kappaB2 p100. J Biol Chem. 280:40578-40582. 
References 116 
Radecke, F., and M.A. Billeter. 1996. The nonstructural C protein is not essential for 
multiplication of Edmonston B strain measles virus in cultured cells. Virology. 
217:418-421. 
Radecke, F., and M.A. Billeter. 1997. Reverse Genetics Meets the Nonsegmented 
Negative-Strand RNA Viruses. Reviews in Medical Virology. 7:49-63. 
Radecke, F., P. Spielhofer, H. Schneider, K. Kaelin, M. Huber, C. Dotsch, G. 
Christiansen, and M.A. Billeter. 1995. Rescue of Measles Viruses from Cloned 
DNA. Embo Journal. 14:5773-5784. 
Rahman, M.M., and G. McFadden. 2011. Modulation of NF-kappaB signalling by 
microbial pathogens. Nat Rev Microbiol. 9:291-306. 
Ramachandran, A., and C.M. Horvath. 2010. Dissociation of Paramyxovirus Interferon 
Evasion Activities: Universal and Virus-Specific Requirements for Conserved V 
Protein Amino Acids in MDA5 Interference. J. Virol. 84:11152-11163. 
Ramachandran, A., J.P. Parisien, and C.M. Horvath. 2008. STAT2 is a primary target 
for measles virus V protein-mediated alpha/beta interferon signaling inhibition. J 
Virol. 82:8330-8338. 
Ramakrishnan, P., W. Wang, and D. Wallach. 2004. Receptor-specific signaling for 
both the alternative and the canonical NF-kappaB activation pathways by NF-
kappaB-inducing kinase. Immunity. 21:477-489. 
Razani, B., A.D. Reichardt, and G. Cheng. 2011. Non-canonical NF-kappaB signaling 
activation and regulation: principles and perspectives. Immunol Rev. 244:44-54. 
Rima, B.K., and W.P. Duprex. 2011. New concepts in measles virus replication: getting 
in and out in vivo and modulating the host cell environment. Virus Res. 162:47-
62. 
Schlender, J., V. Hornung, S. Finke, M. Gunthner-Biller, S. Marozin, K. Brzozka, S. 
Moghim, S. Endres, G. Hartmann, and K.K. Conzelmann. 2005. Inhibition of 
toll-like receptor 7- and 9-mediated alpha/beta interferon production in human 
plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J 
Virol. 79:5507-5515. 
Schlender, J., J.J. Schnorr, P. Spielhoffer, T. Cathomen, R. Cattaneo, M.A. Billeter, V. 
ter Meulen, and S. Schneider-Schaulies. 1996. Interaction of measles virus 
glycoproteins with the surface of uninfected peripheral blood lymphocytes 
induces immunosuppression in vitro. Proc Natl Acad Sci U S A. 93:13194-
13199. 
Schneider, H., K. Kaelin, and M.A. Billeter. 1997. Recombinant Measles Viruses 
Defective for RNA Editing and V Protein Synthesis Are Viable in Cultured Cells. 
Virology. 227:314-322. 
Schuhmann, K.M., C.K. Pfaller, and K.K. Conzelmann. 2011. The measles virus V 
protein binds to p65 (RelA) to suppress NF-kappaB activity. J Virol. 85:3162-
3171. 
Schwarz, A.J. 1962. Preliminary tests of a highly attenuated measles vaccine. Am J Dis 
Child. 103:386-389. 
References 117 
Sen, R., and D. Baltimore. 1986. Multiple nuclear factors interact with the 
immunoglobulin enhancer sequences. Cell. 46:705-716. 
Senftleben, U., Y. Cao, G. Xiao, F.R. Greten, G. Krahn, G. Bonizzi, Y. Chen, Y. Hu, A. 
Fong, S.C. Sun, and M. Karin. 2001. Activation by IKKalpha of a second, 
evolutionary conserved, NF-kappa B signaling pathway. Science. 293:1495-
1499. 
Seth, R.B., L. Sun, C.K. Ea, and Z.J. Chen. 2005. Identification and characterization of 
MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and 
IRF 3. Cell. 122:669-682. 
Shabman, R.S., E.E. Gulcicek, K.L. Stone, and C.F. Basler. 2011. The Ebola virus 
VP24 protein prevents hnRNP C1/C2 binding to karyopherin alpha1 and 
partially alters its nuclear import. The Journal of infectious diseases. 204 Suppl 
3:S904-910. 
Shaffer, J.A., W.J. Bellini, and P.A. Rota. 2003. The C protein of measles virus inhibits 
the type I interferon response. Virology. 315:389-397. 
Shah, S., S. Tugendreich, and D. Forbes. 1998. Major binding sites for the nuclear 
import receptor are the internal nucleoporin Nup153 and the adjacent nuclear 
filament protein Tpr. The Journal of cell biology. 141:31-49. 
Sidorenko, S.P., and E.A. Clark. 2003. The dual-function CD150 receptor subfamily: 
the viral attraction. Nat Immunol. 4:19-24. 
Solt, L.A., and M.J. May. 2008. The IkappaB kinase complex: master regulator of NF-
kappaB signaling. Immunologic research. 42:3-18. 
Sparrer, K.M., C.K. Pfaller, and K.K. Conzelmann. 2012. Measles virus C protein 
interferes with Beta interferon transcription in the nucleus. J Virol. 86:796-805. 
Spooren, A., K. Kolmus, L. Vermeulen, K. Van Wesemael, G. Haegeman, and S. 
Gerlo. 2010. Hunting for serine 276-phosphorylated p65. Journal of biomedicine 
& biotechnology. 2010:275892. 
Sun, S.C. 2011. Non-canonical NF-kappaB signaling pathway. Cell Res. 21:71-85. 
Tahara, M., M. Takeda, Y. Shirogane, T. Hashiguchi, S. Ohno, and Y. Yanagi. 2008. 
Measles virus infects both polarized epithelial and immune cells by using 
distinctive receptor-binding sites on its hemagglutinin. J Virol. 82:4630-4637. 
Takaki, H., Y. Watanabe, M. Shingai, H. Oshiumi, M. Matsumoto, and T. Seya. 2011. 
Strain-to-strain difference of V protein of measles virus affects MDA5-mediated 
IFN-β-inducing potential. Molecular Immunology. 48:497-504. 
Takayama, I., H. Sato, A. Watanabe, M. Omi-Furutani, A. Sugai, K. Kanki, M. Yoneda, 
and C. Kai. 2012. The nucleocapsid protein of measles virus blocks host 
interferon response. Virology. 424:45-55. 
Takeda, K., and S. Akira. 2004. TLR signaling pathways. Seminars in immunology. 
16:3-9. 
Takeda, M., M. Tahara, T. Hashiguchi, T.A. Sato, F. Jinnouchi, S. Ueki, S. Ohno, and 
Y. Yanagi. 2007. A human lung carcinoma cell line supports efficient measles 
References 118 
virus growth and syncytium formation via a SLAM- and CD46-independent 
mechanism. J Virol. 81:12091-12096. 
Takeuchi, O., and S. Akira. 2010. Pattern Recognition Receptors and Inflammation. 
Cell. 140:805-820. 
Tatsuo, H., N. Ono, K. Tanaka, and Y. Yanagi. 2000. SLAM (CDw150) is a cellular 
receptor for measles virus. Nature. 406:893-897. 
Thanos, D., and T. Maniatis. 1995. Virus induction of human IFN beta gene expression 
requires the assembly of an enhanceosome. Cell. 83:1091-1100. 
Toolan, H.W. 1954. Transplantable human neoplasms maintained in cortisone-treated 
laboratory animals: H.S. No. 1; H.Ep. No. 1; H.Ep. No. 2; H.Ep. No. 3; and 
H.Emb.Rh. No. 1. Cancer Res. 14:660-666. 
Wang, J., S.H. Basagoudanavar, X. Wang, E. Hopewell, R. Albrecht, A. Garcia-Sastre, 
S. Balachandran, and A.A. Beg. 2010. NF-{kappa}B RelA Subunit Is Crucial for 
Early IFN-{beta} Expression and Resistance to RNA Virus Replication. J 
Immunol. 185:1720-1729. 
Wang, X., S. Hussain, E.J. Wang, M.O. Li, A. Garcia-Sastre, and A.A. Beg. 2007. Lack 
of essential role of NF-kappa B p50, RelA, and cRel subunits in virus-induced 
type 1 IFN expression. J Immunol. 178:6770-6776. 
Wardrop, E.A., and D.J. Briedis. 1991. Characterization of V protein in measles virus-
infected cells. Journal of Virology. 65:3421-3428. 
WHO. 2012. Fact sheet on measles. WHO fact sheet #286. 
Xu, L.G., Y.Y. Wang, K.J. Han, L.Y. Li, Z. Zhai, and H.B. Shu. 2005. VISA is an adapter 
protein required for virus-triggered IFN-beta signaling. Mol Cell. 19:727-740. 
Yamamoto, M., K. Takeda, and S. Akira. 2004. TIR domain-containing adaptors define 
the specificity of TLR signaling. Mol Immunol. 40:861-868. 
Yanagi, Y., M. Takeda, S. Ohno, and T. Hashiguchi. 2009. Measles virus receptors. 
Curr Top Microbiol Immunol. 329:13-30. 
Yasumura, Y.K., Y. 1963. Studies on SV40 virus in tissue culture cells. Nippon Rinsho. 
21:1201-1215. 
Yokota, S., T. Okabayashi, N. Yokosawa, and N. Fujii. 2008. Measles virus P protein 
suppresses Toll-like receptor signal through up-regulation of ubiquitin-modifying 
enzyme A20. FASEB J. 22:74-83. 
Yoneyama, M., M. Kikuchi, K. Matsumoto, T. Imaizumi, M. Miyagishi, K. Taira, E. Foy, 
Y.M. Loo, M. Gale, Jr., S. Akira, S. Yonehara, A. Kato, and T. Fujita. 2005. 
Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and 
LGP2 in antiviral innate immunity. J Immunol. 175:2851-2858. 
Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. 
Taira, S. Akira, and T. Fujita. 2004. The RNA helicase RIG-I has an essential 
function in double-stranded RNA-induced innate antiviral responses. Nat 
Immunol. 5:730-737. 
References 119 
Yoneyama, M., W. Suhara, Y. Fukuhara, M. Sato, K. Ozato, and T. Fujita. 1996. 
Autocrine amplification of type I interferon gene expression mediated by 
interferon stimulated gene factor 3 (ISGF3). J Biochem. 120:160-169. 
Yoshikawa, Y., K. Mizumoto, and K. Yamanouchi. 1986. Characterization of 
messenger RNAs of measles virus. J Gen Virol. 67 ( Pt 12):2807-2812. 
Zarnegar, B., S. Yamazaki, J.Q. He, and G. Cheng. 2008. Control of canonical NF-
kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci U 
S A. 105:3503-3508. 
Zheng, C., Q. Yin, and H. Wu. 2011. Structural studies of NF-kappaB signaling. Cell 
Res. 21:183-195. 
Zhong, H., R.E. Voll, and S. Ghosh. 1998. Phosphorylation of NF-kappa B p65 by PKA 
stimulates transcriptional activity by promoting a novel bivalent interaction with 
the coactivator CBP/p300. Mol Cell. 1:661-671. 
Zhu, J., Y. Ding, F. Gao, T. Wu, C.W. Zhang, P. Tien, Z. Rao, and G.F. Gao. 2003. 
Crystallization and preliminary X-ray crystallographic analysis of the trimer core 
from measles virus fusion protein. Acta crystallographica. Section D, Biological 
crystallography. 59:587-590. 
 
6 List of abbreviations 
5’-ppp 5’-triphosphate 
A  alanine 
aa amino acid 
AP-1 activator protein 1 
APS ammonium persulfate 
BAFFR B-cell activating factor receptor 
BCR B-cell receptor 
bp base pair 
CARD terminal caspase activation and recruitment domain 
CBP CREB-binding protein 
cDNA copy DNA 
CDV  Canine distemper virus 
CIAP calf intestine alkaline phosphatase 
List of abbreviations 120 
cIAP cellular inhibitor of apoptosis 
CMV cytomegalovirus 
CoIP co-immunoprecipitation 
cRNA copy (antigenomic) RNA 
C-terminus Carboxy-terminus 
DCs dendritic cells 
DI defective interfering 
DMEM Dulbecco's Modified Eagle Medium 
DNA deoxyribonucleic acid 
ds double-strand 
DTT 1,4-dithiothreit 
E. coli Escherichia coli 
EDTA ethylene-diamin-tetraacetic acid-disodium salt 
EMCV encephalomyocarditis virus 
EV empty vector 
F fusion protein 
FADD Fas-associated death domain 
FCS fetal calf serum 
ffu focus forming units 
FITC fluorescein isothiocyanate 
G guanosine 
GFP green fluorescent protein 
H hemagglutinin protein 
HA hemagglutinin tag 
hnRNP c1c2 Heterogeneous nuclear ribonucleoproteins C1/C2 
HRP horseradish peroxidase 
IFN  interferon 
IFNR IFN receptor 
IKK IκB kinase 
IL interleukin 
IPS-1 interferon beta promoter stimulator 1 
IRAK interleukin-1 receptor associated kinase 
IRF interferon regulatory factor 
List of abbreviations 121 
ISG interferon stimulated genes 
IκB inhibitor of κB 
JAK Janus kinase 
K lysine 
KO knock out 
L large protein 
LB lysogeny broth 
Le leader 
LGP2 laboratory of genetics and physiology 2 
LTβR lymphotoxin-β receptor  
M matrix protein 
MAPK mitogen-activated protein kinase 
MCP membrane cofactor protein  
MDA5 melanoma differentiation-associated gene 5 
MOI multiplicity of infection 
MV measles virus 
MyD88 myeloid differentiation factor 88 
N nucleocapsid protein 
NBD nemo binding domain 
ncp nuclear pore complex 
NEMO NF-κB essential modifier 
NF-κB  nuclear factor κB 
NIK NF-κB-inducing kinase  
NiV Nipah virus 
NLS nuclear localization signal 
N-terminus Amino-terminus 
OAS 2’5’-oligoadenylate synthetase 
OD optical density 
P phosphoprotein 
p.i. post infection 
p.t. post transfection 
PAGE polyacrylamide gel electrophoresis 
PAMP pathogen-associated molecular pattern 
List of abbreviations 122 
PBMCs peripheral blood mononuclear cells  
PBS Phosphate buffered saline 
PCR polymerase chain reaction 
pDCs plasmacytoid dendritic cells 
PEI polyethyleneimine 
PFA paraformaldehyde 
PIV 5 Parainfluenza virus type 5 
PO peroxidase 
Poly(I:C) polyriboinosinic:polyribocytidylic acid 
PRR pattern recognition receptor 
PVDF polyvinylidene fluoride 
PVRL4 poliovirus receptor-like protein 4 
RD regulatory domain 
RHD Rel homology domain 
RIG-I retinoic acid-inducible gene I 
RIP1 receptor-interacting protein 1 
RL Renilla luciferase 
RLR RIG-like receptor 
RNA ribonucleic acid 
RNP ribonucleoprotein 
RT reverse transcriptase 
RV  rabies virus 
S serine 
SDS sodium-dodecyl sulfate 
SLAM Signaling lymphocytic activation molecule  
ss single-strand 
SSPE Subacute sclerosing panencephalitis 
STAT signal transducer and activator of transcription 
TAB TAK1 binding protein 
TAD transactivation domain  
TAK transforming growth factor β 
TANK TRAF family member-associated activator NF-κB 
TBK-1 TANK-binding kinase 1 
List of abbreviations 123 
TCR T-cell receptor 
TEMED tetramethylenediamine 
TIR Toll/interleukin-1-receptor 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
Tr trailer 
TRADD TNF receptor 1-associated death domain protein 
TRAF TNF-receptor-associated factor 
TRIF TIR domain-containing adapter inducing IFN-β 
TRIM tripartite motif 
vRdRp viral RNA-dependent RNA polymerase 
vRNA viral (genomic) RNA 
WB Western blot 
WHO world health organization 
wt wild-type 
 
 
7 List of figures 
Figure 1-1 Measles virus – the basics .............................................................................2 
Figure 1-2 Measles virus P gene products ......................................................................3 
Figure 1-3 The mammalian NF-κB family and its inhibitors ............................................9 
Figure 1-4 Two different NF-κB signaling pathways .....................................................10 
Figure 1-5 Endosomal TLR-signaling .............................................................................14 
Figure 1-6 RLR signaling pathways ...............................................................................16 
Figure 3-1 Measles virus P gene products suppress NF-κB activation upon TNFR 
stimulation ..................................................................................................................60 
Figure 3-2 NF-κB signaling via PRRs can be suppressed by MV P gene products ...........61 
Figure 3-3 MV V inhibits NF-κB signaling downstream of the IKK complex ...................63 
Figure 3-4 MV V specifically binds the NF-κB subunit p65 ............................................65 
List of figures 124 
Figure 3-5 RHD of p65 is sufficient for interaction with MV V ......................................66 
Figure 3-6 Binding of MV V to p65 is mediated via both the N- and the C-terminal 
domain of the RHD of p65 ...........................................................................................68 
Figure 3-7 Binding of MV V to p65 does not compete with binding of p50 or IκBα to 
p65 ..............................................................................................................................69 
Figure 3-8 MV V prevents nuclear translocation of p65 ...............................................70 
Figure 3-9 Nuclear translocation of p65 upon TNFα treatment in the presence of MV P 
and C ...........................................................................................................................72 
Figure 3-10 MV V does not directly bind to the NLS of p65 or interfere with importin α 
5 binding to p65 ..........................................................................................................74 
Figure 3-11 The CTD of MV V is sufficient for p65 binding and suppression of p65/p50-
mediated NF-κB activity ..............................................................................................75 
Figure 3-12 Mutational analysis of MV V .....................................................................77 
Figure 3-13 The V protein of the measles wild type isolate D5 inhibits NF-κB activity 
and binds to p65..........................................................................................................80 
Figure 3-14 CDV V and NiV V act like MV V and suppress classical NF-κB activity .........82 
Figure 3-15 The Rel homology domain of p65 is also bound by CDV V and NiV V .........84 
Figure 3-16 Binding of P gene products to other NF-κB subunits .................................86 
Figure 3-17 Inhibition of the alternative NF-κB pathway ..............................................88 
Figure 3-18 Generation and characterisation of recombinant viruses MV-vac2, MV-
MCS, MV-VKO, MV-VKO+V ..........................................................................................90 
Figure 3-19 NF-κB activation upon infection with MV-MCS, MV-VKO, MV-VKO+V .......92 
 
